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Abstract 
Testis specific protein Y chromosome encoded (TSPY) is a multicopy gene located on 
the human Y chromosome. It has been reported that the human genome harbours 
between 20 to 40 copies of the gene. Mammalian homologues of human TSPY were 
also found to be repetitive. The gene is expressed in human foetal and adult testis. The 
precise function of the expressed TSPY gene product is not fully defined, but it has 
been postulated to regulate proliferation of testicular spermatogonia. Up-regulation of 
TSPY expression has been detected in gonadoblastoma, testicular cancer and prostate 
cancer. The contribution of abnormal expression of TSPY to prostate carcinogenesis 
has not been investigated. Prostate cancer (CaP) and benign prostate hyperplasia 
(BPH) are the most common diseases of the human prostate. Prostate cancer is a 
disease of the elderly and is the second most common cancer and second most 
common cause of death from cancer among men in UK. 
In this thesis, the role of TSPY in prostate carcinogenesis was studied in four related 
aspects. First, TSPY protein and transcript expression pattern in CaP compared to 
Benign Prostate Hyperplasia (BPH) was studied using a combination of 
immunohistochemistry and mRNA in situ hybridisation. Second, the ability of TSPY 
to regulate cellular proliferation was investigated by transfection experiments of the 
prostate cancer LNCaP cell line. Third, TSPY genomic copy number in prostate 
cancer was characterised and compared to BPH. Finally, the downstream genes 
regulated by TSPY were investigated using high density microarray gene profiling 
method. 
An anti-human TSPY polyclonal antibody was developed for immunodetection of 
TSPY expression level in resected prostate tissues. In total, 72 cases of patients with 
prostate cancer and 20 cases of patients affected with BPH were studied by 
immunohistochemistry. TSPY was predominantly detected in the prostatic epithelium. 
In the benign gland, TSPY expression was limited to the basal cells compartment. 
TSPY expression was significantly up-regulated in prostate cancer when compared to 
BPH (P<0.0001). Furthermore, increased TSPY expression level was associated with 
aggressive disease (tumour with high Gleason score; P<0.02) and the presence of 
bone metastasis at the time of diagnosis (P<0.028). To address the functional role of 
3 
TSPY in prostate cancer, FLAG-TSPY was cloned and stably transfected into LNCaP 
cells. The presence of transfected TSPY increased LNCaP proliferation by two fold 
compared to empty vector control, consistent with a mitogenic function in CaP 
(P<0.0001). 
An absolute quantitative real time PCR based on Taqman assay was established and 
validated. TSPY genomic copy number was determined from comparing 161 samples: 
CaP-serum (n=47), resected tumour (n=31); BPH-serum (n=27), resected prostate 
(n=13) and control-serum (n=45). Of the clinical samples analysed, interpersonal 
variability of TSPY copy numbers was observed with the majority of cases containing 
between 20 to 50 TSPY copies per genome. Although, there were variability in TSPY 
copy numbers among individuals, there was no statistically significant correlation 
between TSPY copy number (serum and prostatic tissue) and the development of 
prostate cancer. 
Studying LNCaP stably transfected with TSPY and empty vector control, the key 
genes mediating the functional effect of TSPY were identified using Affymetrix 
oligonucleotide microarray method. In total, 332 genes have been altered 1.5 to 90 
fold due to the effect of TSPY over-expression. Ten genes were selected and the gene 
expression levels were confirmed using semi-quantitative RT-PCR method. Gene 
clustering analysis has indicated changes in genes that regulate cellular differentiation 
(NRDG1, NF2, C-MAF and BMP11), apoptotic gene (BAX), cell cycle gene (cyclin 
G), detoxification gene (GST-2A) and genes linked to adhesion (PCDH7a, PLOD2 
and IRS 1). 
In summary, TSPY is over-expressed in prostate cancer. This abnormal expression is 
linked to prostate cancer progression and metastasis. The up-regulation of TSPY 
expression is unlikely to be due to increased copy number. Expression of exogenous 
TSPY in prostate cancer cells enhanced cellular proliferation. The gene meditates its 
effect by down-regulating the expression pattern of selected differentiation, apoptosis 
and adhesion genes. Hence, over-expression of TSPY contributes to prostate 
carcinogenesis. 
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Chapter 1 
General Introduction 
Chapter 1: General Introduction 
1.1 Introduction 
1.1.1 Physiology and anatomy of prostate gland 
The human prostate is a male accessory sex gland that weighs approximately 20 gm 
and is shaped liked a chestnut. The gland lies below the bladder and encircles the 
upper part of urethra. This anatomical location allows direct deposition of prostatic 
fluid into urethra during ejaculation. The secreted prostatic fluid is milky in colour 
and is rich in citric acid, fibrinolysin and enzymes, particularly acid phosphatase. 
These prostatic secretions play a key role in liquefying semen and activating sperm 
(Shipley, 1999). 
The prostate gland is anatomically divided into four distinct zones (McNeal, 1981): 
peripheral zone, central zone, transition zone and the non glandular anterior 
fibromuscular stroma (Figure 1.1). The peripheral zone accounts for 75% of the 
normal adult glandular tissue in the prostate. The peripheral zone is the most 
susceptible region to develop prostate cancer. The second major region of the prostate 
is the central zone which forms 20% of prostate glandular tissue. The central zone is 
cone-shaped and surrounds the ejaculatory duct. The transitional zone makes up 5% 
of the prostate glandular tissue and is the primary site for the development of benign 
prostatic hyperplasia (BPH). The anterior fibromuscular stroma forms a non-glandular 
part of the gland consisting predominantly of collagenous stroma and muscle fibres. 
19 
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Figure I. I. Prostate gland zonal anatomy. 
The prostate is anatomically divided into four distinct zones; peripheral, central, 
transitional and non-glandular fibromuscular stroma. The peripheral zone forms the 
major part of the gland and directly surrounds the prostatic urethra and indirectly 
surrounds the ejaculatory duct. The central zone is the second largest region of the 
gland that directly surrounds the ejaculatory ducts. The transitional zone accounts for 
the minor part of the gland and surrounds the prostatic urethra. The non-glandular 
fibromuscular stroma is located anterior to the gland (Mundy et al., 1999). 
1.1.2 Histology of Prostate gland 
The human prostate gland consists of two compartments, ducts and the surrounding 
stroma. The prostate ductal epithelium is composed of basement membrane lined with 
three distinct cell types: luminal, basal and neuroendocrine cells (Figure 1.2). These 
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cells can be distinguished by their morphology and the expression of molecular 
markers (Abate-Shen and Shen, 2000). The secretory luminal cells represent the 
predominant cell type in the prostate epithelial compartment (Figure 1.3). They are 
terminally differentiated and columnar in shape producing prostatic secretory proteins 
and are positive for the expression of androgen receptor, cytokeratin 8,18 and cell 
surface marker CD57. The basal cells, the second major epithelial cell type, are 
cuboidal in shape and are located between columnar cells and the underlying 
basement membrane. The basal cells are distinguished from luminal cells by the 
expression of cytokeratin 5,14 as well as CD44. These cells are androgen 
independent, but remain androgen responsive. Analysis of cytokeratin expression 
patterns in prostate epithelium has identified transient populations of prostatic 
epithelial cells that have both basal and luminal characteristics (Schalken and van 
Leenders, 2003). This suggests the existence of prostate stem cells which could give 
rise to transiently proliferating cells that can divide to generate all types of prostate 
epithelial cells. The third prostate epithelial cell type is the neuroendocrine cells. This 
minor cell population is characterised by expression of hormones and secretory 
proteins such as Chromogranin A, secretogranin II, neurone specific enolase (marker 
of neuroendocrine differentiation) and serotonin (Abrahamsson, 1999). Chromogranin 
A is a member of the family of acidic secretory proteins found in the secretory 
granules of endocrine cells and neurones. The exact function of chromogranin A is 
not yet clear (Huttner et al., 1991). However, it may have extracellular bioactivity that 
acts as autocrine and/or paracine regulatory agent in the secretory process. Serotonin 
is another secretory hormone protein produced by neuroendocrine cells which can be 
involved in mediating growth activity, regulating morphogenesis and secretory 
peptide hormones from endocrine cells. In general, the function of neuroendocrine 
cells in the prostate remains unknown. Nevertheless, they appear essential for growth, 
differentiation and the regulation of secretory processes in the prostate. 
The second compartment of the prostate gland is the stroma. It consists of dense 
collagen, fibroblasts, smooth muscle fibres, skeletal muscles, 
blood vessels, 
neuroendocrine cells as well as sympathetic nerves (Young and 
Heath, 2000) (Figure 
1.3). Interaction between stroma and epithelium plays a vital role in prostate 
organogenesis. Aberrant interaction between stroma and epithelium contributes 
to 
prostatic diseases including CaP and BPH 
(Chung, 1995). 
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Figure 1.2. Schematic representation of prostate gland. 
The normal human prostate is made up of glands surrounded by stroma. The prostatic 
gland epithelium consists of three distinct cell types lining the basement membrane: 
luminal secretory cells, basal cells and neuroendocrine cells. The luminal secretory 
cells are the predominant cell type in prostate epithelium and are columnar in shape. 
The basal cells are located between the columnar cells and the basement membrane 
and are cuboidal in shape. The neuroendocrine cells are minor cell types that are 
present within the prostatic epithelium. The stroma surrounds the basement membrane 
and mainly consists of fibroblasts, muscle cells, nerve, and blood vessels (Marker et 
al., 2003). 
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Figure 1.3. Histological structure of normal prostate gland. 
The normal human prostate is composed of glandular secretory epithelium surrounded 
by stroma. In histological cross section of the prostate, glands appear to be rounded to 
irregular branching in shape. The basement membrane of the gland is lined with two 
cell layers, tall columnar secretory cells (C) and cuboidal basal cells (B). The glands 
are surrounded by fibromuscular stroma which accounts for about half of the volume 
of prostate (http: //www. medlib. med. utah. edu). The stroma composed of smooth 
muscles, nerve supply, fibroblasts, and blood vessels. 
1.1.3 Pathology of Prostate Gland 
Common pathological conditions of the human prostate gland include prostatitis, 
benign prostatic hyperplasia, prostate cancer and its precursor lesion, prostatic 
intraepithelial neoplasm. 
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1.1.3.1 Benign prostatic hyperplasia 
Benign nodular hyperplasia or benign prostatic hyperplasia (BPH) is a non-neoplastic 
enlargement of the prostate gland. The incidence of BPH increases with age and is 
detected in approximately 20% of men 40 years of age, increasing to 70% at the age 
of 60 and 90% at the age of 70 (Arrighi et al., 1991). More than 400,000 prostates 
are resected each year in USA (Cotran et al., 1999). BPH does not predispose to 
prostate cancer. Hence, the disease is not considered to be a pre-malignant lesion 
(Cotran et al., 1999). On average, prostates affected by BPH weigh 60-100 gm 
(compared to normal prostate weighing 20g). Less commonly, the prostate can weigh 
up to 200 gm (10 times normal prostate) in patients with BPH. BPH is characterised 
by hyperplasia of both stroma and epithelium, resulting in formation of large discrete 
nodules in the transitional zone of the prostate (Steers and Zorn, 1995). The glandular 
acini are larger than normal and the epithelium is characterised by numerous 
infoldings (Figure 1.4). 
The development of BPH occurs in two phases, pathological and clinical BPH. The 
pathological phase is divided into microscopic and macroscopic BPH. Nearly all men 
throughout the world will develop microscopic BPH if they live long enough. In about 
half of men with microscopic BPH, enlargement of prostate will progress to 
macroscopic BPH. In ageing men with macroscopic prostatic enlargement, only about 
half will progress to produce clinical BPH (Isaacs and Coffey, 1989). Men affected by 
BPH, develop lower urinary tract symptoms in keeping with bladder outlet 
obstruction. The hyperplastic nodules compress the prostatic urethra and obstruct the 
urinary flow, resulting in gradual hypertrophy of the bladder and dilation of ureter. 
Severe or untreated BPH may eventually lead to recurrent urinary infections, 
haematuria and ultimately impaired renal function (Underwood, 1998). 
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Figure 1.4. Histological morphology of BPH. 
Microscopic appearance of BPH resected tissue. The glandular structure of the 
prostate is preserved. However, enlarged glands separated by stroma are noted. The 
glands retain glandular basement membrane lined with columnar cells and cuboidal 
cells (www. medlib. med. utah. edu). 
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1.1.3.1.1 Aetiology 
The cause of BPH is not known. However, age, race, family history and hormone are 
potential risk factors for BPH. The incidence of BPH increases with increasing age 
(Berry et al., 1984, Isaacs and Coffey, 1989). The incidence of BPH is highest in 
African Americans and lowest in native Japanese populations. However, the incidence 
increases in Japanese immigrants to Western countries due to either environmental or 
dietary factors (Ekman, 1989). Family history is another risk factor for the 
development of BPH. Recent studies have indicated that patients with a positive 
family history of BPH have larger prostates than controls (Sanda et al., 1997). Dietary 
fat intake, vitamin supplements and obesity, which cause disturbances in hormone 
balance, have also been suggested as risk factors (Ziada et al., 1999). Mounting 
evidence suggests that prostate enlargement is related to the action of 
dihydrotestosterone (DHT), a metabolite of testosterone which plays a vital role in 
regulating prostate development, growth and differentiation (Droller, 1997). DHT is 
produced from testosterone by the action of steroid, 5-a-reductase type 2 (Figure 1.5). 
The enzyme is produced primarily by the stromal cells. DHT can act on both stromal 
and epithelial cells in autocrine and paracrine manners, respectively. In both cell types, 
DHT binds to androgen receptor which translocates to the nucleus to regulate 
transcription of genes regulating growth of epithelial cells and stromal cells. In men 
with BPH, the use of 5 a-reductase inhibitor significantly reduces prostatic volume 
(Walsh, 1996). 
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Figure 1.5. Androgen receptor activation. 
Testosterone is converted into dihydrotestosterone (DHT) by the action of cellular 5 
a- reductase type II (SRD5A2). Active DHT binds to AR and translocates it from 
cytoplasm to the nucleus. In the nucleus the activated AR binds to androgen response 
elements of genes that regulate growth of epithelial and stromal cells and regulate 
their transcription. 
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1.1.3.1.2 Treatment 
If the symptoms from BPH severely affect micturition, the patient can be treated with 
medication or by surgical procedure. Medication aims to relax smooth muscles within 
the prostate stroma. Surgical removal of the enlarged part of the prostate by means of 
transurethral resection is the most reliable treatment to give long term relief from 
symptoms of BPH. 
1.1.3.2 Prostatic intraepithelial neoplasia 
Prostatic intraepithelial neoplasia (PIN) has been previously referred to as putative 
precancerous dysplastic, intraductal dysplasia, large acinar atypical hyperplasia and 
atypical primary hyperplasia. The incidence of PIN detected in transurethral resected 
prostates from patients varies from 2.8-33% (Mundy et al., 1999). PIN is divided into 
two grades; low grade and high grade (HGPIN). Low grade PIN is often detected in 
young men. The frequency of high grade PIN increases with advancing age (Sakr et 
al., 1993). HGPIN is the most likely precursor lesion of prostatic adenocarcinoma and 
has high predictive value as a marker for CaP (Bostwick et al., 1996). Several lines of 
evidence support the hypothesis that PIN is an intermediate lesion between normal 
and malignant prostate. In nearly 80 % of confined prostate cancer cases, there is 
evidence of co-existing PIN (Graham, 1992). In addition, molecular genetic analysis 
of PIN and CaP lesions reveals many genetic alterations in common. These include 
aneuploidy as well as loss of heterozygosity (LOH) at several genetic loci. For 
instance, at 8p12 loci, there is LOH in 64 % and 91 % in PIN and prostate cancer, 
respectively (Haggman et al., 1997b). Furthermore, it has been suggested that 
approximately 30% of PIN may progress to invasive cancer over a period of 10 year 
(Bostwick, 1996). Moreover, cytological features of PIN closely resemble those of 
invasive carcinoma (Bostwick et al., 1993). Further study has shown that in the 
prostate transgenic mice model expressing SV40 large antigen driven by the prostate 
specific promoter probasin, multifocal loci of high-grade dysplasia similar to PIN 
have developed (Kasper et al., 1998). 
The peripheral zone of the prostate is the most common location 
for PIN development 
(Bostwick et al., 1993). PIN epithelium is histologically characterised 
by disruption of 
basal cell layer and retained basement membrane 
(Bostwick and Brawer, 1987) 
(Figure 1.6). The epithelial cells of low grade PIN are crowded and irregularly spaced 
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and cells of HGPIN are more crowded and characterised by nuclear and nucleolar 
enlargement. PIN differs from prostate carcinoma in that PIN lesions do not invade 
normal stroma and PIN can only be detected by biopsy samples (Haggman et al., 
1997a). 
Figure 1.6. Morphological structure of prostatic intraepithelial neoplasia (PIN). 
PIN is characterised by atypical basal cell hyperplasia, preservation of basement 
membrane, replacement of normal luminal secretory cells with neoplastic cells and 
crowded epithelial cells. (www. medlib. med. utah. edu). 
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1.1.3.3 Prostate cancer 
Prostate cancer is the third most common cancer in men in the world (Quinn and 
Babb, 2002a, Quinn and Babb, 2002b) and is the second most common cancer in men 
in UK. It is a rapidly growing global health problem as the numbers of detected and 
reported prostate cancer cases are continuously increasing. Although there are more 
than 1.5 million persons diagnosed with prostate cancer, there are more than 500,000 
new cases reported every year worldwide (Parkin et al., 2001). Prostate cancer is a 
disease of the elderly with approximately 75% of cases diagnosed in patients over 65 
years old (Dijkman and Debruyne, 1996). It has been anticipated that more than 1.25 
million new cases of prostate cancer will be detected annually by year 2050. Thus, by 
the middle half of the century, prostate cancer will be the second most common 
cancer in men. Mortality from prostate cancer has increased and it accounts for 
204,000 deaths per year. It has been estimated that this number will double in less 
than 50 years. In England, 23,109 new cases of prostate cancer were reported in the 
year 2000 and 9,004 deaths were confirmed due to prostate cancer (Cancer 
registrations in England, 2003). 
Clinical symptoms associated with locally advanced prostate cancer and/or metastatic 
disease are bone pain, spinal cord compression and urinary tract obstruction. At the 
initial stage of prostate cancer formation, tumours originate in the peripheral zone, 
invade and spread through several routes; direct local invasion, lymph and blood 
vessels. Prostate cancer can spread directly from within the gland and to the extra- 
capsular adjacent structures. Invasion of prostatic stroma towards the peri-urethral 
tissue and base of the bladder is common. Extension through the prostate capsule to 
the seminal vesicle is also common. Lymphatics vessels provide an important route of 
dissemination of prostatic carcinoma, leading to metastasis in lymph nodes. These 
may result in lymphatic obstruction and oedema of the legs. Prostate cancer can 
spread through the vascular route and metastasise to bone, lung and 
liver. The most 
frequent sites of bone metastasis are pelvis, spine and ribs. 
1.1.3.3.1 Diagnosis of CaP 
Several diagnostic tools are available to aid the detection of prostate cancer in men. 
Careful digital rectal examination (DRE) is a useful direct method 
for early detection 
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of prostatic carcinoma, since the posterior location of most tumours (peripheral zone), 
renders them palpable. DRE is carried out by inserting a gloved finger up the rectum 
of a patient by a physician to detect any lumps or hardening of the prostate gland. 
DRE alone is not sufficient to detect CaP early disease. Transrectal ultrasonography is 
another important diagnostic tool for early detection as well as assessment of local 
spread of the tumour and transrectal biopsy is required to confirm the diagnosis. 
Several procedures are used to detect prostate metastasis. Pelvic lymphadenectomy is 
used to detect microscopic metastasis to the lymph nodes. Metastasis to bone can be 
detected by radionuclide bone scanning. The introduction of a blood test for prostate 
specific antigen (PSA) in 1986 had accelerated the efficiency of detecting prostate 
cancer at early stages. PSA is a serine protease which functions to cleave and liquefy 
the seminal coagulum formed after ejaculation. The PSA protein is produced by the 
normal gland in low amounts (4 ng/ml) and the serum levels of PSA increase with age. 
Furthermore, PSA levels can be spuriously elevated in BPH and inflammation of the 
prostate (prostatitis). It has been estimated that nearly 25% of men with abnormal 
DRE and PSA tests actually they do not have CaP. Combination of DRE and PSA 
testing can increase the detection efficiency of CaP up to 85% (Jones, 1997). It is now 
suggested that men should have an annual PSA test at the age of 50 for white men and 
age 40 for black persons. Once the CaP is diagnosed, histological grading and staging 
of tumour are determined to assess the degree of differentiation, size and location of 
tumour. 
1.1.3.3.2 Gleason classification of CaP 
Gleason system is widely accepted for histological assessment of prostate tumour 
grade (Gleason, 1992). Based on glandular pattern and 
degree of differentiation as 
inspected under low magnification, prostate cancer is divided 
into five distinct grades 
on a scale of 1-5. Grade 1 represents the 
best differentiated tumour in which the 
neoplastic glands appear uniform and tend to 
be packed into well circumscribed 
nodules. Occasionally the glands are somewhat 
larger with a papillary pattern. The 
glands are lined with a single uniform 
layer of columnar epithelium. The basal cell 
layer is absent. The nuclei of the tumour cells are 
large, vacuolated and contain one or 
more large nucleoli. On the other 
hand, grade 5 tumours lack glandular differentiation 
with tumour cells infiltrating the stroma as nest 
of cells (Figure 1.7). Because CaP is 
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markedly heterogeneous in nature, two grades are used to describe an individual 
tumour, with primary grade for the dominant pattern and a secondary grade for the 
second commonest pattern. The primary and secondary grades are added to obtain the 
Gleason sum score. In tumours that are homogeneous, the primary and the secondary 
grades are the same and can be added up to give the Gleason score. The most well 
differentiated tumour has a Gleason score of 2 and the least differentiated tumours are 
score 10. The low grade tumours progress slowly and high grade tumours grow 
rapidly. 
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Figure 1.7. Histological features of prostate cancer with Gleason patterns (single 
grades) from 2-5. 
In Gleason grade 2, the cancer glands are slightly variable in size, shape and spacing. 
The glands spread though the surrounding stroma. Gleason grade 3 is the most 
detected pattern. The malignant glands are variable in size, shape and spacing. The 
glands are discrete and infiltrate the stroma. The most distinguishable feature of 
Gleason grade 4 is fused glands. The glands are no longer recognised as individual 
units. The tumours in Gleason grade 5 grow as solid sheets with loss of gland features 
(http: //prostate-help. org/cagleas. htm). 
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1.1.3.3.3 Pathological staging 
Clinical staging of prostate cancer is the assessment of tumour size and location and is 
important in determining the appropriate form of cancer therapy. Currently, there are 
two different staging systems for prostate cancer: ABCD (Whitmore-J. Wett) system 
(Whitmore, 1984) and the tumour nodes metastasis (TNM) system (Schroder et al., 
1992) (Table 1.1). The TNM staging system is now more widely used and describes 
the tumour size (T) and whether the cancer has spread to lymph node (N) or 
metastasised to distant sites. Tumour size is assessed on the scale of 1-4. Generally, 
Ti tumour is confined to the prostate gland and so small that it cannot be detected by 
either DRE or ultrasound. T2 lesions are localised in the prostate and are detectable by 
DRE and TRUP. T3 and T4 prostate cancers have spread beyond the prostate into 
adjacent organs such as bladder, seminal vesicles and pelvic side wall. Involvement of 
prostate cancer in the lymph nodes is graded on the scale NO-N3. NO means that the 
tumour has not spread to the lymph node. The number and the size of lymph nodes 
involved indicate whether the cancer is N1, N2 or N3. Metastasis to different organs 
is rated 0 or 1. MO means no metastasis has occurred and M1 means metastasis has 
been detected at a distant location. 
Whitmore-J Wet 
No tumour palpable 
Al 
A2 
Intracapsular 
BI 
B2 
B3 
Extra capsular tumour 
C1 
C2 
Disseminated tumour 
D1 
D2 
D3 
TNM-1992 
TO 
Ti 
Tla 
Tlb 
Tic 
palpable tumour 
T2a 
T2b 
T2c 
T3a 
T3b 
T3c 
T4 
Nx 
NO 
NI 
N2 
Mx 
MO 
MI 
a= 
b= 
c= 
Description 
No local tumour detectable. 
Local tumour cannot be evaluated. 
Tumour found in <5% of excised tissue. 
Tumour found in >5% of excised tissue. 
Tumour confirmed by needle biopsy. 
Tumour limited to half of 1 lobe or less. 
Tumour has spread to half of 1 lobe but not both. 
Tumour has spread to both lobes. 
Unilateral extra capsular spread. 
Bilateral extra-capsular spread. 
Tumour has spread to one or both seminal vesicles. 
Tumour has invaded adjacent structure other than seminal 
vesicles. 
loco-regional lymph nodes can't be evaluated. 
No lymph node involvement. 
Metastasis in I node, <2 cm. 
One node only >2 cm or <=5 cm; multiple <=5 cm. 
Distant metastases cannot be evaluated. 
No distant metastasis. 
Distant metastasis present. 
Lymph node on the other than regional one. 
Skeletal. 
Other sites. 
Resistant to hormone therapy. 
Table 1.1. TNM staging system for prostate cancer 
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1.1.3.3.4 Treatment 
Treatment of prostate cancer depends on the disease stage, Gleason score, age of the 
patient and PSA level. Several different methods are available to treat CaP, including 
watchful waiting, surgery (prostatectomy and orchidectomy), radiotherapy and 
endocrine therapy. Localized prostate cancer that has not spread to adjacent organs 
can be treated by surgical removal of the entire prostate (radical prostatectomy) or 
radiotherapy using high energy source of X-ray. Another option is watchful waiting, 
alternatively called observation or surveillance. The patient receives no active 
treatment unless symptoms appear or the disease progression is suggested by serial 
PSA or DRE. Endocrine therapy is the mainstay for treatment of advanced and/or 
metastatic disease. Androgen deprivation can be achieved by surgical castration 
(orchidectomy) or medical castration by administration of oestrogens or synthetic 
agonists of luteinizing hormone-releasing hormone. Oestrogen inhibits testicular 
androgen synthesis directly by suppression of pituitary luteinizing hormone secretion 
which in turn causes the reduction of testicular release of testosterone. Steroidal anti- 
androgens and 5 a-reductase inhibitors are other available treatment options. 
1.1.3.3.5 Aetiology of prostate cancer 
The cause(s) of CaP are not known. However, several risk factors are associated with 
CaP such as age, race, family history, environmental factors and hormone levels 
(Chan et al., 1998a). Age is a strong risk factor contributing to prostate cancer. The 
incidence of prostate cancer increases with age more than any other cancers. It is 
common among men between the age of 50 and 70 years. This trend can be explained 
by accumulation of genetic changes with age (Chan et al., 1998b). Positive 
associations between CaP and dietary intake of animal fat, red meat and dairy 
products have been reported (Kolonel, 1996). It has been suggested that dietary fat 
intake influences the levels of hormones such as testosterone, which in turn affect the 
growth of prostate. Race is one of the well established risk factor for CaP. In USA, the 
disease is 66% more common and twice as likely to be fatal among African-American 
than Caucasian. Japanese and Chinese men have lower rates of CaP (Giovannucci, 
2001). 
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Familial predisposition to development of prostate cancer has been observed since 
1956 (Gonzalgo and Isaacs, 2003). Men with a first degree relatives affected by 
prostate cancer are at higher risk of developing the disease than those without such a 
family history. Familial prostate cancer studies have found that patients have 3 fold 
excess risk of developing CaP if their first or second degree relatives have CaP. The 
risk tends to increase with increased numbers of relatives with CaP (Carter et al., 
1992) and inherited CaP tends to develop at an earlier age compared to sporadic CaP 
(Bova et al., 1998). A cohort twin study of CaP risk among 44,788 pair from Sweden, 
Denmark and Finland has indicated that more than 40% of CaP cases were attributed 
to inheritance and that highly penetrant susceptibility genes account for only 10% of 
CaP cases (Lichtenstein et al., 2000). Hereditary CaP does not differ clinically from 
disease that arises sporadically. Genome wide linkage analysis in familial prostate 
cancer cases has led to identification of CaP susceptibility loci. So far, seven 
susceptibility loci associated with prostate cancer have been identified. This suggests 
that the predisposition factors to prostate cancer are heterogeneous and may involve 
multiple genes and variable phenotypic expression. Three susceptibility loci on 
chromosome 1 have been identified; l q24-25 hereditary prostate cancer 1 (HPC 1) 
(Smith et al., 1996); l q42.2-43, predisposing for prostate cancer (PCaP) (Berthon et 
al., 1998) and l q36; cancer of prostate and brain (CaPB) (Gibbs et al., 1999). Other 
loci have been identified on chromosome 16 (16q23.2) (Suarez et al., 2000), 
chromosome 17 (17p or, hereditary prostate cancer 2, HPC2) (Tavtigian et al., 2001), 
chromosome 20 (20q13 or HPC20) (Berry et al., 2000) and chromosome X (xq27-28 
or HPCX) (Xu et al., 1998). Putative susceptibility genes in these regions have rarely 
been identified. Demonstrating linkage of currently known candidate genes have 
proven problematic (Simard et al., 2002). 
The familiar clustering may also occur because of polymorphism in genes that are 
important for prostate development and function. Polymorphism involving genes 
coding for AR and 5 a-reductase type II (SRD5A2) 
have been associated with 
increased risk of developing CaP. Different allele length of repetitive elements or 
substitution polymorphism can modulate susceptibility 
to CaP. AR gene is located on 
chromosome Xg11.2. The gene product 
is composed of three domains, N-terminus 
(transactivation) domain, DNA binding domain (DBD) and C-terminus 
(ligand 
binding) domain. The transactivation domain encoded by exon 1 
has nucleotide repeat 
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variants (CAG) with different transcriptional activities. The CAG sequence varies in 
length from 11-31 repeats in healthy men. There is an inverse relationship between 
the number of CAG repeats and the transcriptional activity of AR. Differences in 
prostate cancer risk among different ethnic groups may be related to polymorphic 
variability of the AR gene CAG repeats. Interestingly, Black American men have the 
highest CaP incidence and mortality rates in USA and they are also found to have 
shorter CAG repeat length in AR compared to other ethnic groups (Chang et al., 2002). 
SRD5A2 gene is another polymorphic gene mapped to chromosome 2 locus. 
Substitution polymorphisms in SRD5A2 gene, A49T and V89L have been reported to 
confer increased risk of CaP. These genetic polymorphisms may affect the catalytic 
activity of the enzyme, thus increasing the likelihood of neoplastic transformation. 
(Makridakis et al., 1999, Nam et al., 2001). 
Several supporting evidences indicate that sex hormones can initiate or promote 
development of CaP (Wilding, 1995). Growth and maintenance of the normal prostate 
epithelium depend on both circulating testosterone and its conversion to DHT within 
the prostate. Prolonged administration of high levels of testosterone induces prostate 
cancer in rats (Noble, 1977). Androgen removal induces tumour regression. Men who 
underwent castration before puberty and those with congenital abnormalities in 
androgen metabolism do not develop prostate cancer (Haas and Sakr, 1997). Studies 
have demonstrated that high circulating levels of testosterone, low oestrogen levels 
and low levels of sex hormones binding globulin (SHBG) may increase the risk of 
developing CaP (Gann et al., 1996). SHBG binds to circulating testosterone thereby 
decreasing its bioavailability. 
Other risk factors such as vasectomy, sexual activity, smoking, alcohol consumption, 
physical activities and social class have not been reliably shown to affect prostate 
cancer risk. 
1.1.4 Prostate carcinogenesis 
Prostate cancer development (carcinogenesis or tumourigenesis) as for other types of 
cancer is a multi-step process that is caused by multiple genetic and epigenetic 
alterations in genes involved in the regulation of diverse cellular biological processes 
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including proliferation, division, apoptosis, differentiation, senescence, DNA repair, 
invasion, metastasis, motility and adhesion. Transformation of normal cells into 
malignant derivates requires cellular acquisition of six capabilities; self-sufficiency in 
growth signals, insensitivity to growth inhibitory signals, evasion of programmed cell 
death, limitless replication potential, sustained angiogenesis and tissue invasion and 
metastasis (Hanahan and Weinberg, 2000). Several lines of evidences support the 
cancer multi-step process. Histopathological analyses of a number of human cancers 
in different organs have revealed multiple stages of tumour development such as 
dysplasia and carcinoma in situ (Foulds, 1958) and some of these lesions appear to 
represent an intermediate step in a process through which cells evolve progressively 
from a normal state via a series of pre-malignant lesions into invasive cancer. Hence, 
accumulation of genetic changes during the multi-step process confers progressive 
growth advantages that result in invasive cancer (Nowell, 1976). In the initial stages 
of prostate cancer, the tumour is localised within the prostate capsule and as it 
acquires more aggressive characteristics, the cancer advances locally and invades 
adjacent structures including the seminal vesicles, followed by distant metastasis 
(mainly affecting bone). This transition to metastasis is followed by a shift from 
androgen dependence to androgen independence, which is induced by androgen 
deprivation therapy (Figure 1.8). 
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Figure 1.8. Prostate carcinogenesis model 
Prostate cancer development and progression. PIN is considered to be the earliest 
precursor for prostate cancer formation. In the initial stages of 
CaP, the tumour is 
localised within the prostate. Upon acquiring further genetic alterations, the tumours 
invade adjacent organs and metastasise to distant sites. The transition to metastasis 
is 
followed by shift from androgen dependent to androgen independent. 
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1.1.5 Chromosomal, genetic and epigenetic changes in CaP 
Accumulation of multiple chromosomal genetic and epigenetic alterations are 
associated with prostate cancer development. Chromosomal aberrations that are 
frequently linked to CaP are ploidy, aneuploidy, duplication or deletion of whole or 
part of chromosome. The chromosomal regions most commonly lost in prostate 
cancer are 6q, 8p, l0q, 13q, 16q and 18q (DeMarzo et al., 2003, Elo and Visakorpi, 
2001, Zenklusen et al., 1994)(Table 1.2 and Table 1.3). Chromosomal gains at 7p, 7q, 
8q and Xq are common changes linked to hormone-refractory and metastatic prostate 
cancer (Alcaraz et al., 1994). 
Chromosomal loss 
8p 
6q 
7q 
9p 
10q 
12p 
13q 
16q 
17p 
18q 
Y loss 
Chromosomal gain 
8q 
7 gain 
X gain 
lip 
199 
3q 
2p 
Y gain 
Table 1.2. Chromosomal alterations associated with prostate carcinogenesis 
Chromosomal abnormalities that are frequently linked to prostate cancer development 
(Ozen and Pathak, 2000). 
Epigenetic events can affect gene expression without altering DNA sequence and this 
may occur through DNA methylation. Many gene promoters harbour CpG rich region 
of DNA knowing as CpG islands. Abnormal methylations of CpG islands located 
within gene promoters are associated with suppressed transcription activity and have 
been implicated in many of tumour types (Jones, 2002). Gene prometers that have 
been found to be methylated in CaP are glutathione S-transferase protein (GTS), RAS 
associated domain family protein 1 isoform A (RASSFIA), ENDRB encoding 
endothelin receptor type B (Nelson et al., 1997) and CD44, a cell adhesion molecule 
(Lou et al., 1999). 
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Chromosome Locus 
Chromosome I 
Chromosome 3 
Gene Function Mechanism of activation and inactivation 
1g24-25 HPCI(RNAseL) RNAseL inhibitor 
3p21 RASSFI A Tumour suppressor gene 
Chromosome 4 4q26-27 bFGF Growth 
Chromosome 5 
4q25 EGF Growth 
5p13 AMACR 
Chromosome 6 
6q loss 6g15-22 
6q23-24 BMP6 induces cell growth 
6p 
Chromosome 7 
7 aneousomy 
Chromosome 8 
8p loss 
6p12 VEGF Angiogenesis 
7g2l-15 
7g21 
7g31 
Mutation 
Hypermethylation 
Over-expression 
Over-expression 
Lipid metabolism Over-expression 
Over-expressed 
Over-expression 
MET Tyrosine kinase receptor Over-expression 
Caveolin I Metastatic suppressor gene Hypermethylationa 
8p2l NKX3.1 Transcription factor Deletion 
8p22 FEZI Tumour suppressor gene Mutations 
MSRI Macrophage scavenger receptor Mutations 
8q gain 8g21 
8q23-4 C-MYC Nuclear transcription factor Amplification 
EIF3S3 Translation initiation factor Amplification and over-expression 
PSCA Prostate stem cell antigen overexpresed 
Chromosome 9 9g21 P16 Cell cycle regulator 
lOp KLF6 Cell proliferation 
Chromosome 10 
I Oq loss IOg23-24 PTEN Lipid phosphatase Mutations 
I Og24 MX[-1 Transcriptional repressor Mutations 
10g26 FGF8 Growth Over-expressed 
lop 
l lpl I KAII Metastatic suppressor gene uown regwareu 
11p13 CD44 Cell adhesion molecules Hypermethylated 
12g12-13 P27 Cell cycle regulator Hypermethlyation and deletion 
12g22-23 EGF-I Growth Over-expression 
Chromosome 11 
Epigenetic l lgl3 GSTPI Detoxifying enzyme Hypermethylated 
Chromosome 12 
Chromosome 13 
13q loss 13g14 RBI Tumour suppressor gene Hypermethylation and 
deletion 
13g21-22 EDNRB Endothelin receptor type B Hypermethylated 
13q33 
13g12.3 BRCA2 Transcription factor Mutation 
Chromosome 16 
16q loss 1622.1 E-cadherin Adhesion molecule 
16g23-24 
lip TSPY 
Chromosome 17 
17q loss 17g21 BRCA1 Transcription regulator 
Mutation 
17p11 2 HPC2 Prostate cancer susceptibility gene 
Mutations 
P53 Nuclear transcription factor Mutations 
Chromosome 18 18g21 BcI-2 Apoptosis 
Chromosome 19 19g13.2 TGF-ß Growth regulator 
Chromosome X 
X812-13 gain Xg12-13 AR 
Transcription factor 
Chromosome Y 
Deletion and hypermethylation 
Mutation 
Hyeprmethylation 
Over-expression 
Over-expressed 
Over-expressed 
Amplification 
Mutations 
Growth regulator over-expressed 
Table 1.3. Chromosomal loci linked to prostate cancer. 
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1.1.6 Genes associated with CaP 
Cellular transformation from normal to malignant phenotype is caused by an 
accumulation of somatic and inherited genetic changes in two major classes of 
cellular genes: dominantly acting growth inducing proto-oncogenes and growth 
inhibitor tumour suppressor genes (TSGs). Proto-oncogenes are defined as a family of 
genes that under normal circumstances encode for proteins that critically regulate 
cellular growth. When they are mutated or activated, they can promote carcinogenesis 
(Stedman, 2000). Mechanisms of oncogene activation include activating mutations 
that cause constitutive functional protein product (e. g., RAS), gene deletion resulting 
in a truncated protein that is constantly active (e. g., truncated tyrosine kinase receptor 
lacking ligand binding domain), abnormal over-expression of oncogene transcript or 
protein due to gene amplification or gene translocation to hyperactive genomic loci. 
Proto-oncogenes usually regulate broad biological processes such as growth factor 
receptor signalling, intracellular signal transduction and transcription. The oncogenes 
are relatively easy identified by their ability to transform immortalised cells such as 
the mouse NIH3T3 cell line to grow in soft agar, loss of contact inhibition, serum 
independent growth and in vivo tumour formation (Mitchell, 1991). 
Anti-oncogenes, more commonly called tumour suppressor genes (TSGs), promotes 
multiple physiological functions and suppress cellular transformation. There is no 
distinct definition of TSGs, but they share common characteristics; inactivation 
mutation and/or inherited mutation contribute towards carcinogenesis while normal 
functional TSG suppresses in vitro cellular growth (Haber and Harlow, 1997). 
Evidence of existence of TSGs arise from somatic cell hybridization which showed 
that fusion of tumour cells with normal cell results in non-tumuorigenic hybrids 
(Sager, 1988). This indicates that tumour cells have acquired genetic sequence(s) that 
are capable of suppressing neoplastic phenotype. A second clue was provided by 
Knudson's work (Knudson, 1971). He proposed the two hits theory: in familial cancer, 
a germline mutation of one allele is inherited and a second mutation is acquired via 
somatic mutation. In sporadic cancer, both alleles are required to be somatically 
mutated. Loss of TSG function can result from inactivating point mutation, gene 
deletion, loss of expression due to promoter hyper-methylation and insufficient level 
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of gene product caused by presence of only one functional copy of TSG 
(haploinsufficiency). 
In addition to oncogenes and TSGs, other classes of genes are found to play roles in 
prostate carcinogenesis including DNA repair gene, telomerase, angiogenic genes, 
detoxification genes and metastasis suppressor genes (adhesion molecules) (Table 
1.4). 
Genes associated with CaP 
Ki-67 
PCNA 
Cyclin dependent kinase inhibitors 
P27 
P16 
P21 
Tumour suppressor genes 
RBI 
P53 
PTEN 
NKX3.1 
Apoptosis 
Bcl-2 
Angiogenesis 
Hif-I 
D31, CD34 
VEGF 
Adhesion 
E-cadherin 
CD44 
PSCA 
PSMA 
a-catenine 
C-CAM 
Ep-CAM 
Cyclooxygenases 
COX-2 
Oncogenes 
C-MYC 
ERBB2/ HER-2/Neu 
Metastasis suppressor genes 
KAI 
Nm23 
Immortalization 
Telomerase 
Growth factors 
FGF, a, ßand8 
TGF-a 
KGF 
TGF-ßl 
BMP-6 
Growth factor receptor 
EGF-R 
P 180-C-ErbB3/C-erb-3 
C-met 
Prolactin receptor 
Growth factor binding proteins 
IGFBP-2 
IGFBP-3 
Nuclear receptors 
AR 
Estrogen receptor-ß 
Carcinogen detoxification 
GSTP1 
Intermediate filaments 
Cytokeratin 5,14 
Table 1.4. Genes involved in prostate cancer development. 
Genes that are linked to prostate cancer development. They play 
diverse roles in 
normal cellular processes and their alterations 
lead to carcinogenesis (Nelson et al., 
2001 b). 
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1.1.6.1 Role of oncogenes in CaP 
Amplification and over-expression of several oncogenes have been found to be 
associated with CaP including growth factors, C-myc, EIF3S3 and MET1. Several 
growth factor families have been implicated in normal prostate growth and in prostate 
carcinogenesis. In general, growth factors regulate diverse cellular processes, 
including proliferation, motility, differentiation and apoptosis. The main growth factor 
families involved in the prostate are Insulin Growth Factor (IGF) family, Epidermal 
Growth Factor (EGF), Transforming Growth Factor-a (TGF-a), Fibroblast Growth 
Factor (FGF) family and Vascular Endothelial Growth Factors (VEGF). These growth 
signalling systems can exert inhibitory and inductive influence on prostate growth, in 
paracrine and /or autocrine manner affecting stromal and epithelial cells. 
The family of Fibroblast Growth Factors (FGF) consists of structurally related 
peptides (Benharroch and Birnbaum, 1990). bFGF gene located on 4q26-27 and KGF 
located on 15g15-g21.1 are members of FGF family. These peptide growth factors 
ligand bind to FGF receptors (1-4) (Partanen et al., 1991) and exert their cellular 
function and play a role in normal and malignant prostate development (Hellawell and 
Brewster, 2002). Elevated levels of bFGF have been reported in prostate cancer 
(Cronauer et al., 1997). FGF8, alternatively referred to as androgen induced growth 
factor, is another member of FGF family located at 10g24 and has been found to be 
over-expressed in prostate cancer (Leung et al., 1996). FGF8 increased expression 
correlated with increased Gleason score and pathological stage of CaP (Dorkin et al., 
1999). Other members of growth factor family are Epidermal Growth Factor (EGF) 
and Transforming Growth Factor- a (TGF- a). EGF and TGF- a are structurally 
similar and bind to EGFR and modulate its function (Carpenter and Cohen, 1979, 
Ullrich et al., 1984). EGF is located at 4q25. Over-expression of EGF, TGF-a and 
EGFR have been detected in prostate cancer (Morris and Dodd, 1990, Turkeri et al., 
1994, Yang et al., 1993). 
ERBB2 (HER-2/neu) is another oncogene and a member of the epidermal growth 
factor receptor (EGFRs) family located at 17q1 1.2-q 12. 
Neu is a tyrosine kinase 
receptor that has been found to activate androgen receptor signalling pathways 
in the 
presence of low levels of androgens 
(Craft et al., 1999, Yeh et al., 1999). This 
implicates ERBB2 as potentially important in the development of androgen- 
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independent prostate cancer. Furthermore, ERBB2 is over-expressed in prostate 
cancer (Gu et al., 1996, Myers et al., 1994, Signoretti et al., 2000) and the expression 
level correlates with advanced disease stages and high Gleason scores (Sadasivan et 
al., 1993). Amplification of ERBB2 gene has also been reported in prostate cancer 
(Ross et al., 1997). 
Other oncogenes linked to CaP are Insulin Growth Factor I and II. They are another 
member of growth families. IGF I and II exert their effects by binding to their 
receptors to modulating cellular growth, division, adhesion, motility and apoptosis 
(Macaulay, 1992). Regional loss of imprinting of the IGF-II gene has been observed 
in prostate cancer (Jarrard et al., 1995). A link between high plasma IGF-I level and 
high risk of developing prostate cancer has been observed (Chan et al., 1998a, Wolk 
et al., 1998). Up-regulation of IGF1R level has been reported in resected prostate 
tumour (Kurek et al., 2000). 
TGF-(3 is a superfamily of proteins that contains 5 isoforms (TGFI3 1-5) (Derynck et 
al., 1985). The gene is located at 19g13.2. These ligands bind to 3 different receptors, 
T(3R1, T(3RII and Tf3RIII. TGF-(3 plays an important role in regulating prostate 
cellular growth and can inhibit cellular proliferation as well as induce apoptosis in 
prostate epithelial cells (Martikainen et al., 1990). Loss of both TßR I and Tf3RII 
receptors correlates with prostate tumour stage, survival and recurrence rate (Kim et 
al., 1998). Bone morphogenic proteins (BMPs) are secreted signalling molecules that 
are member of TGF-ß superfamily. BMPs represent almost one third of the TGF-ß 
superfamily with more than 30 members already described (Ducy and Karsenty, 
2000). They play a role in regulating cellular function including proliferation, 
differentiation, apoptosis, morphogenesis and organogenesis (Graff, 1997). One 
member of BMP family, BMP-6 gene, located at 6p23-24, has been found to be 
implicated in prostate cancer metastasis to the bone. BMP-6 over-expression appears 
to be restricted to tumours showing evidence of bony metastasis with no expression 
detected in organ confined prostate cancer. BMP-6 expression also correlates with 
increased recurrence states and decreased survival 
(Thomas and Hamdy, 2000). 
Other member of the growth family is Vascular 
Endothelial Growth Factor (VEGF). 
VEGF is a glycoprotein located on 6p12 and exists 
in at least 5 isoforms (Ferrara and 
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Davis-Smyth, 1997). They mediate their effects via tyrosine kinase receptors located 
in the cytoplasmic membrane of endothelial cells. VEGF plays a role in prostate 
growth and deregulated expression can induce angiogenesis and permit tumour 
growth. Increased VEGF expression has been reported to correlate with increased 
stage and Gleason score in CaP (Jackson et al., 1997, West et al., 2001). 
One of the frequently genetically altered oncogene in CaP is C-MYC. The gene 
encodes a transcription factor that plays a significant role in regulating various 
cellular processes such as growth, proliferation, differentiation and apoptosis. The c- 
MYC oncogene is located at chromosomal band 8q24 which is one of the most 
frequently amplified regions in advanced prostate cancer (Elo and Visakorpi, 2001). 
C-MYC gene has been found to be amplified in 8% of primary prostate carcinoma 
and in 11-35% of advanced prostate tumours (Bubendorf et al., 1999, Jenkins et al., 
1997, Nupponen et al., 1998, Reiter et al., 2000). Amplification of MYC gene has 
been shown to correlate with over-expression of C-MYC gene product as well as 
tumour grade and poor prognosis (Sato et al., 1999). In vitro and in vivo functional 
studies of c-MYC have demonstrated that abnormal MCY expression can contribute 
to prostate cancer. In vitro knock out of c-MYC by anti-sense technique causes anti- 
proliferative effect in prostate cancer cell lines (Balaji et al., 1997). Transgenic mice 
over expressing c-MYC develop prostate epithelial abnormalities similar to 
low-grade 
PIN lesions in human (Zhang et al., 2000). 
Another oncogene that inhibits apoptosis and has been implicated 
in CaP is Bcl-2. 
The gene is located at 18g21.3 and encodes an integral outer mitochondrial membrane 
protein. Bcl-2 is expressed only in basal cells 
in normal prostate epithelium 
(McDonnell et al., 1992). High level expression of Bcl-2 
has been detected in prostate 
cancer especially after androgen withdrawal and 
in hormone-refractory tumours 
(McDonnell et al., 1997, Stattin et al., 1996). 
It has been demonstrated that Bcl-2 
protects prostate cells against apoptosis and 
increases their tumourigenicity (Raffo et 
al., 1995). Inhibition of Bcl-2 expression 
has been found to trigger apoptosis in 
prostate cancer cells (Dorai et al., 
1999) and delay the progression of hormone- 
refractory tumour after castration 
in the xenograft mouse model (Miyake et al., 1999). 
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Other putative candidate oncogenes that is found to be linked to CaP are EIF3S3 and 
MET. EIF3S3 is a subunit of a translation initiation factor eIF3. EIF3S3 is located at 
8q23 and is amplified in 30% of hormone-refractory prostate cancers and in 50% of 
metastatic lesions. EIF3S3 amplification has been shown to be associated with high 
Gleason score (Saramaki et al., 2001). MET is located at chromosome 7 (7g31) and 
encodes a tyrosine kinase receptor for hepatocyte growth factor (HGF). MET over- 
expression at protein and mRNA levels have been detected in high grade tumours and 
metastases (Humphrey et al., 1995, Knudsen et al., 2002, Pisters et al., 1995). 
1.1.6.2 Role of TSGs in CaP 
Loss of functions of several tumour suppressor genes have been detected in CaP. Ras 
Associated Domain Family Protein 
, 
Isoform A (RASSFIA) is a candidate TSG 
located on chromosome 3p21. LOH of this region and silencing of the remaining 
RAS SF 1A allele is a frequent event in prostate tumourigenesis. The RASSF 1A 
promoter is hypomethylated in normal prostate tissue, whereas RAS SF 1A 
hypermethylation has been reported to occur in 60-70% of CaP (Kuzmin et al., 2002). 
RAS S1 FA methylation is more frequent in high grade prostate cancer (Liu et al., 
2002). The gene is a candidate tumour suppressor gene and has been found to induce 
cell cycle arrest (Mathe, 2004). 
NKX3.1 is a putative prostate specific tumour suppressor gene located on 8p2 and 
encodes a prostate specific homobox protein essential for normal development of 
prostate (Sciavolino et al., 1997). NKX3.1 gene product binds DNA and represses 
expression of PSA gene (Chen et al., 2002). Neither mutations nor loss of expression 
of NKX3.1 have been detected in CaP (Voeller et al., 1997, Xu et al., 2000). In 
animal models, NKX3.1 expression is detected in early stages of murine prostate 
development as well as in all subsequent stages of prostate epithelial 
differentiation. 
NKX3.1 knock-out mice have defects in prostate ductal morphogenesis and secretory 
protein production. PIN and dysplasia were also 
detected and increased in severity 
with age (Bhatia-Gaur et al., 1999). 
Conditional loss of NKX3.1 in adult mice has 
been shown to induce PIN lesions, thus supporting 
the role of NKX3.1 in prostate 
carcinogenesis (Abdulkadir et al., 
2002).. 
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PTEN (phosphatase and tensin homologue) is another tumour suppressor gene located 
on chromosome 10g23. PTEN encodes 403 as protein that shows homology to the 
protein tyrosine phosphatase family and to two cytoskeleton proteins, tensin and 
auxilin. The gene product has phosphatase activity for proteins and lipids. PTEN can 
regulate G2 cell cycle arrest via negative regulation of PI3K-Atk signalling pathway 
and is frequently mutated and deleted in prostate cancer cell lines and tumours (Li et 
al., 1997, Ramaswamy et al., 1999). Loss of PTEN expression correlates with high 
Gleason score and advanced stage (McMenamin et al., 1999). In the PTEN knockout 
mice model, PTEN heterozygous (+/-) mice develop PIN in 50% of cases indicating 
that haploinsufficiency of PTEN prostate carcinogenesis (Kwabi-Addo et al., 2001). 
Another putative tumour suppressor gene is Kruppel like factor 6 (KLF6), located on 
chromosome l Op 15 and encodes a Zinc finger transcription factor that has been 
implicated in CaP carcinogenesis. Approximately, 77% LOH has been detected in 
primary prostate tumours. KLF9 expression in culture cells decreased cell 
proliferation and increased p21 expression (Narla et al., 2001). 
The tumour suppressor gene CDKN 1B is located on chromosome 12p 12, a region 
frequently deleted in advanced CaP (Kibel et al., 1998). The gene encodes for a cyclin 
dependent kinase inhibitor. The p27 protein regulates cell cycle progression from G1 
to S phase via inhibition of the cyclin E/cdk2 complex. P27 inactivation occur through 
aberrant phosphorylation and/or ubiquitination resulting in loss of expression or 
altered sub-cellular localisation (Loda et al., 1997). Decreased expression of P27 is 
common in early prostate cancer and is associated with increased risk of disease 
recurrence in patients following radical prostatectomy (Cote et al., 1998). P27 
expression level is affected by PTEN, which negatively regulates PI3K-Akt signalling 
pathway (Graff et al., 2000). Thus, decreased levels of p27 can be a consequence of 
PTEN loss. 
The RB 1 tumour suppressor gene is located on chromosome 13q. Loss of this region 
occurs in at least 50% of prostate cancers (Cooney et al., 1996, Melamed et al., 1997). 
Mutation of Rb 1 gene and loss of expression have been reported in clinically localised 
as well as more advanced prostate carcinoma (Bookstein et al., 1990, Cunningham et 
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al., 1996). RB1 encodes a nuclear phosphoprotein that plays a key role in negative 
regulation of cell proliferation during G-S phase transition (Weinberg, 1995). 
Another cell cycle regulator is P16 TSG located at 9g21. Most studies have reported 
that p16 is rarely mutated in primary prostate carcinoma, but mutated in advanced 
metastatic disease (Chen et al., 1996, Tamimi et al., 1996). It has been suggested that 
in primary tumour, inactivation of p 16 may occur by deletion of one allele, combined 
with promoter methylation of the remaining allele (Jarrard et al., 1997). 
P53 tumour suppressor gene located on 17pl3.1, is involved in regulating multiple 
cellular biological processes. Loss of 17p has been detected in 50% of metastatic 
prostate cancers and 65% of androgen refractory cancers (Cher et al., 1994, Saric et 
al., 1999). Mutations in P53 occur infrequently in early invasive carcinoma (Voeller 
et al., 1994). In contrast, p53 mutations are detected in advanced stage of CaP as well 
as recurrent metastasis disease (Bookstein et al., 1993, Eastham et al., 1995). P53 
encodes 53KDa nuclear phosphoprotein that regulates the cell cycle and induces 
growth arrest at the G-S 1 phase (Vogelstein and Kinzler, 1992). In addition, the gene 
regulates differentiation, senescence and maintains genomic stability (Aloni-Grinstein 
et al., 1995, Atadja et al., 1995). 
1.1.6.3 Other genes 
In addition to the role of oncogenes and tumour suppressor genes 
in prostate 
carcinogenesis, other genes that regulate normal cellular processes such as adhesion, 
detoxification and maintaining telomeres length have been implicated in CaP. 
Several 
genes involved in invasion and metastasis of cancerous cells 
have been characterised 
and are called metastasis suppressor genes. These genes 
do not affect the cell growth 
of primary tumour, but can inhibit development of 
distant metastasis. E-cadherin 
metastasis tumour suppressor gene is a member of 
the Cadherin transmembrane 
protein family that regulates cell adhesion 
(Hajra and Fearon, 2002). Although no 
mutations have been detected in E-cadherin gene so 
far (Otto et al., 1993, Umbas et 
al., 1994, Umbas et al., 1992), 
decreased expression of E-cadherin was detected in 
prostate cancer and it is associated with 
high grade disease (Umbas et al., 1994). 
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Furthermore, E-cadherin has been shown to play a role in the suppression of invasion 
and metastasis of prostate cancer (Bryden et al., 2002). Other member of the cadherin 
signalling pathway such as a-catenin are also found to be altered in CaP. DC44 is 
another metastatic tumour suppressor gene and is down-regulated in high grade and 
metastatic prostate cancer (Gao et al., 1997). 
Another gene that has been frequently found to be altered in CaP is Glutathione-S- 
Transferase isoform Pi (GSTP 1). The gene belongs to a super-family of enzymes 
responsible for detoxifying environmental electrophilic carcinogens and oxidants, 
preventing oxidant and electrophilic DNA damage which may cause mutations 
(Nelson et al., 2001 a). The gene is located at 11 q 13. In normal prostate epithelium, 
GSTP 1 is expressed in basal cells but not in the columnar secretory cells. 
Hypermethylation of the regulatory region of GSTP 1 locus is the most common 
somatic genetic alteration reported in prostate cancer and represents an early event in 
neoplastic transformation. GSTP 1 methylation occurs in approximately 70% of PIN 
lesions and in more than 90% of prostate carcinomas, but not in normal or BPH 
tissues (Lee et al., 1994). 
Telomere sequences located at the tips of chromosomes contain hundreds of tandem 
sequences of which 50-200 nucleotides are shortened at each cell division. In contrast, 
cancer cells do not show loss of telomere length during cell division. Telomerase is a 
ribonucleoprotein enzyme that functions to maintain the telomere length. The protein 
consists of two components: an RNA moiety encoded by gene located at 3q26 and a 
catalytic subunit (TERT, reverse transcriptase) located at 5pl5.33. Telomerase is 
associated with cellular immortalization and cancer. In normal cells the activity of 
telomerase is barely detectable. However, malignant tumour cells often have 
detectable activity of telomerase. Telomerase activity has been detected in 84% of 
prostate cancers (Sommerfeld et al., 1996). This suggests that telomerase plays an 
important role in the development of prostate cancer. 
1.1.7 Y chromosome abnormalities in CaP 
Y chromosome abnormalities are one of many cytogenetic abnormalities reported 
in 
human prostate cancers. However, the frequencies of Y chromosomal loss and/or gain 
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vary. Loss of Y chromosome is among one of the most common cytogenetic 
abnormalities detected in prostate cancer (Arps et al., 1993, Brothman et al., 1991, 
Lundgren et al., 1992, Micale et al., 1992, Webb et al., 1996, Zitzelsberger et al., 
1996). Loss of Y chromosome was detected in 10-50% of prostate cancers (Alers et 
al., 1998, Alers et al., 1997, Alers et al., 2000, Breitkreuz et al., 1993, Brothman et al., 
1999, Jordan et al. , 2001, Konig et al. , 1996, Lundgren et al. , 1992, Takahashi et al. , 
1996, Zitzelsberger et al., 1996). Interestingly, loss of Y chromosome was detected in 
89% of hormone-refractory prostate cancers (Haapala et al., 2001) and Y aneuosomy 
was closely associated with metastatic prostate cancer (Takahashi et al., 1996). Y 
chromosome gain has been detected in 5-30% of prostate cancer (Baretton et al., 1994, 
Brothman, 1997, Brothman et al., 1999, Brown et al., 1994, Cher et al., 1994, Konig 
et al., 1996, Qian et al., 1997, Visakorpi et al., 1994) and is also associated with poor 
prognosis and less favourable survival outcome (Takahashi et al., 1996). 
1.1.7.1 The Structure of Y chromosome 
The Y chromosome is the smallest chromosome in the human genome. It is 63 mb in 
length and represents only 2-3% of the haploid genome. Early chromosome banding 
studies have identified different regions: pseudoautosomal parts and non-recombining 
region (NRG), also called male specific Y chromosome (MSY). The pseudoautosomal 
regions (PARs) constitute 5% of the total Y chromosome length and are divided into 
two separate distal parts, PART and PAR2. PART is located at the terminal region of 
the short Y chromosome (Yp) arm and is 2.6 Mb in length. PAR2 is located at the tip 
of the long arm (Yq) and is 420 kb in length. The PAR regions on the Y chromosome 
pair and exchange genetic material with the PAR region on the X-chromosome during 
meiosis. PART harbours 10 genes that function in different pathways including bone 
growth, melatonin synthesis, cytokine signalling and cell surface antigens. PAR2 
contains only two genes. 
MYS region constitute 95% of the Y chromosome and is made up of 
heterochromatin 
and euchromatin. Approximately, two thirds of 
MYS region consists of 
heterochromatin. The rest constitutes euchromatin region. The heterochromatin region 
comprises distal Yq. This part of the 
Y chromosome is considered to be genetically 
inert and polymorphic in length 
in different male populations. It is composed of 
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mainly highly repetitive sequences (Quintana-Murci and Fellous, 2001). The 
euchromatin region consists of the short arm of the paracentromeric region, the 
centromere and the paracenteric long arm. The euchromatin region is divided into 3 
classes: X-transposed, X-degenerate and ampliconic. These classes constitute 156 
known transcription units including 78 protein-coding genes which collectively 
encode for 27 distinct proteins. The X-transposed sequences show 99% identity to the 
X chromosome. The X-degenerate sequences are remnants of the ancient autosomes 
from which X and Y chromosome originated. The ampliconic class includes large 
regions (30% of MYS euchromatin) where sequence pairs show greater than 99.9% 
identity which is maintained by frequent non-reciprocal recombination (gene 
conversion) (Rozen et al., 2003, Skaletsky et al., 2003). This region contains nine 
families of genes encoded for Y specific proteins, the copy number of these genes 
ranges from 2 to 35 copies (Hawley, 2003) (Table 1.5). 
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Figure 1.9. Y chromosome structure 
Schematic representation showing the structure of Y-chromosome. The Y 
chromosome is 63 Mb in length and is divided into two pseudoautosomal regions 
(PARI and PAR2) and male specific region (MSY). PARI and PAR 2 region each 
contains 10 genes and 2 genes, respectively. The MSY part consists of Euchromatin 
and heterochromatin regions. Heterochromatin region is inert part. The genes within 
the euchromatin region are categorised into three classes: X-transposed, X- 
degenerated and ampliconic. 
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Chapter 1: General Introduction 
1.1.7.2 Role of Y chromosome in diseases 
Although the Y chromosome harbours limited number of genes, some of these genes 
have been found to be linked to sex determination, fertility and diseases. The human 
SRY gene mapped to the short arm of Y chromosome, in close proximity to the PART 
boundary is responsible for male sex determination (Sinclair et al., 1990). The gene 
consists of one exon, encoding for 204 amino acids protein and contains a conserved 
DNA binding domain (high mobility group, HMP). SRY is required for initiation, 
development and differentiation of testes. The role of Y-chromosome in 
spermatogenesis was suggested by the presence of gross cytogenetic deletions in 
patients with azoospermia (absence of mature spermatozoa in semen fluid). 
Azoospermia loci were postulated in Y chromosome and called AZF (Tiepolo and 
Zuffardi, 1976). Y chromosome play a role in male sex oncogenesis. It has been 
suggested that Y-chromosome harbours both oncogenes and TSGs, one example is the 
gonadoblastoma locus (GBY). Gonadoblastomas are rare gonadal neoplasms that are 
composed of aggregates of germ cells and sex cord elements (Scully, 1970). These 
neoplasms arise within the dysgenetic gonads of individuals who possess Y 
chromosome in their genome (Vergnaud et al., 1986). The disease occurs in 
individuals who are phenotypically female known as sex-reversed females. The 
frequency of occurrence of gonadoblastoma in patients who have gonadal dysgenetic 
and Y chromosome exceeds 30% (lezzoni et al., 1997). In contrast to 46, XY sex- 
reversed females, 45, X females who have dysgenetic gonads do not develop 
gonadoblastoma. Page, postulated the existence of a GBY locus on the Y 
chromosome that predisposes the dysgenetic gonads of XY sex-reversed females to 
develop gonadoblastoma (Page, 1987). GBY candidate gene may act as an oncogene 
only in a dysgenetic gonad, while it may regulate spermatogenesis in the normal testis. 
Using a panel of DNA from sex-reversed and gonadoblastoma patients, the 
GBY 
locus was mapped to the short arm of Y chromosome and on the long arm 
(Disteche 
et al., 1986, Magenis et al., 1984, Petrovic et al., 1992). 
A refined deletion map 
analysing material from gonadoblastoma patients 
localised GBY to a small region in 
the short arm of the Y chromosome (Vollrath et al., 
1992). This GBY critical region 
was estimated to be 1-2 Mb in size; within this, 
TSPY is thought to be the most likely 
candidate gene for GBY. There are multicopies of 
TSPY within the GBY critical 
regions. 
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1.1.8 Role of TSPY in male sex cancers 
In the testes, TSPY transcript expression is detected during testes organogenesis and 
persists throughout adulthood. Immunohistological staining of normal testis for TSPY 
protein confirms its expression primarily in the cytoplasm of spermatogonial cells 
around the basal lamina of seminiferous tubules of the adult testis (Figure 1.10). 
TSPY expression was also detected in the nuclei of a relatively small proportion of 
spermatogonial cells. Hence, it has been hypothesised that TSPY regulates the normal 
proliferation of spermatogonia and marks the entry of the spermatogonia into meiotic 
differentiation. Expression analysis studies have shown that TSPY is over-expressed 
in spermatogonia at early stages of testicular cancer, in carcinoma in situ of the testis 
and as well as in seminomas. These results suggest that TSPY is aberrantly expressed 
in the tumours with germ line origins (Schnieders et al., 1996). Further studies have 
shown that TSPY was also found to be over-expressed in sex-reversed patients with 
gonadoblastoma (Hildenbrand et al., 1999). Recently, TSPY was found to be over- 
expressed in prostate clinical samples compared to BPH. Using in situ mRNA 
hybridization and immunostaining techniques, up-regulated expression of TSPY was 
detected in prostate cancer (Lau et al., 2003). 
Testis 
Seminiferous tubule 
" Spermatozoa 
Sperrnatids 
Sertclü calCs 
Spýrma. tc>cytes 
Spefmatogonia 
Leydig cells 
Figure 1.10. Cross section of testis seminiferous tubules 
Sperms are generated from testicular spermatogonial cells. 
Spermatogonial cells 
divide to generate spermatogonia cells and cells that will 
differentiate to 
spermatocytes that eventually will generate mature sperm 
(Damjanov and McCue, 
1996). 
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1.1.8.1 TSPY Expression Regulation 
Molecular mechanism regulating TSPY expression in not yet known. However, 
several evidences are accumulating indicating several potential genes involved in 
regulating TSPY expression. Indirect evidence has demonstrated that TSPY can be 
potentially expressed in different organs and tissues. A transgenic mouse harbouring 
1.3 Kb of 5' flanking region of human TSPY regulatory gene fused with simian virus 
40 (SV40) large antigen Tag was generated and characterised. The Tag gene product 
under the control of TSPY regulatory region was expressed in variable tissues 
including spleen, seminal vesicle, pituitary gland, adrenal glands as well as testis 
(Tascou et al., 2003). This indicates that the expression of TSPY may not be tissue 
specific. It has been found that TSPY transcript expression was up-regulated upon 
addition of increasing amount of androgen analogue R1881 to androgen receptor 
expressing prostate cancer cell line (LNCaP) that was cultured in medium depleted of 
hormones (Lau and Zhang, 2000). This observation was confirmed by semi- 
quantitative RT-PCR and Northern blot method, supporting a potential role for TSPY 
in regulating prostate growth and carcinogeneis. Recently, Li et al have found out 
that TSPY promoter was among promoter regions bound by C-MYC gene product. 
Thus, this provides evidence that C-MYC can regulate the transcription level of TSPY 
(Li et al., 2003). Epigenetic changes are frequent phenomena that can modulate the 
expression level of transcript through methylation of CpG islands that are common in 
the promoter region of a gene. Hypermethylation of these islands can suppress normal 
transcription of the gene and block its expression. The role of methylation was 
examined in the prostate cell line ND1 by treatment with 5'-aza'3 deoxycytidine (a 
demethylating agent). TSPY expression is normally not detectable in ND I cell line 
and is re-expressed following demethylation treatment. Hence, TSPY expression 
is 
affected by the methylation status of the TSPY promoter (Dasari et al., 
2002). 
1.1.8.2 Genomic TSPY structure 
Testis specific protein Y chromosome encoded 
(TSPY) is a multicopy gene that is 
located on Y chromosome. Each copy 
is embedded in 20 Kb tandem repeat units 
(DYZ5) along the Y chromosome (Manz et al., 
1993). Approximately, 20-40 copies 
of TSPY clustered on the short arm of 
the human chromosome (Yp). Additional 
copies are also present on the 
long arm of the Y chromosome. TSPY gene family 
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members occur in at least six locations on the human Y-chromosome and each cluster 
contains a unique combination of variants (TSPYA, B, C, D, E and F). The majority 
of TSPY copies map to interval 3C on Yp11.2 (TSPYA). Minor locus (TSPYB) exists 
in an interval proximal to 3D, close to the centromere (Dechend et al., 2000). A new 
member of TSPY gene family (TSPYg1) was isolated from subinterval 6E (Ratti et 
al., 2000). TSPY consists of six exons and five introns distributed over 2.8 Kb 
(Schnieders et al., 1996) (Figure 1.11). Individual human TSPY members of the 
cluster are not identical, but rather show microheterogeniety of up to 10% at the 
genomic level and about 3% at the transcript level. Homologues of human TSPY 
contain multicopies and are located on the Y chromosome in rodents and other 
mammals including great apes, pigs, cattle, sheep, goats and horses (Conrad et al., 
1996, Glaser et al., 1998, Kim et al., 1996, Mazeyrat and Mitchell, 1998, Schempp et 
al., 1995, Vogel et al., 1997a, Vogel et al., 1997b). 
5 UTR Exon 1-6 
3 UTR 
Figure 1.11. Genomic structure of TSPY. 
The gene is 2.8 kb in length and consists of 6 exons spaced by 5 introns. The 
3 and 5 
untranslated regions (UTR) were identified. Small duplication 
in exon 1 is represented 
in red and transcription imitation site is indicated. 
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Male specific bovine genomic homologues of the human TSPY are located on the Y 
chromosome and are also repetitive. The gene is part of a clustered array of 50-200 
repeated sequences on the Y chromosome resembling the arrangement present in the 
human genome (Jakubiczka et al., 1993). The bovine TSPY homologue (bTSPY) is 
1266 bp in length and consists of seven exons (Figure 1.12). Microheterogeneous 
sequence variation is found between TSPY family members (Jakubiczka et al., 1993). 
Bovine genomic DNA TSPY shows 53% of DNA homology to human TSPY. In 
Japanese monkey, TSPY gene was also cloned and contained an open reading frame 
of 246 amino acids. This coding fragment shared 89% nucleotide sequences identity 
and 81 % amino acid identity with the human homologue of TSPY. The rat homologue 
of human TSPY (rTSPY) has been isolated and characterised. The rTSPY genomic 
size is 2624 bp and the gene consists of 6 exons and 5 introns and is organised 
similarly to human TSPY (Dechend et al., 1998). Mouse TSPY (mTSPY) has been 
identified and was found to consist of 6 exons. Sequence comparison between mouse 
and rat TSPY has revealed that 92% of coding exons are identical. The putative rat 
TSPY protein is 88% identical to the murine TSPY. Rat TSPY is 47% identical to 
human TSPY (Mazeyrat and Mitchell, 1998) (Table 1.6). 
Amio acid homology Exon I Exon 2 Exon 3 Exon 4 Exon 5 
Mouse/Human 63 86 73 57 44 
RatfHuman 65 88 70 59 55 
Table 1.6. Amino acid homology between mouse, human and rat TSPY. 
Bovine TSPY (bTSPY) 
©000 
Mouse (mTSPY) 
Rat (rTSPY) 
Human (hTSPY) 
Figure 1.12. Genomic structure of hTSY, bTSPY, mTSPY and rTSPY. 
Genomic structure of TSPY from bovine, mouse, rat and human. All consist of 
6 
exons except for bovine TSPY which consists of 7 exons. 
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1.1.8.3 TSPY haplotype 
Several variants of the TSPY gene have been identified including base substitutions 
and 18 bp tandem duplication (Krick et al., 2003). Nucleotide substitutions have been 
described in exon 1 and exon 3 (135G-A silent and 584 C-G) (Table 1.7). The 18 
duplications in exon 1 (221-238) were detected at loci TSPY-A and TSPY-B, whereas 
TSPY-D, TSPY-E and TSPY-F harbour only 18 alleles. TSPY-A locus contains the 
majority of TSPY gene copies whereas TSPY-B, C, D, E loci contain fewer copies. 
Each locus on Yp (TSPY A-D) contains both G and A variants at nucleotide 135. The 
interval 18 tandem duplication at position 221-238 in TSPYA-B does not affect the 
ORF of TSPY major. 
Locus 135G-A 584 C-G Duplication 18 bp 
TSPY A (Yp) G/A C 36 
TSPY B (Yp) G/A G 36 
TSPY C (Yp) G/A C 18 
TSPY D (Yp) G/A C 18 
TSPY E (Yq) GC 18 
TSPY F (Yq) GG 18 
Table 1.7. Haplotypes identified in TSPY transcripts 
TSPY sequence variants isolated from prostate and testis cDNA including base 
substation, and short tandem duplication (Krick et al., 2003). 
1.1.8.4 Transcriptional & post-translation variants 
Three transcripts have been described in testicular specimens: a major transcript 
called TSPY major and two shorter transcripts TSPY A and B that were generated 
from 
alternative splicing of exon 1 (Schnieders et al., 1996) (Figure 1.13). 
In addition to the 
three transcripts detected, other TSPY alternative splice forms have been detected 
from a collection of normal testes, testicular cancer and prostate cancer 
(Lau et al., 
2003). TSPY major transcript (full length) encodes for 308 a. a. 
Western blot indicated 
that TSPY is a phosphoprotein and two protein forms exist, 
33 kDa unphosphorylated 
protein and 38 kDa phosphorylated protein 
(Schnieders et al., 1996). TSPY protein 
structure suggests the presence of a 
bipartite nuclear localisation signal (NLS) at the 
N-terminus. This NLS is similarly observed in Xenopus oocyte protein nucleoplasmin 
(Dingwall and Laskey, 1991). Similar 
bipartite signals are found in proteins that 
demonstrate nuclear localisation such as transcription 
factors, polymerases, 
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topoisomerases and nuclear hormone receptors (Dingwall and Laskey, 1991). The 
NLS appears to be conserved in bovine TSPY suggesting a functional significance 
(Figure 1.14). 
Type 1 
Type 2 
Type 3 
H71 
H104 
H109 
H106 
H80 
H30 
H51 
Figure 1.13. TSPY alternative splice forms. 
TSPY alternative splice forms isolated from testis and prostate cDNA (Lau et al., 
2003). 
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10 20 
MRPEGSLTYR VPERLRQGFC 
30 40 
GVGRAAQALV CASAKEGTAF 
50 60 
RMEAVQEGAA GVESEQAALG 
70 80 
EEAVLLLDDI MAEVEVVAEE 
90 100 110 120 
EGLVERREEA QPRQQAVPGP GPMTPESALE ELLAVQVELE 
130 140 150 160 
PVNAQARKAF SRQREKN1ERR RKPHLDRRGA VIQSVPGFWA 
170 180 190 200 
NVIANHPQMS ALITDEDEDM LSYMVSLEVE EEKHPVHLCK 
210 220 230 240 
IMLFFRSNPY FQNKVITKEY LVNITEYRAS HSTPIEWYPD 
250 260 270 280 
YEVEAYRRRH HNSSLNFFNW FSDHNFAGSN KIAEILCKDL 
290 300 308 
WRNPLQYYKR MKPPEEGTET SGDSQLLS 
PKC phosphorylation site 
8 TYR 
33 SAK 
269 S'. \' K 
Casein kinase II phosphorylation site 
33 SAKE 
107 SALE 
174 TDED 
233 TPIE 
300 TSGD 
Nuclear localisation signal 
127 NLS 
Figure 1.14. TSPY putative phosphorylation sites. 
Potential phosphorylation sites and their corresponding kinases have been predicted 
using phosphobase site (http: //phospho. elm. eu. org). 
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1.1.8.5 TSPY function 
Although TSPY gene product is postulated to regulate cellular proliferation of 
spermatogonia, it biological function is not yet known. Detailed database and 
comparison sequence analysis reveals that TSPY shows homology members of super- 
family containing SET and NAP proteins (Schnieders et al., 1996). TSPY shows 
homology to SET oncogene. SET was initially identified in patient with acute 
undifferentiated leukaemia who harboured chromosomal translocation on 
chromosome 9 (von Lindern et al., 1992). This leads to fusion of CAN with SET to 
create SET-CAN chimeric that encodes 155 KD putative oncoprotein. C-SET gene 
encodes 32 KD protein that is widely expressed in numerous tissues and cell types, 
including testis (Adachi et al., 1994). SET has also been identified as the template- 
activating factor, TAF-1 (Nagata et al., 1995) and is a potent inhibitor of protein 
phosphatase 2A (PP2A) (Li et al., 1996). PP2A is an abundant, multifunctional 
serine/threonine-specific phosphatase that stimulates DNA replication (Lin et al., 
1998). PP2A antagonises cyclin B complexes to regulate cell cycle progression at the 
G2 stage. Furthermore, SET and related protein, nucleosome assembly protein 
1(NAP-1), interact specifically with mitotic cyclin B (Kellogg et al., 1995). 
Nucleosomal assembly proteins are histone chaperones that transport histone protein 
from cytoplasm into the nucleus across the nuclear membrane. Deposited histone into 
the replicative DNA is required to form nucleosomes and regulate the cell cycle. 
NAP-1 was found to be located in the cytoplasm during the G2 phase of the cell cycle 
and it is found in the nucleolus in the S phase (Ito et al., 1996). NAP-1 plays a role in 
regulating gene expression, through its affect on the maintenance of chromatin in a 
dynamic state. A genome wide analysis study of NAP-1 deficiency in Saccharinyces 
cerevesiae yeast has indicated that 10% of all genes were affected, some being up 
regulated and other being down-regulated. Approximately, 35% of NAP-1 regulated 
genes are clustered together, suggesting that NAP-1 might function in large 
chromosome domains (Ohkuni et al., 2003). Further study in S. cerevesisae has 
shown that NAP-1 also participates in the control of mitotic events through an 
interaction with C1B2, a protein belonging to the cyclin B family (Kellogg et al., 
1995). NAP-1/2 knock out mice are embryonic lethal at mid gestation stage. There is 
accompanied overproduction of neural precursor cells suggesting a role for NAP-1 in 
regulating neuronal cell proliferation (Rogner et al., 2000). 
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While the exact function of TSPY remains to be fully examined, there is mounting 
evidence to suggest a role for TSPY in development and pathogenesis of male 
associated accessory organs, including the testis and prostate. In this thesis, work has 
been carried out to test our hypothesis: 
TSPY plays a key role in human prostate carcinogenesis with aberrant gene 
expression or genetic alteration. 
1.2 Overall aims 
To investigate the role of TSPY in prostate cancer and study its functional role in 
prostate cancer development. 
1) To investigate TSPY expression product profile in clinical prostate cancer 
compared to BPH using IHC method and generated peptide TSPY polyclonal 
antibody. 
2) To determine the functional effect of expressing TSPY in LNCaP cell lines. 
3) To investigate if TSPY gene copy number is associated with prostate cancer. 
4) To identify altered genes associated with LNCaP cells over-expressing 
TSPY using microarray method. 
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Chapter 2: General Materials and Methods 
2.1 Molecular biology 
2.1.1 Cloning TSPY gene 
A full length TSPY cDNA I. M. A. G. E. bacterial clone was selected from the 
I. M. A. G. E. consortium (accession number, 5269330) web site and purchased from the 
HGMP Resource Centre in the UK. The clone is part of an adult testis cDNA library 
generated by unidirectional insertion of cDNA fragments into the ECOR I and Not I 
restriction site of PT7T3-pac vector (Figure 2.1). The clone was maintained in 
DH10B host bacteria. The selected clone contained 924 bp insert of TSPY. The 
bacterial clone was streaked from slab culture into LB agar (1% Bacto-tryptone plate 
Petri dish containing 100 µg/ml Ampicillin and incubated O/N at 37°C to form 
separate individual colonies each arising from a single bacterial cell. Midi scale 
plasmid DNA was prepared from a single selected bacterial colony and the presence 
of the TSPY insert was confirmed by restriction digestion and sequencing (Molecular 
Biology Unit, Newcastle upon Tyne University) using universal T7 promoter and T3 
promoter primers. 
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HindlI 
NuLl 
_: EcaE21 
Pacl 
. AMr, i i 
ßpml 
Bs: ýl 
Ahdl 
BamHl 
Sr idBI 
EcoRl 
SFiI 
Aval 
X`101 
Figure 2.1. PT7T3d-pac vector. 
The vector is 2.9 kb in length and the multiple cloning site is flanked by T3 promoter 
and T7 promoter. The vector contains an ampicillin resistance gene as a selectable 
marker. 
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2.1.1.1 TA cloning and adding FLAG tag at 5'end of TSPY 
cDNA 
TA cloning kit provides a one-step cloning procedure for the direct insertion of a PCR 
product into a plasmid vector (PCR2.1). The kit depends on the ability of Taq DNA 
polymerase to add a single deoxyadenosine (A) nucleotide to the 3' ends of PCR 
product. The linearised vector (PCR2.1) supplied with the kit have overhanging 
deoxythymidine (T) residues at the 3' ends. The multiple cloning site for the vector is 
located within the LacZ gene. Insertion of DNA fragment into this site will inactivate 
the LacZ gene and white bacterial colonies are formed in the presence of X-Gal 
solution (substrate for LacZ gene). Thus, LacZ gene is used as selectable marker for 
successful insertion of DNA fragment into the vector. 
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Figure 2.2. TA cloning vector. 
(A) The vector is 3.9 kb in length and two antibiotic selectable markers included in 
the vector, ampicillin and Kanamycin. The multiple cloning site is located within the 
LacZ gene and is used as a marker for selecting bacterial colonies that contain that 
insert. (B) The linearised TA cloning vector has overhanging 3' ends with T 
nucleotide and the PCR amplified fragment with A nucleotide added by Taq 
polymerase. 
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To clone the full length of TSPY coding region, two sequential subcloning strategies 
were carried out. In the first step, the gene was simultaneously amplified and tagged 
with FLAG epitope at the 5' end and subcloned from the I. M. A. G. E. vector (PT7T3- 
pac) to PCR2.1 vector using TA cloning kit (Invitrogen). In the second step, a FLAG 
tagged TSPY gene was subcloned into the mammalian pcDNA3.1 vector. 
In step 1 
Subcloning from PT7T3D-pac into PCR2.1 vector 
The following 5' end FLAG tagged TSPY forward primer 5'-ATG GAC TAC AAA 
GAC GAC GAT GAC AAA GAG GTC GTG CAG GAG GGG-3' and reverse 
primer with stop codon at the end, 5'- GGG ACT CCC AGT TGT TGA GTT GA-3' 
were synthesised and purchased from Thermohybaid (Thermo BioSciences GmbH, 
Germany). The IMAGE clone insert was used as a template to amplify the 924 bp 
TSPY insert in PCR reaction (Figure 2.3). 
ATG 
7 
FLAG 1 924 bp 
4 
STOP 
7 7 
6 
Figure 2.3. Schematic representation of TSPY cDNA exon structure. 
TSPY full length (924 bp) that includes 6 exons was subcloned into pcDNA3 vector 
and a short FLAG-tag was added at the 5' end. 
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2.1.1.2 Geneclean 
Geneclean is a very basic method is used to recover nucleic acid fragments from 
agarose gel for further DNA manipulation. In this method, the required fragment was 
excised from the gel, transferred into an eppendorf tube and weighed. Three volumes 
of 3M NaI were added. The tube was placed on 55 °C water bath for 5 minutes until 
the gel dissolved. Then, 5µl of Glass milk (Biolabs) that binds DNA was added and 
the tube was placed on ice for 10 minutes. The tube was centrifuged at 14000 g for 1 
min and the supernatant was discarded. The pellet was resuspended in 3 volumes of 
New wash solution and centrifuged at 14000 g for 1 min, the supernatant was 
discarded. The previous step was repeated twice. Finally, the pellet was resuspended 
in 15 µl of ddH2O heated to 55 °C and supernatant containing the DNA was separated 
from Glass milk by centrifugation at 14000 rpm for 1 min. 
2.1.1.3 DNA Ligation 
Once the TSPY fragment was recovered, it was inserted into PCR2.1 vector in a 
ligation reaction. A ligation mixture was set up by adding a linearised PCR2.1 
plasmid and DNA fragment at a ratio of 1: 3 respectively, 1 µl of lOX ligation buffer 
(60 mM Tris-HC1, pH 7.5,60 mM MgCl2,50 mM NaCl, 1 mg/ml bovine serum 
albumin, 70 mM mercaptoethanol, 1 mM ATP, 20 mM dithiothreitol and 10 mM 
spermidine), 1 µl of T4 DNA ligation enzyme (Invitrogen) and ddH2O to a final 
volume of 10 µl. The reaction was incubated at 14 °C O/N. 
2.1.1.4 Transformation 
TOP 10 competent cells (Invitrogen) were thawed out on ice (50 µl). Three microlitres 
of overnight ligation mixture were added to the cells and incubated on ice for 30 min. 
The cells were heat shocked for 45 sec at 42 °C and placed on ice for 2 min. Then 500 
µl of SOC medium (2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl, 2.5 mM KC1,10 
mM MgC12,10 mM MgSO4 and 20 mM glucose) was added and the cells were 
incubated at 37°C for l hr in a shaking incubator to allow expression of antibiotic 
resistance marker. From these transformed cells, 100 
d of bacterial culture was 
spread onto LB agar plate containing 100 p g/ml ampicillin and 
40mg/ml X-Gal 
solution (400 mg X-Gal in 10 ml dimethylformamide). 
The plate was incubated ON 
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at 37°C to allow formation of colonies. Selection for the correct colonies with insert is 
based on the colour of the colonies. Insertion of the DNA fragment into the Lac Z 
cloning site will inactivate the gene and colonies that harbour the insert will be white 
in colour. 
2.1.1.5 Restriction digestion 
Successful insertion of PCR product into flanked EcoR I restriction site in TA vector 
was further checked by restriction digestion of plasmid isolated from bacterial clones. 
All restriction digestion reactions were carried out in a final volume of 20 µl. 
Restriction enzyme master mix was prepared by adding the following: 2 µl Restriction 
enzyme buffer (Promega), 0.2 µl 100 X BSA, 1 µl EcoR I restriction enzyme (5 units) 
and 1 µg of plasmid DNA. Reactions were incubated at 37°C for 90 min. Digestion 
product size was checked on 1% agarose gel. 
Step 2 
Subcloning FLAG tag TSPY gene from PCR2.1 into pcDNA3.1 vector 
The FLAG-tagged TSPY (FLAG-TSPY) fragment was digested out from the pCR2.1 
plasmid using EcoRI restriction enzyme to release the FLAG-TSPY fragment. The 
digestion product was visualized on 1% agarose gel and gel extraction was performed 
as given in section 2.1.1.. The pcDNA3 vector (Invitrogen) was also digested with the 
same restriction enzyme and the vector was dephosphorylated to remove the 
phosphate groups at the 5' ends of the linearised pcDNA3.1 plasmid DNA to prevent 
self ligation (Figure 2.4). The dephosphorylation step was carried out by adding 20 µl 
EcoRI-digested pcDNA3.1 product, 2.5 µl lOX Alkaline phosphatase buffer 
(Promega), 2 units of Alkaline phosphatase (Promega) in a tube and incubating at 37 
°C for 30 min. The FLAG-TSPY fragment, the linearised and dephosphorylated 
pcDNA3 plasmid were ligated, transformed and colonies were screened and selected 
using colony PCR method. 
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Figure 2.4. pcDNA3.1 mammalian expression vector. 
The vector is approximately 5.4 kb in length and contains a neomycin selection 
marker for generating stable clones in mammalian cells. It also includes ampicillin 
selectable maker for selection in bacterial cells and an origin of replication for 
propagating the vector in bacterial cells. A strong CMV promoter derives expression 
of downstream cloned genes. 
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2.1.2 Plasmid Midi preparation 
A single bacterial colony was inoculated into 5 ml LB medium containing 100µg/ml 
Ampicillin and left to grow at 37 °C overnight in a shaking incubator. One hundred 
microlitres from the overnight bacterial growth were re-inoculated into fresh 100 ml 
LB medium and left to grow O/N at 37 °C with vigorous shaking. The bacterial 
culture was centrifuged to pellet the cells at 10000 rpm for 10 minutes at 4°C and the 
supernatant was discarded. The bacterial cell pellets were resuspended in 3 ml cell 
resuspension solution (12.5 mM Tris-HC1,2.5 mM EDTA and 100 pg /ml RNAase A). 
Then, 3 ml of cell lysis solution (200 mM NaOH and 1% SDS) were added and the 
tubes inverted many times. Immediately, 3 ml of neutralizing solution (3 M Potassium 
acetate and 11.5 % Glacial acetic acid) were added and mixed by gentle inversion 
many times. Tubes were centrifuged at 10000 rpm for 20 minutes. The supernatants 
were filtered through Miracloth and 10 ml of resin solution (66.64 g Guanidine 
hydrochloride (SIGMA), 33.33 ml Neutralizing solution, 1.5 ml NaOH and 1.5 g 
Diatomaceous Earth) were added and mixed with the samples. The mixture was 
filtered through Promega Wizard columns. The DNA bound to the columns was 
washed twice using 20 ml column washing solution (10 mM Tris-Cl, 100 mM NaCl, 
2.5 mM EDTA and 50 % ethanol). Then, columns were placed into eppendorf tubes 
and centrifuged at 14000 rpm for 2 minutes to remove any traces of washing solution. 
DdH2O was warmed to 65 °C and 300 µl of was added to each column and left at 
room temperature for 2 minutes. The DNA was eluted by centrifuging at 14000 rpm 
for 2 minutes. The DNA concentration was determined using a spectrophotometer 
(Wallac). 
2.1.3 Plasmid Mini-preparation. 
One bacterial colony was picked and transferred into 5 ml LB containing 100 µg/m1 
Ampicillin in a universal tube. The tube was incubated at 37 °C ON with shaking. 
The next day, the content of overnight culture was sequentially transferred 
into 
eppendorf tube and centrifuged at 14000 rpm for 20 sec. The supernatant was 
discarded and the pellet was resuspended in 100 µl of solution I (250 mM 
Glucose, 
125 mM Tris-cl and 50 mM EDTA, pH 8). Then, 
200 µl of solution II (200 mM 
NaOH and 1% SDS) was added and the tube was mixed 
by inversion. Immediately, 
200 pi of Solution III (3 M Potassium acetate and 
11.5 % Glacial acetic acid) was 
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added and mixed again by inversion. The tube was centrifuged at 14000 rpm for 10 
min. The supernatant was transferred into fresh tube and 500 µl of phenol : 
chloroform : isoamylalcohol mixture (ratio 25: 24: 1, respectively) was added and 
mixed by shaking. The tube was centrifuged at 14000 rpm for 3 min. The upper 
aqueous layer was transferred to a fresh tube and 900 µl of 100 % Ethanol was added 
and the tube was kept at -80 °C for 10 min. The DNA was precipitated by 
centrifuging at 14000 rpm for 10 min. The DNA precipitate was washed with 70% 
Ethanol, air dried and resuspended in 50 µl of ddH2O. 
2.1.4 Conventional PCR 
Polymerase chain reaction method selectively amplifies a specific segment of nucleic 
acid using specific pair of primers that bind to the target sequence. The method was 
set up as follow: into the PCR HYBAID omnitubes, the following PCR mix was 
added; 5 µl of 10 X PCR buffer (160 mM (NH4)2SO4., 670 mM Tris-HCL, pH, 8.8 
and 0.1% Tween-20), 1.5 µl of 5 mM MgCL2,2 µl of 5 mM dNTPs (Sigma), 50 
pmole/µl of forward and reverse primers, 0.25 units of Taq DNA polymerase 
(BIOLINE), 0.1-0.5 µg DNA and ddH2O up to 50 µl. The tubes were inserted into 
HYBAID PCR EXPRESS thermal cycler. The following 3 stages of PCR cycles were 
carried out: denaturation step at 95 °C for 3 min, amplification step consisting of 3 
steps at 95 °C for 1 min, 65 °C for 1min and 72 °C for 30 sec, the cycle number was 
between 30-35 cycles and extension step at 72 °C for 10 min. The PCR product was 
mixed with 6X loading buffer (0.25% Bromophenol blue, SIGMA, 0.25% Xylene 
Cyanole FF, SIGMA, 30% Glycerol, BDH and 50 mM EDTA, pH 8) and loaded into 
1% agarose gel. 
2.1.5 Agarose gel electrophoresis 
It is a method that is used to separate DNA fragments based on their size to determine 
the length of the separated DNA fragments by comparison to a standard marker with 
known fragment sizes. In this method the agarose gel was prepared by adding 1-2 g of 
agarose electrophoresis grade (GibcoBRL) into 100 ml 1x TAE electrophoresis 
buffer (242 g Tris (TRIZMA BASE, SIGMA), 57.1 ml glacial acetic acid (BDH), 100 
ml of 0.5 M EDTA (pH, 8.0) and ddH2O to 
final volume of 1 litre) depending on the 
product size. The mixture was heated using a microwave until 
boiling to dissolve the 
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agarose. Then, the gel was allowed to cool to 50 °C before adding 5 µl of 10 mg/ml 
Ethidium bromide (SIGMA). Immediately, the gel was poured into glass plate and left 
to solidify for 10 minutes. The gel was placed in electrophoresis tank and filled with 1 
x TAE buffer. Samples were mixed with 6x loading buffer and 5 µl of DNA Hyper 
ladder markers (BIOLINE) IV or V were loaded into each well and the gel was 
exposed to 100 V. for 30 minutes. The gel was exposed to U. V. source and molecular 
analysis software was used to view and capture pictures of the gel. 
2.1.6 Colony PCR 
Colony PCR is a simple PCR based method that was developed to check the presence, 
absence or the orientation of insert during DNA cloning procedure. Colonies were 
selected and transferred into eppendorf tubes containing 100 p1 of ddH2O, mixed and 
10 µl were streaked onto plates. The cells were boiled for 10 min to release plasmid 
DNA and the tubes were pulse centrifuged to collect cell debris. Colony PCR was 
carried out by adding 3 µl of boiled bacterial supernatant into a standard PCR master 
mix and the presence or absence of the insert was determined by using TSPY forward 
and reverse primers. The insert orientation in each clone was identified using TSPY 
reverse primer and T7 promoter primer. Once the correct clone was identified, a maxi 
DNA plasmid was prepared using Qiagen endotoxin free plasmid maxi preparation kit 
following the manufacture's instructions. 
2.2 Mammalian Cell Culture 
2.2.1 Cell lines 
Three mammalian cell lines were used: the androgen-responsive human prostate 
carcinoma cell line, LNCaP purchased from the American Type Culture Collection 
(ATCC, Rockville, Maryland, U. S. A. ). The androgen unresponsive human prostate 
carcinoma cell line, PC3M purchased from the European Collection of Animal 
Cell 
Cultures (ECACC, Salisbury Wiltshire, U. K. ). NIH Swiss mouse embryo fibroblast 
cells 3T3, were also purchased from the European Collection of 
Animal Cell Cultures. 
2.2.2 Thawing cells 
Frozen cells in a cryovial were thawed at 37°C. 
Immediately, the contents were 
removed into 9 ml of pre-warmed complete medium 
in a universal tube. Cells were 
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resuspended and the tube was centrifuged at 2000 rpm for 5 min. The supernatant was 
discarded and the cell pellet was resuspended in 5 ml complete medium. The 
suspended cells were transferred into 75 cm2 vented flask and complete medium was 
added to a final volume of 15 ml. Cells were incubated at 37°C in humidified 
conditions supplemented with 5% CO2. Medium was changed the next day and the 
cell condition and viability was observed and reported. 
2.2.3 Cell culture 
Each cell line was grown in its recommended medium. LNCaP and PC3M were 
cultured in RPMI (Sigma) and NIH/3T3 was cultured in DMEM (Sigma). Both RPMI 
1640 medium containing 25 mM HEPES buffer and DMEM were supplemented with 
20 mM L-Glutamine (Sigma), 10 % heat inactivated foetal calf serum (Sigma), 
Penicillin (100 IU/ml; Sigma) and streptomycin (100 µg/ml; Sigma). Cell lines were 
routinely maintained in 100 cm dishes or 75 cm2 flasks and incubated at 37 °C in the 
presence of 5% CO2. Media were changed three times a week and the cells were sub 
cultured very often when they were 70% confluent. The medium was discarded and 
the cells were washed with 1X PBS. They were covered with 0.2% Trypsin/EDTA 
solution and incubated at 37 °C for 2-10 minutes until the cells detached and floated 
freely. The Trypsin was inactivated by adding 10 ml of complete medium and cells 
were resuspended and centrifuged at 2000 rpm for 5 min. The cell pellet was 
resuspended in 10 ml complete medium. The cell number was determined using a 
haemocytometer and were split into 10 cm dishes at required densities. The cell lines 
were routinely tested for mycoplasma contamination using Mycoplasma PCR kit. 
2.2.4 Freezing cells 
Frozen stocks of all cultured cells were generated. Cells were grown to 90% confluent 
in 10 cm dish. The cells were detached and the cell pellet was resuspended in 1-2 ml 
of freezing medium (10% FCS, 10% DMSO and basal medium). Cell suspension was 
aliquoted into 1 ml cryovial tubes, frozen gradually and stored in 
liquid nitrogen. 
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2.3 Transfection 
2.3.1 Transient Transfection 
Cells were counted and 1X 105 cells/well were plated into 6 well plate. After 
incubation for 24 hr, the cells were washed with 1X PBS and 1 ml of RPMI 1640 
basal medium containing 3 µg of Plasmid DNA and 9 µl of Superfect (Qiagen) were 
added to each well. The cells were incubated at 37 °C for 3 hr before the mixture was 
removed and replaced with 3 ml of RPMI 1640 complete medium. The cells were 
cultured for additional 48 hr before they were put forward for further analysis. 
2.3.2 Stable transfection 
In 10 cm dish, 0.5 X 106 cells were plated and left for 24 hr. The medium was 
removed, cells were washed with 1X BPS and 4 ml of basal medium was added. DNA 
and superfect complex was prepared by adding 30 µg of FLAG-TSPY-PCDNA3 
plasmid DNA or PCDNA3 vector DNA only into 300 µl of basal medium in a 
microfuge tube. Then, 90 µl of Superfect (Qiagen) was added, mixed and the DNA- 
Superfect complex was left for 10 min at RT. Basal medium was added to the 
microfuge to a final volume of 1000 µl. The mixture was added to dishes and the cells 
were incubated at 37 °C for 3 hrs. The medium was replaced with complete medium 
and the cells left at 37 °C for another 48 hrs. Geneticin was added at concentration of 
500 µg/ml to the cells and they were left for 2-3 weeks until visible colonies were 
formed (killing curve for LNCaP cell line had already been carried out and the 
minimum concentration of the antibiotic required to kill all the cells in a period of 3 
weeks was pre-determined). 
2.3.3 Ring cloning 
Colonies formed were marked. The cells were washed in 1X PBS and 2 µl of 0.2 % 
Trypsin /EDTA was used to detach each colony from the dish. The detached cells 
from selected colonies were placed into 48 well plate and 
left for another 1 week to 
grow. Stable clones were then replated onto 12 well plate 
in duplicate for screening 
and expanding. The presence of exogenous constitutive expressed 
FLAG-TSPY in 
each clone was assessed using Western 
blot method. Clones that showed strong and 
weak expression were selected, expanded and 
frozen stock were generated. 
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2.4 Biochemical methods 
2.4.1 Western blot 
2.4.1.1 Protein lysis 
Cells were washed in PBS and 100-800 µl of 1X SDS-sample buffer (125 mM Tris- 
Cl, pH 6.8,2% SDS, 10% Glycerol, 10% ß-mercaptoethanol and 0.001% 
Bromophenol Blue) was added according to cell number and left for 2 minutes. The 
cells were sheared by pipetting and transferred into eppendorf tubes. The cell lysates 
were boiled for 10 min, centrifuged at 14000 rpm for 1 minute and 15 pl volume was 
loaded into 12 % SDS-PAGE gel. 
2.4.1.2 12 % SDS-Polyacrylamide gel electrophoresis (SDS- 
PAGE) 
BIO-RAD Mini Protean II apparatus was used to set up 12 % SDS-PAGE. Running 
gel (375 mM Tris-HcL, pH 8.8,0.1 % SDS, 12% acrylamide/bis-acrylamide gel, 0.1 % 
Ammonium persulphate and 0.1 % TEMED) was loaded between two glass plates and 
left to set for 15 minutes. A stacking gel (125 mM Tris-HC1, pH 6.8,0.1 % SDS, 6% 
acrylamide/bis-acrylamide gel, 0.1 % Ammonium persulphate and 0.1 % TEMED) was 
loaded into the top of the running gel and left to set for 10 minutes. The plate set was 
transferred into electrophoresis tank containing running buffer (25 mM Tris-HC1,190 
mM glycine and 0.1 % SDS). The gel was electrophoresed at 200 V for 45 minutes to 
allow separation of proteins. 
2.4.1.3 Immunodetection 
Proteins on the gel were transferred into Hybond C++ membrane (Amersham 
Biosciences) using the Bio-Rad protein transfer apparatus. The gel and the filter were 
sandwiched between two Whatman paper and two mats. A transfer tank was filled 
with transfer buffer (25 mM Tris-HC1,150 mM glycine and 10% methanol) and the 
proteins were transferred overnight by applying 30 V. The filter was blocked in 5% 
Marvel skimmed milk dissolved in TBS buffer (20 mM Tris-HC1 and 500 mM NaCl) 
for 1 hr with shaking at RT. The membrane was washed twice in 1X TTBS (20 mM 
Tris-HC1,500 mM NaCl and 0.1% tween-20) for 10 minutes before placing it into a 
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plastic bag filled with 1% Marvel in TTBS buffer and the diluted primary antibody. 
The antibody was left to hybridise for lhr shaking at RT. Unbound antibody was 
removed by washing the membrane twice in Ix TTBS for 5 minutes before adding 1% 
blocking solution with 1: 1000 dilution of secondary antibody conjugated to horse 
radish peroxidase (Dako). The membrane and the secondary antibody were left 
shaking at RT for 1 hr. Then, the membrane was washed twice in 1X TTBS for 10 
minutes and once in 1X TBS for 10 minutes. ECL Western blotting detecting reagent 
kit (Amersham Biosciences) was used to develop the signal. 
2.4.1.4 Stripping membrane 
After the signal development, the membrane was washed twice in lx TTBS. Then, 
placed in 50 ml stripping solution (62.5 mM Tris-HC1, pH 6.7,2% SDS and 0.78% ß- 
mercaptoethanol) and left shaking for 30 minutes at 50 °C. The membrane was 
washed twice in 1X TTBS for 10 minutes and re-used for further few times. 
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Chapter 3: Expression and Functional Analysis of TSPY in Prostate Cancer 
3.1 Introduction 
The expression of TSPY transcript is detected in testes during early foetal stage and 
persists in the adult males (Lau et al., 2000). The gene product was previously thought 
to be organ specific and the testes were the only tissues to express TSPY. Subsequent 
studies have detected TSPY expression in prostate glands (Lau et al., 2003). In 
normal adult testes, TSPY expression is predominantly detected in cells lining the 
seminiferous tubules, specifically spermatogonia and to a lesser degree in early 
spermatocytes (Schnieders et al., 1996). Spermatogonia cells are the stem progenitor 
cells that either divide to generate new spermatogonia or differentiate to produce 
mature spermatocytes. TSPY protein expression was mainly detected in the cytoplasm 
of spermatogonia while a few cells expressed the gene product in the nucleolus. 
Aberrant expressions of TSPY gene product have been reported in sex-reversed 
females developing gonadoblastoma, testicular cancer and recently in prostate cancer. 
Hildenbrand has used TSPY anti-fusion protein antibody in immunohistochemistry 
method on the Turner mosaic patient (45X/46XY) gonads. The patient had developed 
a unilateral microscopic gonadoblastoma and had aY chromosome lacking the distal 
Yq arm. Strong TSPY immunoreactivity was detected in gonadoblastoma tumour 
cells of the gonad (Hildenbrand et al., 1999, Lau et al., 2000). Furthermore, TSPY 
was strongly expressed in testicular seminoma and carcinoma in situ of the testis 
(Schnieders et al., 1996). 
3.2 Aims: 
1) To characterise TSPY expression in human prostate cancer. 
2) To define the functional significance of TSPY over-expression in prostate cancer. 
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3.3 Materials and Methods 
3.3.1 Patient samples 
For immunohistochemistry, prostate tumour specimens were obtained from Freeman 
Hospital, Newcastle upon Tyne, U. K. between years 1989 to 1995. Seventy two 
patients with locally and advanced prostate cancer and 20 patients with BPH were 
examined. The samples were collected with patient consent. Clinical and pathological 
reports were collated for each case and in most cases, follow up status was available. 
Normal adult testis was used as a positive control. Biopsies from female liver, lung 
and kidney were used as negative controls. For validation of TSPY expression at 
mRNA level, tissue in situ hybridisation was carried out in selected cases of CaP and 
BPH. 
3.3.2 Tissue preparation 
Tumour specimens were fixed in formalin and embedded in paraffin. The tumours 
were sectioned at a thickness of 4 pm and adhered onto APES coated slides. The 
sections dehydrated in graded ethanol, deparaffinized in xylene, stained by 
Haematoxylin & Eosin and graded according to Gleason's score system (Gleason, 
1992) by a pathologist. Six of the cases were grade 2-5 and 66 cases were grade 6-10. 
The tumours were also classified according to TNM staging criteria (Schroder et al., 
1992) and 30 cases were T1/T2 and 24 cases were T3/T4. 
3.3.3 TSPY expression analysis 
3.3.3.1 Generating TSPY polyclonal antibody 
TSPY peptide (-AVPGPGPMTPGC-) corresponding to amino acid sequence 96-106 
of the TSPY protein (accession number AAB51693) was selected with the assistance 
of Dr. Jo Gray, Molecular Biology Unit, University of Newcastle upon Tyne). The 
synthesised peptide was conjugated to Keyhole Limpet Haemocyanin (KLH) via 
cystine residue. Pre-immunised serum was collected from two different rabbits prior 
to injecting conjugated peptide. First bleed and final bleed were also collected and 
tested for the presence of anti-peptide antibody using Enzyme Linked Immunosorbent 
Assay (ELISA), dot blot and Western blot. 
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3.3.3.2 Enzyme Linked Immunosorbent Assay (ELISA) 
ELISA is a very sensitive and simple method to detect and quantify antibody or 
antigen in solutions using an enzyme linked to antibody and a substrate that forms a 
coloured reaction product. ELISA method was used to detect the presence of TSPY 
specific immunoglobulin generated from both rabbit sera. The procedure is as follow: 
wells of 96 well Immunol 2 plates (BD Biosciences) were coated with 0.5 µg of 
synthetic TSPY peptide dissolved in 50µ1 of 0.1 M Carbonate buffer, pH 9.2. The 
plates were incubated ON at 4 °C. Excess peptides were removed by washing the 
wells three times with 300 µl of PBS/0.1%Tween-20. Non-specific sites on the bases 
of the wells were blocked by addition of 300 µl of 3% fat skimmed Marvel milk 
dissolved in PBS/0.1%Tween 20 and incubating for two hours. The wells were rinsed 
once with PBS/0.1%Tween. The pre immune-serum and final bleed serum were 
diluted in PBS, 1: 50,1: 200,1: 400, and 1: 800,1: 32000,1: 12800 and 1: 125600 in PBS. 
Fifty microlitres of diluted sera were added in triplicate to each well coated with 
peptide. Wells that are not coated with the TSPY peptide but blocked with Marvel 
milk were used as negative controls. The plate was incubated at RT for 2 hr. Wells 
were washed three times in PBS/0.1 Tween to remove excess serum and unbound 
primary antibodies. A Swine anti-rabbit antibody conjugated to Horse radish 
peroxidase was diluted 1: 1000 in PBS and 50 µl was added to each well and left for 
two hrs. Unbound secondary antibody was removed by washing three times in 
PBS/0.1%Tween. The presence of TSPY antibody was detected by adding 100 gl of 
Tetramethylbenzidine (TMB) Solution (1 tablet of TMB into lml DMSO, 9 ml 0.05 
M Phosphate-Citrate buffer, pH, 5.0 and 2 µl of 30% H202) to each well and 
incubating for 30 min at RT. The reaction was stopped by adding 50 µl of mM H2SO4. 
The plate was read in ELISA plate reader using a 450 nm filter, data was collected 
from the reader using Dynex Revelation software. 
3.3.3.3 Dot blot 
Dot blot is another method for detecting the presence of specific protein (antigen or 
antibody) in a solution. A spot of solution containing antigen is dotted onto special 
protein binding membrane and the antibody is allowed to bind. The presence of 
protein/antibody complex is visualised using a secondary antibody conjugated to 
horse radish peroxidase and ECL detection reagent. In the current study, dot blot 
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method was used to detect the presence of TSPY antibody in rabbit serum. TSPY 
peptide and non-specific peptide were dissolved in PBS and diluted to 10 µg, 1 µg, 
0.1 µg, 0.01 pg and 0.001 µg and 1 µl of each diluted peptide solution was spotted 
onto Hybond C++ membrane (Amersham) and left to dry for 15 min (Figure 3.1). The 
membranes were washed in TBS (20 mM Tris-HC1 and 500 mM NaCI)) for 5 min 
and blocked in blocking solution consisting of 5% Marvel non-fat milk dissolved in 
TBS for 1 hr. This step is essential to block non-specific binding sites on the filters. 
The filters were washed twice in TTBS (20 mM Tris-HC1,500 mM NaCl and 0.1% 
Tween-20) for 10 min. Crude serum absorbed with TSPY specific peptide, non-TSPY 
peptide and non absorbed crude serum were added to the membranes at 1: 2000 
dilution in 1% blocking solution and incubated for 1 hr on shaking platform. The 
membranes were washed twice in TTBS to remove unbound antibodies and non- 
specific bound proteins. Swine anti-rabbit immunoglobulin conjugated to horse radish 
peroxidase was diluted in 1% blocking solution and added to the membranes and 
incubated for 1 hr. The membrane was washed twice in TTBS and one in TBS and the 
signal was developed in a form of dots on the membranes using ECL kit (Amersham). 
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Figure 3.1. Schematic representation of dot blot 
The presence of TSPY antibody in rabbit crude serum was tested using dot blot 
method. TSPY and non-TSPY peptide (TIP60) were serially diluted and dotted onto 
filters. PBS was used as negative control. Eight membranes were prepapred for every 
rabbit serum and various treatment protocols were carried out as following: (A) 
Rabbit serum diluted to 1: 2000 was absorbed with 1µg TSPY peptide, (B) Rabbit 
serum diluted to 1: 2000 was absorbed with 10µg TSPY peptide, (C) Rabbit serum 
diluted to 1: 2000 was absorbed with 100µg TSPY peptide, (D) Rabbit serum diluted 
to 1: 2000 was absorbed with 1 µg non-TSPY peptide, (E) Rabbit serum diluted to 
1: 2000 was absorbed with 10 µg non-TSPY peptide, (F) Rabbit serum diluted to 
1: 2000 was absorbed with 100 µg non-TSPY peptide, (G) Unabosorbed Crude 
immune serum was used as positive control and (H) pre-immune serum was used as 
negative control. 
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3.3.3.4 Affinity Chromatography 
Affinity Chromatography is a technique that is used to separate and purify molecules 
(protein or antibody) from a mixture based on the binding affinity between the two 
molecules after one of them has been attached to a solid inert support substance. The 
mixture is passed through the column containing the molecule (ligand) attached to the 
stationary substance and only the molecule that has affinity to the ligand will bind and 
the rest will pass through the column. Once the molecule (antibody) of interest is 
captured, it is dissociated from the column by using low pH buffer. TSPY antibodies 
were purified from the rabbit crude serum using affinity chromatography. A 
disposable polystyrene column (Pierce) was assembled by inserting Polyethylene disk 
at the bottom and capping the end. The column was filled with I ml of Affi-gel beads 
(Bio-Rad) and left to set and separate into two layers, upper aqueous and lower solid 
gel beads. Once the aqueous layer was discarded, the gel is washed in 10 ml TBS. 
Meanwhile, the rabbit serum was prepared by adding 10 µl of 5% sodium azide to the 
TSPY crude serum and heating to 37 °C for 5 min. The serum was passed through the 
column twice and eluted by gravity force. Non specific molecules bound to the 
column or weak interactive molecules were removed by washing the column twice in 
20 ml TBS. The captured immunoglobulins were eluted from the column by adding 8 
ml of Elution buffer, pH 2.7. Approximately, 8 fractions, 1 ml each were collected in 
tubes containing 100 µl of neutralising buffer (1M Tris-HCL, pH 8; 1.5 M NaCl; 1 
mM EDTA and 0.5 % azide). Only the first 3 fractions were pooled and added to the 
centriplus tubes (Peirs) and centrifuged for 45 min at 3000 rpm to concentrate the 
antibody. Aliquots of elutes were collected after each step, mixed in 750 µl of ddH2O 
and 200 µl Bio-Rad protein assay kit and the optical density (O. D. ) at 595 nm was 
reported. 
3.3.4 Immunohistochemistry (IHC) 
Immunohistochemistry is a method used for detecting, semi-quantifying and locating 
the presence of specific protein in tissues or cells. Fixed cells or tissues on glass slides 
are prepared and primary antibody is added to each slide to bind to its specific antigen. 
The slide is treated with a secondary antibody that specifically recognises the primary 
antibody and is linked to an enzyme. The immunoreactivity is detected by addition of 
enzyme chromogenic substrate and visualising the staining under the bright field 
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microscope. Purified TSPY specific peptide antibody was used to detect TSPY 
protein expression level using IHC method. Different paraffin embedded prostate 
sections from different patients on APES coated slides were immersed in xylene for 
10 minutes, rehydrated in graded series of ethanol at 100%, 70 % and 50% ethanol 
and washed in ddH2O for 5 minutes. Endogenous non specific hydrogen peroxide 
activity sites on the tissue sections were blocked in 0.5% H202 (SIGMA), prepared in 
180 ml of methanol, for 10 minutes. The slides were washed again in ddH2O and 
incubated in PBS until processed for antigen retrieval. A pressure cooker (PC) was 
filled with 1.5 litre of 10 mM Citrate buffer pH and heated in a microwave for 16 
minutes until boiling. The slides were inserted into PC and placed in the microwave 
and heated for another 4 minutes. After the sections were cooled, non specific serum 
binding sites on the tissues were blocked in 10% normal goat serum prepared in PBS 
and incubated for 1 hr at RT. The optimal dilution of TSPY affinity purified peptide 
polyclonal antibody was determined by using serial purified TSPY antibody and 
sections from prostate cancer specimens found to express TSPY gene product. TSPY 
antibody was diluted 1: 1000 in PBS and 200 µl of the it was added to the slides. The 
sections were incubated ON at 4 °C. Unbound primary antibody was discarded and 
slides were washed twice in PBS for 10 min. The biotinylated goat secondary 
antibody (DAKO) generated against rabbit immunoglobulin was diluted 1: 250 in PBS 
and 200 µl was transferred onto each slide and left at RT for 30 minutes. Excess 
unbound antibody was removed by washing twice in PBS for 10 min. 
Immunodetection was performed using Vectastain Avidin Biotin Complex kit (ABC 
kit, Vector laboratories, CA, USA) following the manufacture's instructions. Each 
tissue section was covered with 200 µ1 of Abiding-Biotin complex for 30 min at RT. 
Extra reagents were washed out twice in PBS. The immunostaining signal was 
detected using chromogen substrate Diamino-benzidine tetrachloride (DAB) solution 
which was prepared by dissolving a white urea tablet and brown DAB tablet (Sigma) 
in ddH2O, and 200 µl was placed on each section for 20 minutes. The DAB reaction 
was stopped by inserting the slides in ddH2O for 5 min. The sections were 
counterstained in Harris' Haematoxylin for 1 minute and destained in 1% HCL 
diluted in Ethanol for 10 seconds. Excess stains were removed by sequential 
immersion of slides in ddH2O. The sections were dehydrated, placed in xylene and 
mounted with DPX (BDH). The signal was detected using 
Leica light microscope at 
lOX magnification. The immuno-specificity of the 
TSPY antibody signal was 
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evaluated by using different approaches; omitting the primary antibody (TSPY 
antibody) and replacing it with PBS, substituting the antibody with pre-immune serum, 
immunoabsorbing the purified TSPY antibody using 100 fold molar excess of TSPY 
specific peptide and using female tissue sections (liver, lung and kidney) as negative 
controls. Positive immunodetecting using the purified TSPY antibody was further 
confirmed by using testis sections as a positive control. 
3.3.4.1 Evaluation of immunohistochemical staining 
The immunostaining signal intensity of hyperplastic and malignant prostate 
epithelium was evaluated semi-quantitatively by a pathologist and the following 
scoring system was adopted; a score of 0 was assigned if staining was absent in 
tumour cells, a score of + was assigned if weak stainings were detected in <10% of 
tumour cells, score ++ if moderate staining intensities were observed in 10-50% of 
tumour cells and score +++ if strong staining was seen in >50% of tumour cells. 
3.3.5 Tissue In Situ Hybridisation (TISH) 
TISH is a semi-quantitative method for detecting and localising a specific transcript 
within morphologically preserved tissues or cells preparations using labelled 
riboprobe. 
3.3.5.1 Patient material 
Slides of paraffin embedded prostate sections removed from patients suffering from 
CaP and PBH were collected from Freeman Hospital. Fifty eight cases of CaP and 30 
cases of BPH were used in the current study. 
3.3.5.2 Riboprobe synthesis: 
An I. M. A. G. E clone number 173557 in pT3T7 vector harbouring 0.6 kb TSPY cDNA 
was ordered from HGMP resource centre. The vector was completely linearised using 
EcoR I or Not I. In eppendorf tubes, the following were added; 14 µl of ddH2O, 2 µl 
of 10 X restriction buffer, 1 µl of 20 X BSA, 1 µg of DNA, 1 µl Not I (10 U/µl) or 1 
µl EcoR I (8 U/µ1). The tubes were incubated at 37 °C for 90 minutes. The digestion 
products were mixed with 3 µl of loading buffer and transferred into 1% agarose gel. 
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3.3.5.3 Phenol extraction and ethanol precipitation. 
Double distilled water was added to each sample to a final volume of 400 µl. Equal 
volumes of phenol : chloroform : isoamyl alcohol (25: 24: 1) were added to each 
sample and mixed. The sample was centrifuged for 3 minutes at 14000 rpm and the 
supernatant was transferred into a new tube. The DNA was precipitated by adding 40 
µl of 3M sodium acetate and 1 ml of 100 % ethanol. The tube was left at -80 °C for 
10 minutes. Then, centrifuged at 14000 rpm for 10 minutes. The supernatant was 
discarded and the pellet was washed with 70% ethanol and dried. The pellet was 
resuspended in 20 µl ddH2O. 
3.3.5.4 Digoxigenin labelling cDNA 
One microgram of linearized plasmid was transferred into eppendorf tube containing 
2 µl of 10 X transcription buffer (Roche), 2 µl 10 X Digoxigenin RNA labelling 
mixture, 0.5 RNAguard, 2.5 µl T3 or T7 RNA polymerase and DEPC ddH2O to a 
final volume of 20 µl. The mixture was placed at 37 °C for 2 hrs. The synthesised 
riboprobe was ethanol precipitated and resuspended in 20 µl DEPC ddH2O. 
3.3.5.5 Riboprobe quantitation 
A control RNA labelled riboprobe (Roche) and the TSPY synthesised riboprobe were 
diluted in DEPC ddH2O into 20ng/µl, 1 ng/µl, 100 pg/µl, 10 pg/µl, 0.1 pg/µl and 0.01 
pg/µl. One microlitre from each dilution was transferred into Nylon membrane 
(Amersham). The membrane was baked at 80 °C for 2 hrs. Then it was washed in 
washing buffer for 2 min at RT. The membrane was blocked in 10 ml of blocking 
solution (1 X washing buffer, 0.1 % Triton-X 100 and 5% Marvel milk) for 30 min at 
RT. Then, an anti-digoxigenin-alkaline phosphatase was diluted to 1/1000 in a fresh 
blocking solution, added to the membrane and left shaking at RT for 1 hr. The 
membrane was washed twice in washing buffer for 5 min, incubated in 10 ml of 
NBT/BCIP at RT for few min and washed in ddH2O for 5 min. The concentration of 
the riboprobe was extrapolated from the intensity and the concentration of the control 
dot. 
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3.3.5.6 In Situ Hybridisation 
Paraffin embedded tissue sections from patients with benign and malignant tumours 
were dewaxed twice in 1X xylene for 10 min, dehydrated twice in 100 % ethanol, 
once in 70 % and 50 % for 5 min. The sections were washed sequentially in 1X PBS 
for 5 min, 1X PBS + 0.3 % Triton X-100 for 15 min and 1X PBS for 5 min. The 
tissues were permeabilized using 20 µg/ml proteinase K (100 mM Tris, pH, 7.4 and 5 
mM EDTA, pH, 8.0) at 37 °C for 30 min, then fixed in 4% paraformaldehyde in PBS 
for 5 min. at 4 °C. The sections were washed twice in 1X PBS for 5 min with shaking 
and acetylated in 0.1 M triethanolamine and 0.25 % acetic anhydride for 10 min. The 
tissues were washed twice in 1X PBS for 5 min. The sections were prehybridized at 
50 °C for 1 hr in 50 % formamide, 10 % dextran sulfate, 1X Denhard's solution, 4X 
SSC, 10 mM DTT, 250 µg/ml E. coli t-RNA and 100 µg/ml sonicated salmon sperm 
DNA. A fresh hybridisation mixture containing 20 ng/ml TSPY Digoxigenin labelled 
riboprobe was added to each section and placed at 50 °C overnight. The tissues were 
washed at increased stringency in 50 % formamide containing 2X SSC (0.3 M NaCI 
and 0.03 M Sodium citrate), 1X SCC and 0.5 SSC at 50 °C for 30 min. 
3.3.5.7 Immunodetection 
The tissues were washed twice in washing buffer for 10 min at RT, then blocked in 1 
X washing buffer + 5% normal sheep serum at RT for 30 min. A fresh solution 
containing 1X washing buffer, 0.1% Triton-X 100,1% sheep serum and an anti- 
Digoxigenin antibody conjugated with alkaline phosphatase at 1/500 dilution was 
added to the sections and left at RT for 2 hrs. The tissues were washed twice in 
washing buffer for 5 min. The sections were covered with NBT/BCIP colour substrate 
solution (0.34 mg/ml Nitroblue Tetrazolium salt, NBT and 0.17 mg/ml 5-Bromo-4- 
Chloro-3-Indoylphosphate, BCIP) and left overnight at RT, rinsed in TE buffer (10 
mM Tris-C1, pH, 8.0 and 1 mM EDTA), ddH2O and counterstained in 0.1% nuclear 
fast red (12.5 g Aluminium Sulfate, SIGMA, 0.25 g Nuclear fast red, SIGMA and 
250 
ml ddH2O). 
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3.3.6 WST-1 cell proliferation assay 
A non-radioactive colourimetric assay for the quantitation of cell proliferation and 
viability. The assay is based on cleavage of Tetrazolium salt (WST-1) to Formazan 
dye by mitochondrial dehydrogenases (Figure 3.2). The amount of dye produced from 
viable cells is quantified by measuring absorbance at 450 nm using microtiter plate 
(ELISA) reader. The assay is carried out as follows: cells were detached, counted and 
8x103 cells in 100 µl of full media were placed in 60 wells of 96 well plate. The cells 
were incubated at 37°C for 24hr. Then, the cells were washed twice in PBS and 100 
µl of basal medium was added. After, 48 hr of incubation, 10 µl of WST1 reagent was 
added to each well and left at 37°C for 1-4 hrs. The plate was inserted into microtiter 
plate (ELISA) reader using a filter suitable for wave length of 450 nm. In each assay, 
samples were performed in 18 replicates. The readings were subtracted from 
background control (blank). Dynex Revelation software was used to collect the data. 
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Figure 3.2. Cell proliferating WST-1 reagent 
WST-1 assay is a non radioactive test that is an alternative to th thymidine 
incorporation assay. It is used to determine proliferation rate of viable cells. The assay 
is based on the cleavage of WST1 reagent (tetrazolium salt) by mitochondrial 
dehydrogenase to formazan that is darker in colour and can be quantified at specific 
wavelength. 
i 
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3.3.7 3H Thymidine incorporation assay 
The Thymidine assay is a very sensitive and simple assay. This assay measures the 
cell proliferation through incorporation of tritiated Thymidine into the DNA of 
replicating cells (S-phase). In this assay, cells were detached, counted and 8x1 03 cells 
in 200 µl of full media was inserted in 60 wells of 96 well plate. The cells were left at 
37°C for 24 hrs. Then, the wells were washed twice in PBS and 200 µl of basal media 
were added to each and left for another 24 hrs at 37 °C. The next day, 200 µl of full 
media was added to each well, combined with 0.6 µ MCi/well H3 Thymidine and 1 
µM cold Thymidine. After 24 hrs of incubation at 37 °C, the media was removed and 
the cells were washed twice in PBS. The cells were detached and lysed by adding 50 
µl of Trypsin/EDTA to each well and the plate was incubated in 37°C incubator. 
After 1 hr of incubation, 200 µl of 12.5 % Trichloroacetic (TCA) was added to each 
well and the plate was cooled on ice for 2 hrs. An automated cell harvester (Wallac) 
was used to transfer the contents of each well onto a glass fibre filter (Wallac). The 
filter was dried and placed in a plastic bag filled with 5 ml of ß-scintillation fluid. 
Then, the filter was inserted into a liquid scintillation counter and the level of ß 
emission was determined and reported as count per second using MicroBeta software. 
Samples were performed in 24 replicates. The readings were subtracted from the 
readings of the blank control. 
3.3.8 Colony formation assay 
This assay determines the ability of single cells to grow in isolation and form colonies. 
Cells were trypsinised, counted, diluted and 500 cells were seeded into 100 mm dish 
in 10 ml full media plus selective media. Cells were left for 2-3 weeks to form 
colonies. The medium was removed and the cell were washed twice in PBS, and then 
fixed in 4% paraformaldyhyde dissolved in PBS for 30 min with shaking. The cells 
were washed two times in PBS before adding 5 ml of 4% Methylene Blue (SIGMA) 
dissolved in 50% ethanol. The cells were left shaking for 30 min to stain. Cold water 
was used to remove excess dye, the cell were dried and the number of colonies 
formed were counted and colony formation efficiency was calculated by dividing the 
counted colony number by initial plated cell number, multiplied by 100. Samples 
were tested in triplicate and the assay was performed 3 times. 
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3.3.9 Immunofluorescence 
Sterile cover glasses sized 22x22 mm were inserted in wells of 6 well plate. Cells 
were seeded on the cover glasses and left for 24-72 hrs at 37°C to grow. The medium 
was discarded and the cells were washed twice in ice cold PBS. Then, cells were fixed 
in 1 ml pre-cooled methanol at -20 °C for 20 minutes. The methanol was removed 
and the cells were air dried. The cells were blocked in 600 µl of I. F. blocking solution 
(10 % Goat Serum, 50 mM Tris and 0.4 % Triton-X) at RT for 1 hr. Then, 600 µl of 
Anti-FLAG M2 monoclonal antibody (SIGMA) diluted 1: 200 in I. F. solution (0.3 % 
Goat Serum, 50 mM Tris and 0.4 % Triton-X) was added and left at 4 °C O/N. The 
next day, the cells were washed three times in 50 mM Tris solution for 5 minutes 
before adding 600 µl of Goat anti mouse immunoglobulin-FITC F (ab')2 diluted 1: 20 
in I. F. solution. The cells were left at RT for 1 hr in dark. The cells on the cover glass 
were washed three times in 50 mM Tris solution for 5 minutes, dried and mounted on 
slides using Vectashield mounting medium with DAPI. The edges of the cover glass 
were sealed using nail vanish. The slides were examined using fluorescent Leica 
microscope. 
3.3.10 Statistics 
All statistical analyses were performed with the statistical software package SPSS. 
Fisher's exact test was used to compare different TSPY expression intensities between 
CaP and BPH, between CaP and clinico-pathological parameters. Correlation between 
immunoreactivity and age was carried out using Spearman's correlation test. Survival 
analysis was performed using the Kalpan-Meier Method and long rank test was 
applied to determine statistical significance. Proliferation rate comparison between 
clones with and without transfected TSPY were performed using Student's T test. P 
values of less than 0.05 were considered statistically significant. 
94 
Chapter 3: Expression and Functional Analysis of TSPY in Prostate Cancer 
3.4 Results 
3.4.1 Validation of anti-TSPY antibody 
A rabbit polyclonal TSPY anti-peptide antibody was generated as described in the 
materials and methods. Rabbit terminal bleeds were tested using ELISA, dot blot and 
Western blot. In the ELISA method, the curve of pre-immune serum shows basal 
detection levels binding activity. On the other hand, constant binding activity was 
detected using immunised rabbit terminal bleed crude serum from dilution 1: 50-1: 800, 
followed by a sharp decrease in antibody detection (Figure 3.3). 
Rabbit 1 Serum 
f Pre-immunised Rabbit 1 Serum 
Final test immunised Rabbit 1 Serum 
ý 
ci 
6 
Serum Dilution 
Figure 3.3. ELISA curve. 
Sera from immunised and pre-immune rabbits were serially diluted as given in the 
graph and analysed by ELISA against TSPY peptide. The immunoreactivity of the 
serum to TSPY peptide was detected indirectly using colorimetric substrate. 
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3.4.2 Detection of rabbit TSPY polyclonal antibody using 
dot blot. 
Successful generation of TSPY immunoglobulin against TSPY peptide was confirmed 
using dot blot analysis. Only the serum from immunised rabbit with or without 
absorption to non-TSPY peptide can detect TSPY bound to filter. (Figure 3.4) 
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3.4.3 Purification of TSPY Antibody by Affinity 
Chromatography 
To eliminate non-specific proteins and antibodies in the serum, TSPY rabbit serum 
was purified using affinity chromatography. Eluted immunoglobulins from affinity 
column was detected (Figure 3.5). The specificity of the purified antibody and the 
optimal dilution for Western blot was tested using PC3M cell line transiently 
transfected with FLAG-TSPY and empty vector. A clear specific protein band for 
TSPY was detected in the lysate derived from cells transfected with FLAG-TSPY but 
not in cells transfected with empty vector control (Figure 3.6). 
Affinity Purification of TSPY ab 1 
012345678 
Fractions 
Figure 3.5. TSPY antibody purification using Affinity Chromatography. 
TSPY antibody was purified from rabbit crude serum using affinity chromatography 
method. Eight fractions were collected from eluted solution and each fraction was 
mixed with Bio-Rad protein detection kit to determine the faction containing TSPY 
antibody. Only the first 3 fractions were pooled together and concentrated. 
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Figure 3.6. Anti-TSPY affinity purified antibody titration for Western blot. 
PC3M cell line was transiently transfected with either FLAG-TSPY-PCDNA3 (A, C, 
D and E) or empty vector (B), and left for three days to grow. Cell lysates were 
collected and used in Western blot analysis. Affinity purified TSPY anti-peptide 
antibody was diluted 1: 500 (A), 1: 1000 (C), 1: 2000 (D) and 1: 4000 (E) and was used 
as primary antibody. Dilution 1: 1000 was selected as the optimal dilution and used in 
further Western blots. SeeBlue standard protein broad range marker (BioRad) was 
loaded in lane M. Top and bottom bands (*) represent non-specific proteins detected 
by antibody. 
3.4.4 Cellular localisation of TSPY 
Cellular localisation of FLAG-TSPY transiently transfected into LNCaP cell line was 
determined using indirect immunofluorescence. Cells transfected with FLAG-TSPY 
were compared to clones transfected with empty vector (negative control). Cellular 
localisation was determined after 3 days. FLAG-TSPY was found to be located in the 
cytoplasm in all transfected cells. Strong peri-nuclear membrane located TSPY was 
observed (Figure 3.7). 
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Figure 3.7. Cellular localisation of FLAG-TSPY in LNCaP cells 
LNCaP cells were transiently transfected with either FLAG-TSPY or empty vector 
(negative control) and left to grow for three days. Anti-FLAG monoclonal antibody 
was diluted and used to detect cellular localisation of recombinant TSPY protein. 
Cytoplasmic fluorescence signal was detected in LNCaP cell line expressing 
exogenous FLAG-TSPY (a). Nuclear DAPI staining of cells (b). No background 
signal was detected in the negative control. Other controls were included such as 
omitting the primary antibody, secondary antibody or both antibodies (data not 
shown). LNCaP transfected with empty vector (c). Neclear DAPI staining of cells (D). 
100 
Chapter 3: Expression and Functional Analysis of TSPY in Prostate Cancer 
3.4.5 Immunodetection of TSPY expression in clinical 
samples 
The optimal dilution of the affinity purified anti-TSPY peptide specific rabbit 
polyclonal antibody was determined using a series of paraffin embedded tissue 
sections from one BPH patient. Dilution 1: 1000 was the optimal concentration. This 
concentration was used in all subsequent IHC to determine the level of TSPY 
expression in CaP compared to BPH cases. In total, 92 cases of prostate paraffin 
embedded sections were used for immunostaining, 72 cases were from patients 
affected by CaP and 20 cases were from patients suffering from BPH. In general, 
TSPY immunoreactivity was present in all BPH and CaP tissue sections. The 
expression was predominantly localised to cytoplasm of the epithelium in CaP and 
BPH. The expression profile in BPH was different from CaP (Figure 3.8). In all BPH 
cases, moderate cytoplasmic expression was detected within the glandular prostate 
epithelial basal cells and the expression within secretory epithelial cells was weak to 
absent. Similar trends of expression were also observed in histological normal and 
hyperplastic granular prostate epithelium adjacent to prostate malignant epithelium in 
CaP cases. In contrast, in the majority of CaP cases, the expression was moderate to 
strong in tumour cells. Statistical analysis has confirmed that TSPY was preferentially 
over-expressed in CaP compared with BPH (P<0.0001) (Table 3.1). The expression 
intensity was correlated to the clinical and pathological parameters available. The 72 
CaP were sub-divided according to Gleason grade into six cases of Gleason grade 2-5 
and 66 cases of Gleason grade 6-10. The expression was weak in only 1 case with 
Gleason 2-5 and 3 cases with higher grade (6-10). The expression was moderate in 
five cases with G 2-5, but strong expression was not detected (Table 3.1). Moderate to 
strong expression was detected in 63 high grade CaP cases. A positive statistically 
significant correlation between TSPY expression and Gleason score was confirmed 
(P<0.02). In the CaP group, 26 patients had positive bone scans signifying the 
presence of bone metastasis. Increased TSPY expression was significantly associated 
with the presence of bone metastasis (P<0.028) (Table 3.1). Pathological stages for 
most of the cases were available. TSPY expression was not found to be associated 
with clinical stage (P<0.4). In addition, in this small cohort of patients with prostate 
cancer, no correlation was observed between TSPY expression and survival outcome 
or patient age (data not shown). 
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Figure 3.8. Immunostaining of prostate sections using TSPY antibody. 
Affinity purified anti TSPY peptide was used in IHC method to determine TSPY expression level in 
prostate resected sections from patients with BPH and CaP. (A) BPH gland showing moderate 
cytoplasmic expression of TSPY in basal cells, with minimal expression in the sceretory epithelial cells. 
(B) Strong cytoplasmic expression in Gleason grade 3 prostate cancer, no evidence of nuclear expression. 
(C) Strong cytoplasmic expression of TSPY in Gleason 4 prostate cancer as shown in the right side of 
the image compared to the adjacent BPH gland on the left. (D) BPH section in which the primary 
antibody was omitted and no signal was detected. (E) Section of testis as positive control showing strong 
nuclear expression of TSPY in speramtocytes (double headed arrow), mature speramtides show no 
expression of TSPY (arrow heads), weak nuclear and cytoplasmic expression is present in the sertoli 
cells (broken arrow). Female liver (F), lung (G) and kidney (H) tissues were used as negative controls. 
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Weak Moderate Strong P -value 
CaP 4 40 28 
BPH 20 P<0.0001 
Gleason score 
2-5 G (n=6) 15 
6-10 G (n=66) 3 35 28 P<0.026 
Metastasis 
Bone scan (n=26) 12 14 
None (n=29) 3 18 8 P<0.028 
Clinical Stage 
Ti (n=11) 
T2 (n=14) 
T3 (n=16) 
T4 (n=8) 
164 
176 
12 4 
143 P<0.44 
Table 3.1. Immunostaining pattern of TSPY in prostate. 
TSPY expression intensity was classified into weak, moderate and strong. Prostate 
cancer cases were categorised according to expression profile, clinical and 
pathological data available. Statistical significance correlation between expression 
level and Gleason score, metastasis or clinical stage was determined using Fisher's 
exact test. 
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3.4.6 TSPY mRNA expression in clinical samples 
3.4.6.1 Probe synthesis 
TSPY sense and anti-sense riboprobes were generated using in vitro transcription 
(Figure 3.9). The riboprobe was diluted, semi-quantified using dot blot by comparing 
the intensity of riboprobe signal to standard control with known quantity of labelled 
probe (Roche) (Figure 3.10). 
Ml 23 
1000 bp 
100bp 
M12 
AB 
Figure 3.9. Generating labelled probes 
Expression and cloning vector harbouring partial TSPY gene sequence including 3' 
end was linearised using EcoR I or Not 1 (A); Hind III cut Lamda DNA marker 
(M); 
lane 1, uncut plasmid; lane 2, EcoR I cut plasmid and lane 3, Not I cut plasmid. 
(B) 
Labelled riboprobe product (M) l kb ladder marker; lane 1, sense riboprobe; 
lane 2 
anti-sense riboprobe. 
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Figure 3.10. Riboprobe quantitation using dot blot. 
A standard labelled probe of known concentration was diluted serially 1: 4 and dotted 
onto filter. Sense and anti-sense riboprobes were also diluted and dotted on the same 
filter and an estimate of synthesised riboprobe quantity is determined by comparison 
with the control. 
3.4.6.2 TSPY mRNA expression in prostate 
For each case of CaP or BPH, both sense and anti-sense riboprobes were generated. In 
keeping with IHC analysis, TSPY mRNA expression was observed predominantly in 
the prostate epithelium and a low level of non-specific signal was detected in the 
stroma ( 
Figure 3.11). The mRNA expression was located in the basal cell and luminal cells of 
the benign epithelium in BPH and CaP. Similar to immunodetected TSPY expression, 
significant signals were observed in the malignant epithelium. Hence, the pattern of 
TSPY expression at both protein and mRNA levels are consistent. 
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Figure 3.1. TSPY expression pattern in prostate sections using TISH. 
Expression patterns of TSPY mRNA and tissue location were detected in CaP and BPH using TISH 
method. Anti-sense probe and sense probe (control) were used for each case. The expression of 
TSPY transcript was detected in the epithelium of BPH gland (A). TSPY was expressed in basal 
cells and luminal cells. Non-specific stromal staining was observed. Expression of TSPY was also 
shown in the malignant epithelium (C). Normal testis sections were used as positive control (E). 
Female tissue sections from liver (G), lung (H) and kidney (I) were used as negative controls. 
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3.4.7 Functional significance of TSPY over-expression 
3.4.7.1 Generation of FLAG-TSPY LNCaP expressing cells 
FLAG-TSPY cloned in pCDNA3 vector was transfected into the human prostate 
cancer LNCaP cell line. Stable LNCaP clones were selected, screened and tested for 
TSPY expression using anti-FLAG monoclonal antibody. In total, 70 clones were 
screened using Western blot analysis and 14 clones expressed TSPY at variable levels 
(Figure 3.12). Clones that contain empty vector were also selected and used as 
reference for comparison. Two positive clones were selected for functional analysis 
(Figure 3.13). 
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Figure 3.12. Screening LNCaP stable clones for expression of FLAG-TSPY 
LNCaP stable clones transfected with FLAG-TSPY were screened for expression of 
exogenous TSPY using mouse monoclonal anti-FLAG-antibody. LNCaP transiently 
transfected with FLAG-TSPY was used as positive control (1 and 12). LNCaP 
transiently transfected with empty vector was used as negative control (10 and 20). 
Clones that either expressed TSPY or not were identified (3-9 and 13-19). SeeBlue 
protein marker was used (2 and 11) 
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Figure 3.13. Selected FLAG-TSPY expression clones 
Quality of total RNA isolated from LNCaP stable clones expressing FLAG-TSPY and 
one clone with empty vector were checked using agarose gel electrophoresis (A). The 
presence of recombinant TSPY was assessed using FLAG-forward primer and TSPY 
reverse primer in RT-PCR (B). Lane 1 and 2 are stable clones expressing FLAG- 
TSPY and lane 3 is an empty vector as a control. Western blot analysis of two stable 
clones expressing FLAG-TSPY and empty vector (C). Lane 1, transiently transfected 
FLAG-TSPY into LNCaP cell line, Lane 2,3,4 are two stable clones and one control 
clone respectively. The membrane was stripped and probed with a-tubulin antibody to 
check for loading (D). 
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3.4.7.2 TSPY over-expression promotes in vitro LNCaP cell 
growth 
1) WST-1 assay 
The proliferative rate of two independent clones expressing FLAG-TSPY and a 
control clone were investigated using WST-1 colorimetric proliferation assay. The 
clone that contained empty vector was used to determine the optimal seeding number 
and incubating time for the assay (Figure 3.14). Presence of exogenous TSPY has 
significantly increased the proliferative rate of LNCaP by nearly two fold compared to 
control (Student's t test, P<0.000, Figure 3.15). The assay was performed 6 times and 
each clone was plated in 18 replicates. 
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Figure 3.14. Cell proliferation assay. 
Optimisation of cell number to be seeded for cell proliferation assay. LNCaP Cells 
were seeded as indicated and left for 24 hr to adhere, followed by serum starvation for 
24 hr prior to addition of full medium for 24 hr followed by adding WST-1 reagent. 
Cell number 8000 was the optimal. 
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Figure 3.15. Proliferation rate of LNCaP clones over-expressing FLAG-TSPY. 
Two independent LNCaP stable clones were selected and proliferation rate was 
compared to a clone that contained only stable empty vector. Two fold increase in cell 
proliferation was observed (P<0.0001). The assay was performed six times. 
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2) Thymidine incorporation assay for DNA synthesis 
Radioactive H3 Thymidine incorporation assay was established and optimal seeding 
LNCaP clone cell number and time of incubation were determined (Figure 3.16). 
There was increased proliferation of LNCaP clones expression TSPY compared to the 
control (Figure 3.17). 
6 hr 12 hr 24 hr 
Time 
30 hr 48 hr 
Figure 3.16. Optimal incubation time for Thymidine incorporation assay. 
Optimisation of incubation time with radioactive Thymidine. LNCaP cells were plated 
in 24 replicates and left to adhere and grow for 24hr. Cells were serum starved for 24 
hr. Full medium was added and H3 radioactive Thymidine was added and cells 
incubated for 6,12,24,30 and 48 hrs. Incubation for 24 hr was the optimal time. 
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Figure 3.17. Cell proliferation of LNCaP clone over-expressing FLAG-TSPY 
Cellular growth of LNCaP cells expressing FLAG-TSPY was compared to LNCaP 
containing empty vector. Two LNCaP different clones were used and 2 fold increase 
in proliferation relative to control vector was observed (Student's t test, P<0.0001). 
The assay was repeated three times. 
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3) Colony formation assay 
LNCaP cells stably over-expressing TSPY showed a3 fold increase in the number of 
colonies when compared to the cells transfected with control vector (Figure 3.18). 
200 -1 
Empty Vector 
Clones 
Clone 1 
Figure 3.18. Colony formation ability of LNCaP cells over-expressing FLAG- 
TSPY 
Colony forming ability of FLAG-TSPY LNCaP clone compared to a clone with an 
empty vector. Up to three fold increase in colony forming ability in clone expressing 
recombinant TSPY was observed (Student's t test, P<0.0001). The assay was carried 
out three times. 
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3.5 Discussion 
An anti-TSPY rabbit polyclonal antibody was generated, validated and applied to 
determine the levels of TSPY expression in clinical prostate specimens. Seventy two 
cases of CaP and 20 cases of BPH were studied and immunostained for TSPY 
expression. The expression pattern within the prostate epithelium of normal and 
hyperplastic glands was similar. The TSPY immunoreactivity was moderate in the 
basal cells and weak to absent in luminal cells which are differentiated and have a low 
rate of proliferation and relatively high apoptotic index. In contrast, basal cells are 
undifferentiated and have a high proliferative capacity and low apoptotic index 
(Schalken and van Leenders, 2003). This indicates that TSPY level of expression is 
higher in prostate dividing cells than non-dividing cells. Similar trend of expression 
has been detected in a study carried out by Lau et al, 2003. He generated a rabbit 
polyclonal antibody raised a gainst a recombinant TSPY protein. Although he 
examined the expression profile of TSPY protein in a limited number of clinical 
prostate sections using IHC, he detected similar level of TSPY expression in 
normal/BPH epithelium. 
Among most of the CaP cases studied in the current study, over-expression of TSPY 
was observed in 68/72 (95%) of the malignant epithelium. TSPY expression in 
prostate cancer was significantly higher than in BPH (P<0.0001, Fisher's exact test). 
Comparable patterns of TSPY expression were also observed between the BPH 
control and the foci of benign glands adjacent to the malignant epithelium in the CaP 
cases. In the benign prostatic epithelium, there is a balance between low rate of cell 
proliferation and apoptosis. This contrasts with 7 to 10 fold increase in the rate of 
proliferation in prostate cancer (Abate-Shen and Shen, 2000). This is in consistent 
with observations reported by IHC analysis carried out by Lau et al, 2003. He 
reported a preferential elevation of TSPY expression in adenocarcinoma cells of the 
prostate compated to normal/BPH epithelial cells. 
Clinical and pathological details for the series of prostate cancers were corroborated 
with TSPY expression pattern. Malignant specimens were 
divided according to their 
Gleason sum scores into score: 2 to 5 and 6-10. There was a strong positive 
association between increased TSPY expression and 
high Gleason sum scores. Similar 
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findings were reported by Lau et al, 2003. He detected that increased TSPY 
expression correlated with high tumour grade, suggesting that its abberant expression 
contributes to prostate carcinogenesis. 
Bone metastasis is frequently associated with advanced prostate cancer and in the 
current study, there was a strong correlation between TSPY expression and bone 
metastasis. Hence, TSPY may have a role in prostate carcinogenesis and disease 
progression. Within this relatively small study, TSPY expression was not found to be 
associated with survival outcome; a larger study with many case of prostate cancer, 
particularly cases with relatively low Gleason scores, is required. 
TSPY immunoreactivity in clinical prostate tissues was detected as a cytoplasmic 
protein. There was no apparent nuclear TSPY immunoreactivity observed in prostatic 
sections. Indirect immunofluorescence analysis has shown that exogenous FLAG- 
TSPY expression in prostate LNCaP cells was also predominantly located in the 
cytoplasm. Thus, TSPY appears to be a cytoplasmic protein in prosate tissues. In this 
study, normal testes sections were used as a positive control, TSPY immunoreactivity 
was detected in the cytoplasm and nucleoplasm of spermatogonial cells. This is 
consistent with observation reported by Schnieder et al 1996: (1) cytoplasmic 
expression of TSPY in spermatogonial cells within the normal testis; (2) ocassoinal 
nuclear staining in a subpopulation in spermatogonial cells. In addition, similar 
findings were also reported by Hilderbrand et al, 1999 and Lau et al, 2000. They 
studied the expression of TSPY in gonadoblastoma resected sections using IHC. 
TSPY was located in the cytoplasm of germ cell tumour with occasional nuclear 
staining of TSPY in few cells. This indicates that TSPY can be expressed in nucleus 
and cytoplasm of cells depending on cell type. The presence of nuclear localisation 
signal in the TSPY protein sequence further support this findings. The significance of 
this nuclear/cytoplasmic is still not unknown. 
Preferential over-expression of TSPY in adenocarcinoma compared to normal and 
BPH was also detected using TISH. Up-regulation of TSPY mRNA correlated with 
increased Gleason grade. Although luminal staining was detected in BPH and normal 
glands, in general there was elevated level of TSPY expression in malignant lesions 
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compared to normal/BPH glands. Similar trend of expression were also observed by 
Lau et al., 2003 study. 
To address the role of TSPY gene in prostate cancer development, stable LN cells 
constitutively expressing exogenous FLAG-TSPY were established and characterised. 
When compared to the empty vector control cells, LNCaP-TSPY expressing cells 
have an increased proliferative rate and enhanced ability to form colonies in in vitro 
assays. 
TSPY is a candidate oncogene located on the Y chromosome that has been postulated 
to be involved in testicular cancer. TSPY protein shows homology to SET oncogene. 
The SET gene was originally identified as a component of SET-CAN fusion gene 
produced by somatic translocation in acute undifferentiated leukaemia (von Lindern et 
al., 1992). The function of SET oncogene is not yet fully known. However, several 
possible functions have been proposed. SET is found to specifically interact with 
cyclin B, but the significance of this interaction is not known (Kellogg et al., 1995). 
SET has been found to interact with p21 and regulate G1/S transition by modulating 
the activity of E-CDK2 (Estanyol et al., 1999). SET was confirmed to be a potent 
inhibitor of protein phosphatase 2A (PP2A) which is a serine threonine phosphatase 
involved in regulating cell proliferation, differentiation and transformation (Mumby 
and Walter, 1993). Thus, SET may play a role in regulating the cell cycle and its 
fusion with CAN protein contributes to leukaemia. 
3.6 Conclusion 
TSPY is over-expressed in clinical prostate cancer and correlated with high grade 
tumours. Over-expression of TSPY in LNCaP cells enhances cellular proliferation and 
colony formation in keeping with a vital role for TSPY in the development of prostate 
cancer. 
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4.1 Introduction 
TSPY gene was first discovered in humans by (J Arnemann, 1987). Subsequently, its 
homologues were detected in other mammals including: apes, cattle, sheep, goats, 
horses, pigs and rodents (Jakubiczka et al., 1993, Kim et al., 1996, Mazeyrat and 
Mitchell, 1998, Vogel et al., 1997b, Zhang et al., 1992). Using semi-quantitative 
Southern blotting, 20-50 copies have been detected in the human genome (J 
Arnemann, 1987, Manz et al., 1993, Schnieders et al., 1996, Tyler-Smith et al., 1988) 
and most of TSPY copies have been found to map to Ypl1.2 (Schempp et al., 1995). 
However, additional TSPY copies are located at Ygl1.23 (Schempp et al., 1995). 
Each copy is embedded within DZY5 repeat units organised in array of 20 kb 
genomic sequence (Manz et al., 1993). The full length genomic sequence of TSPY 
has been identified, cloned and characterised by two independent groups (Arnemann 
et al., 1991, Zhang et al., 1992). The gene is 2.8 kb in length and consists of 6 exons 
and 5 introns. 
As described in the previous chapter, TSPY was found to be over-expressed in CaP. 
The molecular mechanism of preferential expression is not yet known. The presence 
of TSPY as a multicopy gene suggests that increased gene copy number might be 
responsible for TSPY abnormal expression. 
Several different methods are available for determining gene copy number from 
clinical materials. Southern blot method is quantitative, but it requires a large amount 
of DNA (>10 µg) and the experiment takes several days to complete. Comparative 
genomic hybridisation (CGH) is one of the most widely used methods to detect 
increase or decrease in gene copy number across the whole genome but at relatively 
low resolution. Fluorescent in situ hybridisation (FISH) is frequently used to detect 
copy number at cellular level but is not suitable for high throughput analysis. It is also 
difficult to study gene copy number of more than 25 copies with FISH. In contrast, 
quantitative PCR based techniques allow amplification and quantification of low 
starting genomic materials. Quantitative (real time) PCR is therefore the most 
common assay that is currently used in oncology for gene dosage determination. 
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4.1.1 Quantitative Real Time PCR 
Quantitative Real Time PCR is simple, rapid, specific and efficient method. The 
method is based on the detection and quantification of a fluorescent reporter. The 
assay monitors the fluorescence emitted during each PCR cycle (i. e., real time), which 
increases in direct proportion to the amount of PCR product in the reaction. This 
method specifically records the fluorescence released during the exponential phase of 
PCR. The detection of the first significant increase in the amount of PCR product 
during the exponential phase of PCR correlates with the initial amount of the target 
template, reviewed in (Bustin, 2000). There are 4 different available real time PCR 
assay formats. The simplest method is DNA-binding dye which specifically binds to 
DNA double strands but not to single strands. The other three (molecular beacon, 
hybridisation and hydrolysis probe) are based on probes designed to bind to specific 
sequence within the amplicon. 
4.1.1.1 DNA binding dye 
This assay is a simple quantitative method, relying on the ability of a SYBER green 
fluorescent dye to bind to double-stranded DNA (dsDNA) but not to single-stranded 
DNA. Therefore, only dsDNA-bound dye emits fluorescence upon excitation. 
Unbound dye usually exhibits very low levels of fluorescence (Figure 4.1). The main 
advantages of this assay are, simplicity, low cost and the fact that there is not need for 
additional specific probes. However, the dye binds to any double stranded DNA 
including both specific and non-specific products. In addition, more dyes will bind 
longer DNA strand than shorter, rendering quantitation inaccurate. 
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Figure 4.1. Dye incorporation method. 
During PCR denaturation step, unbound SYBR Green I dye exhibits little 
fluorescence. At the annealing step, the dye molecules bind to the double stranded 
DNA, resulting in light emission upon excitation. During polymerisation step more 
dye molecules bind to the newly synthesised DNA and the increase in fluorescence 
can be detected in real time. In the denaturation phase, the dye molecules detach from 
the DNA and the fluorescence signal returns to background level. 
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4.1.1.2 Molecular beacon probe 
Molecular beacons are DNA hybridisation probes that are synthesised to be partially 
self anneal to form stem and loop (hairpin structure). The loop part of the probe 
recognises a specific DNA sequence and the stem is formed by self annealing of the 
complementary ends of the probe. A fluorescent dye is linked to one end of the probe 
arm and a quencher is attached to the other end. The hairpin structure of the probe 
keeps the dye in close proximity to the quencher, hence suppressing the emission of 
fluorescent signals. During the annealing step of PCR, the molecular beacon arms 
detach and the probe binds to its target DNA. This separates the dye from the 
quencher, leading to emission of fluorescence upon excitation (Figure 4.2). This assay 
is specific, as a single nucleotide mismatch between the probe and the target sequence 
will prevent the beacon probe from hybridising and the probe will remain in hairpin 
form. The main obstacle associated with molecular beacons method is the probe 
design. The molecular probe, may fold to a conformation that displaces the quencher 
from the dye leading to high background fluorescence. On other hand, if the two ends 
are bound strongly, the binding of the probe to its target sequence may be impaired. 
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Figure 4.2. Molecular beacon assay. 
The assay is based on hybridisation of a probe (a short synthetic oligonucleotide) that 
specifically recognises the target sequence; fluorescent dye is attached to one end of 
the probe and a quencher is linked to the other end. In solution, the probe, assumes a 
hairpin structure due to the annealing of the two complementary ends. This brings the 
fluorescent dye close to the quencher suppressing emission of fluorescence. During 
the denaturisation step of PCR, the probe dissociates at the two ends. This is followed 
by the annealing phase when the molecular beacon binds to its specific DNA target 
(amplicon) and generates a fluorescent signal. If the DNA target is absent, the probe 
will anneal to its complementary ends and no fluorescent emission is produced. At 
polymerisation step, temperature is increased and the probe dissociates from its target, 
re-form the hairpin structure and fluorescence is suppressed. At every new PCR cycle, 
the probe hybridises to its target at the annealing step and the intensity of the 
fluorescent signal indicates the amount of amplicons accumulated at the end of the 
previous cycle. 
II 11111111 II 111111111111111 II 1111111 
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4.1.1.3 Hybridisation probe 
In this method, two probes are designed to obtain high specificity. One probe is 
synthesised to have a fluorescence donor dye at the 3' end that emits a green 
fluorescent signal upon excitation and the other probe is produced with acceptor 
fluorophore attached at the 5' end. In solution, the two probes are apart and only 
green background signal is emitted from the donor. At the annealing step of the PCR, 
the two probes are bound to their target sequence head to tail so that the donor dye is 
in close proximity to the acceptor. Upon excitation of the donor, fluorescence 
resonance energy transfers to the acceptor resulting in emission of red fluorescence 
(Figure 4.3). One of the major advantages of this assay is its high level of specificity 
as fluorescent signals will only be detected when both probes bind to their specific 
target. 
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Figure 4.3. Hybridisation probe method. 
At the denaturation step, both probes remain apart, a low level of emission signal is 
present. During annealing step both probes hybridise to target sequence in a head to 
tail arrangement. The two dyes come into close proximity and the emitted energy 
from one dye excites a second dye that emits a fluorescent signal. At the 
polymerisation step, both probes separate and the fluorescent signal returns to 
background level. 
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4.1.1.4 Taqman hydrolysis assay 
Taqman assay is among the most commonly used quantitative real time fluorescent 
PCR methods. The Taqman assay using hydrolysis probe is based on the 5'-3' 
exonuclease activity of Taq polymerase. A short fluorescent oligonucleotide probe is 
generated. The probe contains a fluorescent reporter (FAM, 6-carboxy-fluorescein) 
and quencher dye (TAMRA, 6-carboxy-tetramethyl-rhodamine) covalently attached at 
the 5' end and the 3' end, respectively (Figure 4.4). The close proximity of the 
quencher dye to the reporter dye quenches the fluorescent signal of the reporter. 
During the extension phase of the PCR cycle, the fluorescent probe hybridises to its 
target sequence and is hydrolysed by the 5'-3' exonuclease activity of DNA Taq 
polymerase. This cleavage of the probe separates the fluorescent dye from the 
quencher dye resulting in fluorescence of the reporter dye (Lie and Petropoulos, 1998, 
Walker, 2002). The fluorescent signal is normalised by dividing the emission intensity 
of the reporter dye by the emission intensity of a passive reference dye (ROC, 6- 
carboxy-X-rhodamine) included in the Taqman buffer to obtain a ratio known as Rn 
(normalised reporter). AR represents the normalised reporter signal (Rn) minus the 
base line signal established in the first 15 PCR cycles. Threshold cycle (Ct) is the 
cycle number in which a statistically significant fluorescence signal is first detected 
during the exponential phase of PCR (Figure 4.4). Ct value is the core of Taqman 
assay and can be converted into quantitative results by constructing a standard curve. 
The Taqman assay is very sensitive, simple and reproducible. The assay is commonly 
used in a wide range of applications. It is used for the analysis of viral DNA copy 
number (Sofi Ibrahim et al., 2003), bacterial and fungal infections (Reiss et al., 1998, 
Rondini et al., 2003), detection of gene amplification in human neuroblastoma cancer 
(Raggi et al., 1999) and breast cancer (Bieche et al., 1999). 
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Figure 4.4. Taqman assay. 
The assay is based on a hydrolysis probe. Taqman probe is generated harbouring a 
fluorescent dye at one end and a quencher at the other end. The close proximity of the 
quencher to the dye suppresses the fluorescent signal. At the annealing phase of PCR, 
the primer and the probe bind to their target DNA. During the polymerisation phase, 
the probe is hydrolysed releasing the dye from the quencher, which results in emission 
the of fluorescent signal. 
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c 
cr- 
Cycle number 
Figure 4.5. Schematic representation of real time PCR amplification plot using 
Taqman assay. 
Threshold cycle (Ct) is cycle number at which a statistically significant increase in 
fluorescent signal above the basal level is first detected at the start of the exponential 
phase of PCR. It is a direct reflection of the initial quantity of target template. 
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4.2 Hypothesis: 
1) Expansion of TSPY copy number is a mechanism for TSPY over-expression in 
prostate cancer. 
4.2.1 Aims: 
To test the above hypothesis by real time PCR method based on Taqman assay to 
study the following cohort of clinical materials: 
1) Blood samples from patients with CaP compared to patients with BPH and a 
control population. 
2) Resected benign and malignant prostate tissues. 
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4.3 Materials and Methods 
4.3.1 Clinical samples 
1) Blood Samples 
Blood specimens from 119 individuals were collected and organised into three groups: 
CaP, n=47; BPH, n=27 and 45 healthy control adult males from North East England. 
All relevant clinical data for each case was collected. The ages ranged from 56-91 
years for the CaP group and from 51-79 years for the BPH group. In the group of 
control men, the age was generally below 50 years. as the development of BPH is 
inevitable in the ageing male. Blood was also collected from 4 healthy adult females. 
These samples were used as negative controls. 
2) Prostate tissues 
Prostate tissues from patients undergoing TURP were collected. The prostate tissues 
were snap frozen in liquid nitrogen and stored at -80 °C until further use. Clinical 
details were obtained. Forty four resected prostate samples were collected: CaP, n=31 
and BPH, n=13. Corresponding blood samples were also available for six of the 
cancer cases and 11 of the BPH cases. The ages ranged from 58-74 and 57-70 years 
for the CaP and BPH groups, respectively. Two female bladder cancer cell lines (T24 
and RT 112) were also included as negative controls. 
4.3.1.1 Genomic DNA isolation 
Genomic DNA was extracted from blood, resected prostatic specimens and cultured 
human cell lines using QlAamp DNA blood mini kit (QIAGEN. The whole blood was 
centrifuged and separated into three layers; plasma at the top, huffy coat containing 
white blood cells in the middle and red blood cells at the bottom. Only, the huffy coat 
was selectively retained and up to 1 ml volume was stored at -80 °C until processed. 
Frozen buffy coats were thawed and 200 µl were transferred into 15 ml Falcon tubes 
and 1X PBS was added to a final volume of 2 ml. White blood cells were digested to 
release genomic DNA by adding 200 pl of QIAGEN protease stock solution 
(20mg/ml) and 2.4 ml of AL buffer to the samples and mixing thoroughly by 
vortexing at least 3 times for 5 seconds each time. The tubes were incubated at 70 °C 
for 10 minutes. Then, 2 ml of 100 % ethanol was added to the samples and mixed by 
vortexing. Cellular lysates were divided into 2 halves and the first halves were placed 
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into QlAamp Midi columns inserted in 15 ml Falcon tube and centrifuged at 3000 
rpm for 3 minutes. The filtrates were discarded and the other halves of the mixtures 
were loaded again into the columns and tubes were spun at 3000 rpm for 3 minutes. 
The filtrates were discarded and the genomic DNA bound to the columns were 
washed sequentially in two different buffers. First, 2 ml of AW 1 buffer were added to 
the columns and the tubes were centrifuged at 5000 rpm for 1 minute. Then, 2 ml of 
AW2 buffer was added to the columns and the tubes were centrifuged at 5000 rpm for 
15 minutes. The QlAamp columns were placed in clean Falcon tubes and 200 µl of 
ddH2O was added and tubes were incubated at room temperature for 5 minutes and 
centrifuged at 5000 rpm for 5 minutes. The eluted DNA was dissolved and its 
concentration was measured using spectrophotometer (Wallac). Genomic DNA from 
50 mg solid tumour tissue specimens and from human male and female cancerous cell 
lines was isolated following the QlAamp DNA mini kit manufacturer's instruction. 
4.3.2 Quantitative Real Time PCR 
4.3.2.1 Primers and probe design and optimisation 
Primers and probes for Taqman assay were designed from TSPY genomic DNA 
sequence deposited in the NCBI database (accession number, 1932824). The TSPY 
sequence region including intron 1 and exon 2 was selected for oligonucleotide design 
(Figure 4.6). Primer express software (Perkin Elmer, PE) was used to select the best 
Taqman probe and primers that fit PE criteria for Taqman assay. These criteria are 
several. First, the probe is always designed before primers and the primers are 
selected to be as close as possible to the probe without overlapping it. Second, the 
melting temperature of the probe is usually higher than the primers by 10 °C and is in 
the range of 68-70 °C. Thirdly, keeping the GC contents in the range 30-80 % for both 
probe and primers is highly recommended. Fourthly, it is essential to avoid oligos that 
contain runs of 4 or more identical nucleotides especially Gs. Fifthly, probes with G at 
the 5' ends were avoided and the probe that has more Cs than Gs were selected. 
Finally, primers that have more than two Gs and/or Cs at the 3' ends were deselected. 
The Taqman probe was synthesised to contains a fluorescent reporter (FAM, 6- 
carboxy-fluorescein) attached to the 5' end of the probe and a quencher dye (TAMRA, 
6-carboxy-tetramethyl-rhodamine) covalently linked at the 3' end. All the probes and 
primers were purchased from PE (Table 4.1). 
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E1 E2 E3 E4 E5 E6 
Figure 4.6. TSPY genomic structure. 
Exons are highlighted in blue boxes and numbered E1 to E6. The line drawn between 
the exons represents introns. Intron 1 and exon 2 boundary were selected for 
designing Taqman probe and primers. Arrows indicate forward and reverse primer 
and the probe is shown in red box. Primers for conventional PCR were also indicated. 
Forward primer was selected at the beginning of exon I and reverse primer was 
chosen at the 3' UTR region. 
Primers and probes Sequences (5'-3') 
Real time PCR 
Forward primer TCTCTTTGACCTAAATCAGATTGCAA 
Reverse primer CTGACCATGTAGCTCAGCATGTCT 
Taqman probe CCAGATGTCAGCCCTGATCACTGACG 
Conventional PCR 
Forward primer ATGCGCCCTGAGGGCTCGCTG 
Reverse primer TTTTCCTTTAGTTCCTGTGCATAAGA 
Table 4.1. Primer and Taqman probe sequences. 
4.3.2.2 Primer concentration optimisation 
To establish the quantitative real time PCR Taqman assay for determining TSPY 
genomic copy number, the optimal probe and primers concentrations were determined 
following PE Taqman assay manual instructions. The forward and reverse primers 
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were titrated to determine the minimum concentration of both primers that will give 
the maximum signal above background in real time PCR method. Both primers were 
diluted to 22.5,7.5 and 1.25 pmole/ µl, mixed in 9 different primer combinations were 
with PCR mix and carried out in triplicate. The optimal concentration for the forward 
primer was found to be 7.5 pmole/µl and 22.5 pmole/µl for the reverse primer, i. e a 
ratio of 1: 3. Once the optimal concentrations of both primers were determined, they 
were used to titrate the probe optimal concentration. 
4.3.2.3 Probe concentration optimisation 
The purpose of this procedure was to determine the minimum Taqman probe 
concentration that will generate a fluorescent signal at the lower PCR cycle number. 
The PCR master mix was prepared and the optimal primer concentrations from the 
previous step were used. The probe was added at 0.65,1.25,1.87,2.5,3.12,3.75, 
4.37,5 and 5.6 pmole/µl concentration to PCR mix in triplicate. The optimal probe 
concentration was found to be 5 pmole/µl. 
4.3.2.4 Establishing TSPY absolute quantitative standard 
curve 
To establish an absolute quantitative standard curve, a DNA sample with known 
genomic TSPY copy number was obtained through collaboration with Dr. Mark 
Jobling at the Department of Genetics, University of Leicester. The genomic DNA 
copy number had previously been determined using pulse field gel electrophoresis 
method (PFGE). The DNA was diluted 10 fold from 105 to 102 copies and stored at - 
20°C until used. The diluted samples were added to the PCR mix that contained the 
TSPY primers and probe in triplicate and recommended PCR cycles were used. TSPY 
absolute quantitation standard curve was established for each PCR run and copy 
numbers of each unknown sample was extrapolated from the standard curve. 
4.3.2.5 Normalisation 
To rule out any effect of inaccuracies in determining the DNA concentration and 
errors due to dilution and pipetting variations, normalisation is integrated as an 
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essential step in the real time PCR quantitative method. The determined genomic 
quantity is normalised to a reference gene. A single copy reference gene RNASE P 
control kit that contains pre-designed, synthesised primers and probe was purchased 
from PE. The endoribonuclease RNase P gene is a ribonucleoprotein complex 
consisting of two subunits, an RNA catalytic subunit and a protein binding subunit. 
The enzyme catalyzes the site-specific cleavage of precursors tRNA to generate 
mature 5' termini reviewed in (Christian et al., 2002, Gopalan et al., 2002, Jarrous, 
2002). It is an essential and ubiquitous enzyme expressed in all cells and cellular 
compartments that synthesised tRNA (Gopalan et al., 2002). The RNase P complex is 
encoded by a single-copy gene and hence is used as a reference for normalisation. 
4.3.2.6 Real time amplification 
The real time PCR reaction was carried out in a final volume of 25 µl. The optimised 
primers (300 nM forward primer and 900 nM reverse primer) and probe (200 nM) 
concentrations were added to 12.5 µl Taqman Universal PCR Master mix that 
contains IOX Taqman Buffer, 200 µM dATP, 200 µM dCTP, 200 µM dGTP, 400 µM 
dUTP, 5 mM MgC12,0.5 Units AmpliTaq Gold, and 0.5 Units of AmpErase Uracil N- 
glycosylase (UNG). Each sample was done in triplicate and transferred into a 
MicroAmp Optical 96 well plate. Each assay included a standard curve DNA diluted 
from 105 to 102 copies, no template control, 100 ng of female genomic DNA as 
negative control, 100 ng of unknown DNA from different clinical sources and 100 ng 
of known genomic DNA as a calibrator. The plate was placed in ABI PRISM 5700 
sequence detector system. A two steps PCR was performed, an initial step at 50 °C for 
2 min. and 95 °C for 10 min and a second step of 40 cycles at 95 °C for 15 sec. and 
60°C for 1 min. Amplification data was collected and analysed using GenAmp 5700 
SDS sequence software (Applied Biosystems), normalised to the reference gene and 
the normalised copy number of each sample was determined. 
4.3.3 Statistical analysis 
Statistical package SPSS was used and graphs were produced using Prisms software. 
Non-parametric statistical method (Mann Whitney U test and Kurskal Wallis test) 
were applied to determine the statistical significance 
difference between means of 
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TSPY copy number from the different groups. Parametric test (Student's t test and 
ANOVA test) were also used. Comparison between pulse field gel electrophoresis 
(PFGE) and Taqman method was tested using Pearson's correlation coefficient. P 
values <0.05 were taken as statistically significant. 
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4.4 Results 
4.4.1 Conventional PCR on resected prostate cancer samples 
Prior to determining the TSPY copy number, all the solid clinical prostate tumour 
samples were tested for the presence or deletion of the structural genomic unit of 
TSPY using conventional PCR. As described in materials and methods, a forward 
primer was selected at 5'end of the TSPY gene and a reverse primer at its 3'UTR. The 
two primers amplify a 2.680 kp fragment from genomic DNA in PCR reaction. All of 
the 31 cases of CaP and 13 cases of BPH contain the full length genomic TSPY 
(Figure 4.7). Conventional PCR was also carried out using genomic DNA extracted 
from prostate cell lines, LNCaP as positive control. 
1 
4.3 kb 
-10 
2.3 kb 
10 
145ý7R9 10 11 l?, 11 
Figure 4.7. Genomic PCR products from different prostate samples. 
Genomic DNA amplification from clinical prostate specimens using TSPY exon 1 
forward primer and exon 6 reverse primer. Both primers amplify 2.68 kb size. Lane 1, 
Hind III digested marker; Lane 2, LNCaP; Lane 3-11 tumour DNA; Lane 12 female 
genomic DNA as a negative control and lane 13 water control. 
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4.4.2 Taqman assay 
Optimal TSPY primer and probe concentrations were used in Taqman assay to 
establish an absolute quantitative standard curve. Authenticity of the TSPY amplicon 
product (85 bp) was confirmed by sequencing the DNA product generated by PCR 
(data not shown). 
4.4.2.1 Validation and evaluation of the standard curve. 
The TSPY absolute standard curve was established (Figure 4.8) and validated using 4 
independent DNA samples obtained from Dr. Mark Jobling (Table 4.2). The TSPY 
DNA copy number for these samples had been previously determined using pulse 
field gel electrophoresis (PFGE) method (Dr. Jobling). As shown in Table 4.2, the 
established quantitative real time PCR assay was used to assay for the TSPY gene 
copy number for all 4 samples. The copy number determined by both methods was 
identical (Pearson's correlation coefficient, r=l). Absolute standard curve for 
endogenous control (RNASE P) was established (Figure 4.9). 
Copy number determined by PFGE Copy number determined by Real Time PCR 
Sample 1 20 20 
Sample 2 28 28 
Sample 3 33 33 
Sample 4 40 40 
Pearson's correlation coefficient, r=1 
Table 4.2. Validation of the established absolute quantitative standard Curve. 
The established absolute quantitative standard curve based on Taqman real time PCR 
was validated by determining the TSPY genomic copy number from samples with 
known gene copy number. 
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4.4.2.2 Genomic TSPY copy number analysis in blood 
samples 
The TSPY gene copy number was determined from 119 blood samples: CaP, BPH 
and control group, n=47, n=27 and n=45, respectively. In the CaP group, the 
minimum TSPY gene copy number was 6 and the maximum was 70 with a mean of 
35 ± 11 and a median of 34 (Figure 4.10). The statistical description of TSPY 
genomic average copy number in the three groups of blood samples is summarised in 
Figure 4.10, C. Figure 4.10, (C) shows that in the majority of the CaP cases, 43 
(91%), the copy number was from 20-50 copies. Only 2 cases (4%) had less than 20 
copies per genome and remaining 4 (9%) caese had more than 50 copies per person. 
In the control group, gene copy number ranged from 16 to 62 copies, with an average 
35 ±9 and median of 34. Most of the control cases, 42/45 (93%) contained 20-50 
copies. In the BPH group, the lowest copy number was 23 and the highest was 51 
copies with an average of 38 ±8 and median of 38; 24 /27 (89%) BPH cases 
contained 20-50 copies per individual. Only 3 cases (11 %) had copies between 51 
and 60. Statistical analysis using one way ANOVA has shown that there is no 
significant difference between the average copy numbers in all three groups (P< 0.31) 
(Table 4.3). 
141 
Chapter 4: genomic TSPY copy number in prostate cancer 
75 
B 
50-1 
M 
Nf 
xr-ºr «, 
25 - 
C 
U 
35 
CAP group BPH group CONTROL group 
Groups 
35 
38 ý 
aua 
n=47 n=27 n=45 
CaP BPH Control 
n=47 n=27 n=45 
TSPY Copy Number CaP 
n=47 
1-20 copy 2 
21-30 copy 12 
31-40 copy 21 
41-50 copy 8 
51-60 copy 3 
61-70 copy 1 
r: 
. ýt ý 
.. rr . "» m 
« 
I 
Figure 4.10. TSPY genomic copy number from blood samples. 
(A) TSPY genomic copy numbers were determined from DNA isolated from the 
blood of 47 CaP, 27 BPH and 45 normal cases. Each dot represents copy number and 
horizontal lines signify the mean copy number for each group. (B) Statistical 
description for Figure A. TSPY genomic average copy number, range and S. D. from 
clinical blood samples, CaP, BPH and control are given. (C) Distribution of increasing 
frequency of TSPY genomic copy number among the three categories of blood 
samples (CaP, BPH and control). 
A 
CAP v BPH CAP v Control BPH v Control CaP v BPH v normal 
Statistical Mann Whitney UT test Student's t test Mann Whitney U test AN'OVA 
test P<0.07 P<0.90 P<0.09 P<0.31 
Table 4.3. Statistical analysis of TSPY genomic copy number in all blood 
samples. 
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Minimum Value 6 23 16 
Maximum Value 70 51 62 
Mean 35 38 35 
Median 34 38 34 
Std. Deviation 11 89 
Std. Error 1.586 1.615 1.360 
BPH Control 
n=27 n=45 
2 
5 11 
11 22 
87 
32 
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4.4.2.3 Genomic TSPY copy number in solid prostate 
tumours. 
Using resected prostate material, abnormal gene TSPY copy number was examined as 
a potential mechanism for its over-expression in prostate cancer. Forty four resected 
prostate samples were analysed: CaP, n=31 and BPH, n=13. In the CaP group, the 
maximum copy number was 85 copies and minimum was 6 copies per genome with 
an average 44 ± 15 and a median of 44 (Figure 4.11). Moer than two third of the 
cancer cases, 23/31 (74%), had 20-50 copies. Only, 8 (26 %) samples had >50 copies 
and 1 cases (3%) had less than 20 copies (Figure 4.11, Q. In the BPH group, the 
highest copy number was 82 and the lowest was 32 copies with a mean of 46 ± 13 and 
a median of 44. The TSPY copy number ranged from 20 to 50 in 9/13 (69%) cases. 
The remaining 4 cases (31%) had more than 50 copies of TSPY genome. Statistical 
analysis using Mann Whitney U test revealed no significant difference in TSPY copy 
number in both groups (P<0.95). 
4.4.2.4 TSPY copy number in paired blood-tissue samples 
TSPY gene copy dosage was determined from 6 resected prostate cancer tissue 
samples obtained by TURP and compared to its matched paired blood specimens. 
Eleven paired blood-tissue specimens were also collected from BPH patients. 
Comparing the copy number for each paired sample revealed no significant statistical 
variation in TSPY copy number in patients affected by CaP (Wilcoxon signed ranks 
test, two tailed, P<0.92) and in patiensts with BPH (Wilcoxon signed ranks test, two 
tailed, P<0.44). 
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Total 31 13 
Figure 4.11. TSPY genomic copy number from prostate solid tumours 
(A) Genomic TSPY copy number from 31 cases of CaP and 13 cases of BPH were 
determined using Taqman assay. The horizontal line represents the mean copy 
number for each group. (B) Statistical description of Figure A. Genomic TSPY copy 
number from the prostate solid tumours. Range, mean, median and S. D. are given. (C) 
Distribution of increasing frequency of genomic TSPY copy number in resected 
prostate tissues: CaP and BPH. 
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4.5 Discussion 
TSPY expression analysis using IHC on resected prostate cancer tissues has shown 
that TSPY is over-expressed in CaP. The cause of TSPY deregulated expression is not 
known. To investigate whether gene amplification is the cause, an absolute TSPY 
genomic DNA quantitative real time PCR method using Taqman assay was 
established and validated. TSPY genomic copy number was determined from 161 
clinical samples obtained from the blood of normal persons, CaP and BPH patients 
and solid prostate tumours. Blood samples from 47 CaP cases, 27 BPH cases and 45 
normal individuals were obtained. Six copies of TSPY was the lowest copy number 
reported in all the clinical samples assessed. The maximum copy number was 70 
copies per genome detected in a CaP patient. In general, it has been noticed that the 
majority of cases studied had 20-50 copies of TSPY per genome. Although there was 
variation in TSPY copy number, there were no statistically significant differences in 
copy numbers of TSPY among the three groups, control, BPH and CaP using the 
current DNA extraction method from resected tissues. Furthermore, TSPY copy 
number analysis in paired blood and tissue samples revealed no significant correlation 
between TSPY copy and tumour formation. This might suggest that abnormal TSPY 
copy number might not be the underlying cause for TSPY over-expression in prostate 
cancer. However, prostate cancer is heterogeneous and multi-focal in nature and 
different grades of tumours can coexist within resected prostate, in addition to normal 
glands, hindering DNA extraction from homogeneous cancerous cells difficult to 
obtain. While the selection of locally invasive cancer with significant tumour 
infiltration is expected to minimise this contamination effect, prostate tissue generated 
by laser captured microdissection will facilitate the extraction of highly pure 
homogenous cancerous samples, allowing more accurate determination of TSPY copy 
number in resected prostate tissues. 
Homologues of human TSPY are multicopy and located on Y chromosome in rodents 
and other mammals including the great apes, pigs, cattle, sheep, goats and horses 
(Conrad et al., 1996), (Kim et al., 1996), (Vogel et al., 1997a, Vogel et al., 1997b), 
(Glaser et al., 1998, Mazeyrat and Mitchell, 1998)). Male specific bovine genomic 
homologue of the human TSPY is repetitive. The gene is part of a clustered array of 
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50-200 repeated sequences on the Y chromosome resembling the arrangement present 
in the human genome (Jakubiczka et al., 1993). 
Besides TSPY, there are further 9 genes known to be present as multicopy genes on 
the Y chromosome. The functions of these genes are not fully known. There are many 
examples of human multiple copy genes in the autosomal chromosomes. The tandem 
repeated multi-gene families encoding large rRNAs, 5S rRNA and Ul and U2 
constitute 2% of the human genome. The human tandem repeated arrays of ribosomal 
RNA are distributed on different chromosomes and include nearly 500 copies of the 
gene (Gonzalez et al., 1988). The multicopy human U2 small nuclear RNA genes are 
located on chromosome 17 in arrays of tandem repeats varying in number from 6 to 
more than 30 repeats (Pavelitz et al., 1995). The snRNA forms part of a large 
spliceosome complex that is involved in removal of introns from pre-mRNA 
(Valadkhan and Manley, 2003). The neuronal apoptosis inhibitory protein (NAIP) 
located on chromosome 5 (5g13.1) is another multicopy gene, (Roy et al., 1995). On 
the same chromosome, there is a further multicopy gene, BTF2p44 (5g13.3), which 
forms a subunit in the RNA polymerase II complex important in transcription and 
transcription-mediated DNA repair (Carter TA, 1997). The human major 
histocompatibility complex located at chromosome 6 contains a multicopy gene 
families including human leukocyte antigen class I (HLAI), MHC class I related 
chain (MIC) and haemochromatosis candidate genes (Kulski et al., 2000). 
This is the first report describes establishing real time PCR assay to determine TSPY 
gene copy number in prostate tumour specimens. Two independent studies have 
reported establishing real time PCR methods for accurate detection and determining 
human and mammalian TSPY gene copy numbers for other research objectives. 
Pierce and his colleagues have described a successful and accurate method for 
determining the human sex of embryos using real time PCR for TSPY gene, based on 
molecular beacon assay (Pierce et al., 2000) as part of their ongoing research on pre- 
implantation genetic diagnosis. Wang and his colleagues have also developed 
quantitative real time PCR based on Taqman assay for detecting and determining 
mice genomic TSPY copy number from male liver cells engrafted into female liver 
tissues (Wang et al., 2002). 
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4.6 Conclusion 
The majority of cases assessed in the present study had between 20 to 50 TSPY copies 
per genome. There were no significant differences between the TSPY copy number in 
CaP patients compared to persons with BPH or to normal individuals. In addition, 
there was no correlation between TSPY copy numbers either with increasing Gleason 
score or increasing age of individuals. Thus, gene amplification might not the 
underlying cause of TSPY over-expression in CaP. 
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5.1 Introduction 
TSPY expression pattern analysis in CaP has revealed that TSPY is over-expressed in 
prostate cancer and the expression correlates with advanced CaP and bone metastasis. 
Furthermore, increased proliferation rate in LNCaP cells over-expressing TSPY has 
been detected by in vitro proliferation assays and colony forming assay. Gene 
expression alterations associated with over-expressing of TSPY are not yet known. In 
the last few years, a high density gene profiling GeneChip (Microarray) method has 
been developed and applied to comparatively analyse the gene expression within a 
genome (Shalon et al., 1996). It provides a powerful tool for screening biological 
samples for alterations in the mRNA expression accompanying certain physiological 
or pathological changes. The microarray is an ordered array of specific and known 
sequences of synthetic oligonucleotide or cDNA that are spotted onto discrete loci on 
a glass, silicon or nylon surface (Harkin, 2000). The chip technique is based on 
hybridisation of a target labelled probe to nucleic acid attached to a solid support. 
Applications of microarrays are diverse. One of the early applications of DNA 
microarray technology was the study of transcriptional profiles of tumours and 
investigating the global patterns that accompany malignant transformation and 
correlation with clinical phenotypes. Several studies have established transcript 
profiling of primary tumours for diagnostic, prognostic and treatment purposes. Welsh 
et al used DNA microarray to identify candidate molecular markers for ovarian cancer 
(Welsh et al., 2001). Dhanasekaran used DNA microarray to derive a prognostic 
marker for prostate cancer (Dhanasekaran et al., 2001). DNA microarray has been 
used in elucidating complex biochemical pathways. The GeneChip array is commonly 
used to identify the signalling pathways that play a role in development, 
differentiation and tumourigenesis. 
Two formats of microarray are in current use: cDNA and oligonucleotide microarrays. 
Although both cDNA and oligonucleotide microarrays are used to analyse the profile 
of global gene expression, fundamental differences exist between these two methods 
(Figure 5.1). 
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Figure 5.1. Oligonucleotide and cDNA microarray. 
Comparison between cDNA and oligonucleotide microarray. In cDNA microarray, 
total RNA from test sample and reference sample are labelled separately with two 
different fluorescent dyes, combined and added to a glass slide dotted with cDNA. 
The slide is excited with laser and the genes that are up-regulated, down regulated or 
unchanged are colour coded, red, green or yellow, respectively. Affymetrix 
oligonucleotide is based on synthesised short oligos attached to glassslide. The total 
RNA is labelled with biotin. Avidin conjugated fluorescent dye is added and the 
signal is quantified (Staal et al., 2003). 
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5.1.1 cDNA microarrays 
cDNA microarrays were pioneered by the Brown Laboratory at Stanford University 
(Schena et al., 1995). They are generated by amplifying cDNA clones in PCR 
reaction using vector based primers flanking the cDNA cloning site. The amplified 
products (ranging in size from 100-2000 bp) are purified from the gel and re-arrayed 
into 96-384 well plate. A robot precisely deposits a defined quantity of double 
standard cDNA at predetermined locations on a solid support such as glass, silicon or 
nylon. Expression profiling using cDNA microarray is accomplished by labelling total 
RNA from the test samples with either fluorescent Cye3 or CyeS-dUTP in reverse 
transcription reaction. The fluorescent labelled cDNA probes are combined and 
hybridised to a single array in a competitive hybridisation reaction. The detection of 
hybridised probe is achieved by laser excitation of the individual fluorescence marker 
followed by scanning with a confocal scanning laser microscopy. The ratio of cye3- 
cye5 is normalised and digitally colour coded as red, green or yellow. The genes that 
are up-regulated are indicated in red colour and genes that are down-regulated are 
represented in green and genes that show no change in expression profile are shown 
as yellow. 
5.1.2 Oligonucleotide microarray 
Commercially available Affymetrix oligonucleotide chips are generated by either 
attaching pre-synthesised oligonucleotide probes to a chip or in situ synthesis of 
oligonucleotide probes on the chip (Figure 5.2). In the latter method, the probe arrays 
are produced by light directed chemical synthesis that combines solid phase chemical 
synthesis with photolithography fabrication techniques. A series of photolithographic 
masks are used to define chip exposure sites followed by specific chemical synthesis 
steps. High density arrays of oligonucleotide with each probe in a predefined position 
in the array are produced. Multiple probe arrays are synthesised simultaneously on the 
chip. Gene expression changes are detected by labelling extracted total RNA from test 
and reference samples as follows: the first strand cDNA is synthesised using olig-dT 
primer containing T7 polymerase site in reverse transcription reaction. A biotin 
labelled cRNA is generated by in vitro transcription of cDNA in the presence of 
biotinylated dNTP (Figure 5.3). The labelled probe is fragmented and hybridised into 
two separate oligonucleotide microarrays. A streptavidin conjugated 
fluorescent 
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marker is added to the bound biotinylated probe. The bound labelled probe is detected 
by laser excitation of fluorescent marker and the intensity of the fluorescent signal is 
scanned using confocal laser microscopy. The fluorescent signal intensity is 
quantified. This represents the alteration in correspondent transcription gene levels. 
1.28 cm 
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Actual strand " 26 bass pairs 
Millions of DNA strands built up in oach call 
Figure 5.2 Oligonucleotide chip. 
Commercially available Affymetrix oligonucleotide chip is based on attaching short 
synthesised 25 bp oligonucleotide. In general, 11 paired probes are synthesised for 
each gene (http: //www. affymetrix. com/index. affx). 
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5.1.3 Affymetrix GeneChip human genome U133 
The Affymetrix oligonucleotide GeneChip human genome U133 consists of a square 
glass in a plastic cartridge set and is composed of two chips: chip A and chip B. Both 
microarrays contain in total 1,000,000 unique synthetic oligonucleotides that were 
generated from the corresponding 39,000 transcript variants which in turn represent 
33,000 human genes. The oligos were designed from DNA sequences deposited in the 
Gene Bank, dbEST and RefSeq. The HU-133 set contains a set of 100 control genes 
(GAPDH, (3-actin. STAT1) for normalisation. Each probe set is composed of 11 pair 
probes and in each pair probe, one probe sequence is identical to the corresponding 
target gene sequence and is termed a perfect match (PM) and another probe has one 
base change in the middle of the sequence and is called mismatch probe (MM). This 
approach forms the core of microarray probe design and allows accurate quantfication 
and subtraction of the real signal from non-specific background and cross 
hybridisation signals. The difference in signal hybridisation within a probe pair and 
the intensity ratio is used as an indicator for abundance of the specific target gene. 
Some probes are selected from gene regions that are shared by gene multiple variants. 
In other cases, a unique sequence that distinguishes between variants is selected for 
probe design. The probes on the HG-U133 set are designed to detect the anti-sense 
strand of the gene of interest and these probes are annotated with the "_at" extension. 
There are three different types of probe sets. Probe sets that are unique to the target 
gene and only specifically hybridise to the corresponding gene sequence are annotated 
with "a at" extension. In other cases, the probe set is generated from target sequence 
that is shared by gene multiple variants and named as "_s_at". Occasionally, it is not 
possible to select either a unique probe set "-a-at" or a probe that detects multiple 
variants "sat". In such cases, some of the probe pairs in probe sets are designed 
from a gene region that is similar or identical to unrelated sequences. These mixed 
probe sets are annotated with "_x_at" extension. 
5.1.3.1 Advantages of Affymetrix GeneChip. 
Oligonucleotides design is based entirely on gene sequences deposited in the NCBI 
and RefSeq databases and no PCR step is required thus decreasing the possibility of 
probe mix up. The use of multiple oligonucleotides enables splice variants and closely 
related members of a gene family to be distinguished. GeneChip can distinguish 
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transcripts that are up to 90 % identical. Shorter nucleic acid fragments are more 
accessible for hybridisation. The main disadvantage with this method is the need for 
special equipment and GeneChips are expensive to purchase. 
5.2 Aims 
1) To apply LNCaP-TSPY clone in gene profiling experiment, determine candidate 
genes and to validate their regulation by TSPY. 
2) To cluster genes into pathways and generate a model for TSPY effector genes. 
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5.3 Materials and methods 
5.3.1 RNA Isolation 
LNCaP cells that constitutively express exogenous FLAG-TSPY and empty vector 
were seeded into 10 cm dishes and left to grow for 3 days until the cells were 70% 
confluent. Total RNA was isolated from both clones using Trizol reagent (Invitrogen). 
The cells were washed twice in BPS and 3 ml of the reagent was added to the cells 
and left at RT for 5 minutes. The cell lysate was transferred into an eppendorf tube 
and 200 µl of chloroform was added, mixed and the tubes were spun at 14000 rpm for 
15 minutes. The upper aqueous layer containing RNA was transferred into a fresh 
tube and 500 µl Isopopranol was added and mixed. The tube was centrifuged for 15 
minutes at 14000 rpm. The RNA pellet was washed in 70% ethanol and left to dry, 
before adding 100 µl of DEPC ddH2O. The total RNA concentration was determined 
using spectrophotometer (Wallac). The quality and integrity of RNA was checked by 
loading 1 µg of total RNA into 1% agarose gel and by RT-PCR using GAPDH 
primers. 
5.3.2 Microarray method 
Approximately, 10 µg of RNA from each clone was handed over to Dr. Peter Heiko at 
the Centre for Life, University of Newcastle upon Tyne. All the necessary 
experiments from probe preparation, hybridisation and washing were carried out by 
Heiko's group. Only Affymetrix GeneChip human Genome U133 set A that contains 
22,285 genes was used. The cut off point for fold expression changes was taken as 1.5. 
5.3.3 Primer design 
All subsequent analyses from Microsuite data output was performed using Affymetrix 
web site. The probe set ID number was used to obtain the corresponding region of the 
gene used to generate the probe. The DNA sequence was inserted into NCBI BLAST 
to confirm the identity of the gene. Once the corresponding gene has been confirmed, 
Map viewer was used to obtain relevant information available on the gene. UCSC is 
used to investigate exon, intron, 5' and 3' UTR regions of genes and their isoforms. 
Once the gene structure has been investigated, a pair of primers was designed using 
primer 3 software. On average, 25-30 mers primers length was selected (Table 5.1). 
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Genes 
BAX-F 
BAX-R 
PCDH7-F 
PCDH7-R 
BMP11-F 
BMP11-R 
IRS 1-F 
IRS 1-R 
MAF-F 
MAF-R 
NF2-F 
NF2-R 
NDRG1-F 
NRDG1-R 
PLOD2-F 
PLOD2-R 
Cyclin G-F 
Cyclin G-R 
GST-F 
GST-R 
GAPDH-R 
GAPDH-F 
5'-3' primers Product size 
CCTTTTGCTTCAGGGGATGATTG 145 
CACCAGTTTGCTGGCAAAGTAGAAA 
GCAAACAGATGCGTCTACATCCATA 309 
CCGCCTCTTTAAGAATGGAATTTCT 
TCATGGAGCTTCGAGTCCTAGAGAA 430 
AGAGGTTAAGTTACCCACCCACCAA 
AGACCTGGATTTGGTCAAGGACTTC 486 
GGCCAGCTAAGTCCTTAAGGTTGAA 
TGCACTTCGA CGACCGCTTC TCCGA 360 
TGGCTAGCTGGAATCGCGTGTCAGA 
TTATGAGGAGAAGGAAAGCCGATTC 444 
TGGCTCTCTTGATATCTGGTCCATC 
GTCCTTATCAACGTGAACCCTTGTG 376 
TCTTGAGGAGAGTGGTCTTTGTTGG 
ATGGCTTGATTTTATCCGGGAGTT 444 
TTCCTCTCATCTTCTCAGCCACAAC 
AAGGGCTGAGTTTGATTGAGGCTAC 318 
CCATCCGTTTTATGTCAGAAGCAGT 
AAATGATCCTCCTTCTGCCCGTA 
ACTTCTTCACTGTGGGCAGGTTG 
279 
GGATTTCCATTGATGACAAGCTTC 147 
GCCTGGTCACCAGGGCTGCTTT 
Table 5.1. Primer pair of each gene selected from the microarray analysis results 
used for RT-PCR. 
Primer pairs of genes that were evaluated by RT-PCR assay to confirm microarray 
data. Primer sequence and product length is given. GAPDH was used as reference 
gene. 
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5.3.4 Semi-quantitative RT-PCR 
Single stranded cDNA was synthesised in a reverse transcription reaction using 2µg 
of total RNA extracted from LNCaP clones with FLAG-TSPY and empty vector. In 
an eppendorf tube the following were added and mixed: 4 µl of 5X Transcriptase 
buffer, 2µl 5mM dNTPs, 1.5 µl OligdTl6,0.3 µl MMLV transcriptase enzyme 
(Promega), total RNA and ddH2O to a final volume 20 µl. The mixture was incubated 
at 37 °C for 1 hr and the enzyme was inactivated by boiling the sample for 5 minutes. 
One microgram of RNA was used in subsequent RT-PCR. PCR cycle conditions were 
identical for all the primers used. Initial one denaturation step at 95 °C for 3 min, then 
95 °C for 30 sec, 65 °C for 20 sec and 72 °C for 30 sec and a final step at 72 °C for 5 
min. RT-PCR was performed for 25 cycles to begin with then increased to 30 cycles 
and finally to 35 cycles depending on the transcript level. The RT-PCR products were 
loaded into 1% agarose gel and the gel image pictures were captured. 
GelBandQuantitation software was used to determine the relative quantity of RT-PCR 
product for each gene from LNCaP clones with and without FLAG-TSPY compared 
to the endogenous reference house keeping gene (GAPDH). 
5.3.5 Gene ontology to determine gene altered in pathways 
Data analysis on Affymterix web site was used to analyse the results generated from 
the microarray data. Gene ontology mining tools were used to determine the genes 
and pathways altered under the current conditions investigated. All the genes listed 
are categorised according to their biological process. Genes that have a similar 
functional processes are grouped together. 
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5.4 Results 
5.4.1 Validation of LNCaP cell sample for gene profiling 
Both LNCaP clones with TSPY-FLAG and empty vector were prepared as given in 
the materials and methods for gene profiling using Affymetrix GeneChip. Before 
carrying out profiling, RNA quality and expression of FLAG-TSPY were validated 
using RNA gel, RT-PCR and Western blot (Figure 5.4). 
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Figure 5.4. Validation of LNCaP cell sample for gene profiling. 
(A) RNA gel, the quality of RNA isolated from LNCaP clones with FLAG-TSPY and 
empty vector was assessed on agarose gel. C indicates clone and V represents vector. 
(M) 1 Kb ladder marker. (B) RT-PCR, cDNAs prepared from both clones amplified 
using GAPDH primers, M represents 1 kb ladder, lane 1 water control; lane 2, LNCaP 
clone with TSPY and lane 3, clone with empty vector. (C) The presence of TSPY 
FLAG protein was checked using Western blot analysis. Lane 1, LNCaP transiently 
transfected with FLAG-TSPY, lane, 2 stable LNCaP Clone expressing FLAG-TSPY 
and lane 3, LNCaP stable clone with empty vector. (D) a-tubulin marker. 
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5.4.2 Microsuite data output 
Global Gene expression level from LNCaP cell line that expressed FLAG-TSPY was 
compared to LNCaP cell line that contained only empty vector using Affymetrix 
GeneChip human genome U133 chip A (22,285 genes). The output data was exported 
into Affymetrix microarray suite (MA) software and analysed (Figure 5.5). TSPY 
expression was prominent in the output analysis. TSPY expression increased by 69 
fold. In total, the expression profiles of 332 genes (excluding TSPY) were also 
significantly altered (increased or decreased) due to presence of exogenous TSPY in 
LNCaP cell line relative to control LNCaP cells (appendix and Table 5.2) Ninety 
eight gene expressions altered by 2-10 fold and 3 gene transcripts changed by more 
than 10 fold. Two to 10 fold decreased transcript expressions were observed in the 63 
genes (Table 5.2) and an increase of 2-10 fold transcript expressions were detected in 
35 genes (Table 5.2). Three gene transcripts had decreased by 10-90 fold. Only genes 
that demonstrated two fold or more decreased changes in transcript levels with change 
p-value >0.99 and gene transcripts that increased two and more fold with change p- 
value <0.0006 were selected for further evaluation. 
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Figure 5.5. Scatter blot representing comparative analysis from LNCaP two 
clones. 
The test RNA sample (LNCaP (C5) that constitutively expressed FLAG-TSPY) is 
labelled with one fluorescent dye (red) and reference sample RNA (LNCaP (V4) 
empty vector as reference for comparison) labelled with another fluorescent dye 
(yellow). The changes in transcript between the two samples are coloured blue. The 
two inner diagonal lines represent the lowest folds of change and any line above the 
left line indicates increased folds of expression and decreased fold of gene 
expressions are lined below the right line. Two examples are highlighted, TSPY and 
PCDH7. 
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Decreased expression Number of genes Percentage 
<2 Fold 138 68% 
2-10 Fold 63 31 % 
>10Fold 3 1% 
Total 204 
Increased expression Number of genes Percentage 
<2 Fold 93 73% 
2-10 Fold 35 27% 
Total 128 
Changes Number of genes Percentage 
<2 Fold 231 69% 
2-10 Fold 98 30% 
>10Fold 3 1% 
Total 332 
Table 5.2. Summary of gene expression numbers altered due to the expression of 
FLAG-TSPY. 
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5.4.3 Genes expression altered by two fold or more. 
Although the MA suite analysis showed expression alterations in many genes that 
play variable roles in regulating cell cycle, growth, adhesion, apoptosis, migration, 
replication, DNA repair damage, angiogenesis (appendix), only those transcripts that 
altered by 2 or more fold are considered for further analysis and verification. Genes 
that were described as hypothetical were deselected. Ten genes out of 101 genes that 
altered 2 fold up to 90 fold were selected and their sequences were investigated 
thoroughly using NCBI, BLAST, Affymetrix web site and DNAstar software. The 
identity of each gene and the DNA segment of the gene selected for probe design 
were inspected. These genes are, BAX, PCDH7, BMP11, IRS-1, MAF, NF2, NRDG1, 
PLOD2, GST-A2 and cyclin G (Table 5.4. ). Up to 90 fold decreased in PCDH7 
transcript level was observed from cell expressing FLAG TSPY compared to empty 
vector (Table 5.3). Decreased PLOD2 expression was the second highest change to be 
noticed. Initially, Mek5c gene was increased by 4 fold and upon closer examining the 
Mek5c probe sequences and the gene sequence deposited into Genbank database, it 
was confirmed that the Mek5c Genbank sequence used for designing the GeneChip 
probe for Mek5C was contaminated with vector sequence. The majority of the probe 
sequence pairs were corresponding to the vector multiple cloning sites. Upon this 
finding, Mek5C was deselected for further analysis. Only two genes with up-regualted 
expression, GST-A2 and cyclin G, were selected for validation,. 
Gene expression fold changes RT-PCR 
Gene Identified by microarray assay 
NF2 -2 --- 
BM P11 -2 -2.7 
NRDG1 -2.1 -3 
MAF -2.3 -3.7 
Bax-delta -3.5 -2.7 
IRS-1 -5 -2 
PLOD2 -14 -11 
PCDH7 -90 -10 
Cyclin G +2 0 
GST A2 +3.7 +2.8 
Table 5.3. Comparison of gene expression changes from microarray and RT-PCR. 
The expression level for each the 10 genes generated by the microarray analysis was 
confirmed using simi-quantitative RT-PCR. 
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5.4.4 Semi-quantitative RT-PCR method to confirm 
microarray data 
The expression patterns of the 10 candidate genes were verified using semi- 
quantitative RT-PCR assay (Figure 5.6). Pairs of primers were designed for each 
gene. Transcript expression level of each gene from LNCaP clone expressing FLAG- 
TSPY was compared to LNCaP clone containing only empty vector. A house keeping 
gene (GAPDH) was used as a reference gene for normalising. Each gene transcript 
level from both LNCaP clones relative to GAPDH internal control was measured 
using GelBandQuantitation software. All 10 genes were assessed and semi- 
quantitative RT-PCR confirmed the expression changes detected by GeneChip assay 
except for NF2 gene. The correct NF2 RT-PCR product was not detected. 
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5.4.5 Clustering genes into functional pathways 
Initial analysis using ontology gene mining tools from Affymetrix web site has sorted 
the altered genes according to their biological processes. The major potential 
biological processes affected by expressing TSPY are apoptosis, cell differentiation, 
cell motility, cell adhesion, cell communication and signal transduction (Figure 5.7). 
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5.5 Discussion 
TSPY over-expression in prostate LNCaP cell line was shown to increase in vitro 
cellular proliferation and ability to form colonies. The molecular mechanism of TSPY 
mediated proliferation is not yet known. To better understand the cellular biological 
effect of TSPY, global gene expression profile from LNCaP cells expressing TSPY 
was compared to LNCaP cells stably transfected with empty vector using Affymetrix 
oligonucleotide GeneChip (U133 set A) method. The chip contains 22,285 probes 
representing different genes. Analysis of microarray gene output results has detected 
alterations in expression of 333 genes (appendix). A threshold for the level of change 
in gene expressions were taken as 2 fold. In total, 101 genes that showed 2 fold and 
more changes (increase or decrease) were selected. Of these, only 10 genes were 
selected for verification and further analysis. Over-expression of TSPY was 
confirmed with 69 fold up-regulation of transcript level in TSPY LNCaP transfected 
clone. The selected genes form part of diverse pathways that potentially regulates 
different biological processes including differentiation, apoptosis, adhesion, cell 
communication and signal transduction. Using gene ontology mining tools available 
on the Affymetrix web site, clustering of the candidate genes into distinct pathways 
was performed. 
The first gene to be inspected was PCDH7 isoform A. Its expression was decreased by 
nearly 90 fold due to the presence of exogenous TSPY. BH-Protocadherin 7 (Heart 
and brain) isoform a (PCDH7) is a member of the cadherin superfamily. The 
superfamily is a diverse and large group of membrane associated glycoproteins. At 
least 80 members of cadherin superfamily sharing common structural features, small 
cytoplasmic domain, transmembrane domain and large extracellular domain 
consisting of repeats of cadherin motifs. The cadherin motif is composed of 110 
amino acid and is suggested to play role in Ca++ dependent homophilic cell-cell 
adhesion (Geiger and Ayalon, 1992, Grunwald, 1993). Cadherin superfamily is 
classified into 4 subfamilies: classic cadherins, desmosomal cadherins, cadherin 
related proteins and protocadherins (PCDH) (Suzuki, 1996a, Suzuki, 1996b). PCDH 
subfamily consists of at least 60 members (Frank and Kemler, 2002). PCDH proteins 
are expressed in various tissues including stomach, brain, heart and thyroid gland and 
seem to function as cell-cell recognition, adhesion and as a component of signal 
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transduction pathway. They are also involved in development and tumourigenesis 
(Yoshida et al., 1998). BH- Protacadhein 7 is one member of PCDH family and is 
predominantly expressed in heart and brain and thus is named BH-PCDH7. The gene 
is located in 4p15 and encodes a protein with an extracellular domain containing 7 
repeats of cadherin motif (EC 1-7). Alternative splicing yields three isoforms with 
unique cytoplasmic tails. These isoforms are, a, b and c. PCDH7 isoform a is 1069 aa, 
isoform b is 1072 as and isoform c is 1200 aa. The protein product of PCDH7C was 
found to interact with protein phosphatase 1 alpha catalytic subunit (Yoshida et al., 
1999). Expression of PCDH7 C has been reported in human lung carcinoma cell line 
A549, HELA cells S3 and human gastric cancer cell lines, MKN28 and KATO-III. 
This locus is reported to show frequent loss of heterozygosity in head and neck 
squamous cell carcinoma. The role of PCDH7 in prostate cancer is not yet 
investigated. However, TSPY has a potential ability to down regulate expression level 
of PCDH7 isoform a and this might indicate that TSPY can be involved in regulating 
attachment and adhesion. The current findings tend to suggest that TSPY decreases 
the ability of the cell to attach and adhere and thus facilitate motility and migration of 
prostate cells and this may participate in prostate cancer development and progression. 
Further evidence supporting the role of TSPY as a potential regulator of attachment 
and adhesion is the observation of decreased levels of expression of PLOD2 by 14 
fold due to the presence of FLAG-TSPY. Procollagen-lysine, 2-oxoglutarate 5- 
dioxygenase (lysine hydroxylase) 2 (PLOD2) is lysyl hydroxylase catalyses the 
hydroxylation of lysyl residues on collagens (a post-translational enzyme of collagen 
biosynthesis). Collagen is a vital part of the extra cellular matrix. Formation of 
hydroxylysines in collagens are essential for the stability of extra cellular matrix (van 
der Slot et al., 2003). Thus, decreased level of PLOD2 can destabilize the extra 
cellular matrix and consequently facilitate detachment and movement of cells. 
Additional confirmation that TSPY can play a role as a potential regulator of the 
process of adhesion is noticed by decreased level of expression of IRS-1 gene by 5 
fold in LNCaP cells. Insulin receptor substrate 1 (IRS 1) is a substrate of the insulin 
receptor tyrosine kinase and a putative participant in insulin signalling. The protein 
functions as a docking protein involved in binding and activating other signal 
transduction molecules after being phosphorylated on tyrosine by the insulin receptor 
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kinase (Sun et al., 1991). It has been reported that expression of IRS-1 in LNCaP 
increased cell adhesion and decreased cell motility (Reiss et al., 2001). As TSPY 
over-expression reduces the IRS-1 transcript level, this may lead to increased 
detachment and cellular motility. 
A fourth line of support for the potential role of TSPY as a regulator of the adhesion 
mechanism is provided by the decreased expression level of NF2 by 2 fold. 
Neurofibromatosis type 2 protein isoform Merl5l (NF2). NF2 or Merlin is a 
candidate tumour suppressor gene that encodes 587-amino acid protein with high 
similarity to ERM family proteins (Ezrin, Radixin and moesin) that link the 
cytoskeleton components with proteins in the cell membrane (Trofatter et al., 1993, 
Xiao et al., 2003). Over-expression of wild type merlin protein has been found to alter 
F-actin organization, decrease motility, cause abnormalities in cell spreading and 
inhibit cell growth (Gutmann et al., 1999). The NF2 gene is implicated in the 
development of sporadic schwannomas and meningiomas (Szijan et al., 2003). 
Apparently, expression of TSPY has a negative influence on NF2 expression and 
decreased expression of NF2 forms part of the mechanism by which TSPY regulates 
adhesion. Although microarray data has shown 2 fold decrease in NF2 transcript, 
semi-quantitative RT-PCR failed to detect NF2. This can be caused by error in primer 
design and future design of a new primer pair is needed. From all the above evidence, 
TSPY is implicated in regulation of cell adhesion and motility. 
Changes in genes that regulate cellular differentiation, proliferation and apoptosis 
were also detected from the GeneChip data output. TSPY caused a2 fold decrease in 
expression of GDF 11. Growth differentiation factor 11 (GDF 11) also known as bone 
morphogenetic protein 11 (BMP 11) is a member of the bone morphogenetic protein 
(BMP) family and the TGF-ß superfamily. Secretory BMPs proteins mediate their 
effect by binding to serine-threonine kinase receptors and transducing signals via 
smads proteins inducing biological cellular changes (Miyazono et al., 2001, von 
Bubnoff and Cho, 2001). They play a role in regulating cellular proliferation, 
apoptosis, differentiation, morphogenesis and adhesion. Thus TSPY contributes to 
regulating cellular proliferation through intermediate effectors such as GDF 11. 
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Another gene down-regulated by TSPY is NDRG 1. The gene is member of the N-myc 
down regulated gene family. The protein encoded by this gene is a cytoplasmic 
protein involved in stress responses, hormone responses, cell growth, and 
differentiation (Lachat et al., 2002). The expression of NDRG1 is repressed by N-myc 
and C-myc. NDRG1 protein expression is down-regulated in neoplastic cells, and is 
up-regulated in differentiating cells. NDRG1 is a tumour metastasis suppressor gene 
and its expression has been found to be inversely linked to the progression of prostate 
cancer (Bandyopadhyay et al., 2003). It has been reported that the gene product level 
is linked to induction growth arrest and inhibition of cellular proliferation (Piquemal 
et al., 1999). The current results from microarray data analysis indicate that TSPY can 
decrease cellular differentiation and increase cellular proliferation in keeping with the 
suppressed expression of NRDG1. 
Another gene that has been reported to regulate differentiation is C-MAF. C-MAF is 
an avian muscloaponeurotic fibrosarcoma oncogene homologue that belongs to MAF 
transcription factors, a unique subclass of basic-leucine zipper transcription (bZIP) 
factors (Nishizawa et al., 1989). Members of the MAF family appear to play 
important roles in the regulation of differentiation (Blank and Andrews, 1997). The 
microarray data has shown that c-MAF expression is down regulated by more than 2 
fold in cells over-expressing TSPY. Thus TSPY can induce proliferation by inhibiting 
differentiation through down regulation of C-MAF. 
As well as alterations of gene expressions related to differentiation, a cell cycle 
regulator gene (cyclin G2) has been found to be up-regulated by two fold in LNCaP 
cells over-expressing TSPY relative to cells containing empty vector. Cyclin G2 has 
been identified as p53 target gene (Okamoto and Prives, 1999) and it increased 
expression is associated with induction of p53 by DNA damage. The gene product is a 
novel cyclin negatively regulating the cell cycle progression, contrary to the 
characteristics of conventional cyclins and its expression is up-regulated as cells 
undergo cell cycle arrest or apoptosis (Bennin et al., 2002). Ectopic expression of 
Cyclin G2 inhibits cell proliferation in Hela cell line, HEK293 and Chinese hamster 
ovary cells (Bennin et al., 2002). Cyclin G2 expression has been detected in kidney, 
spleen and prostate (Horne et al., 1996). Although cyclin G2 gene expression profile 
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from genechip analysis has indicated a change in the gene expression, there was no 
alteration in expression between tested sample and control as tested by RT-PCR. 
Regulation of apoptosis is another mechanism for controlling proliferation and it is 
the counter act of proliferation and ability to suppress apoptosis is another way of 
regulating proliferation. Over-expression of TSPY down regulates BAX delta isoform 
expression by nearly 4 fold. BAX is Bcl 2 associated X protein. Six alternatively 
spliced transcript variants, which encode different isoforms, have been reported for 
this gene: a, ß, y, 6, c and ý. The protein encoded by this gene belongs to the BCL2 
protein family. BCL2 family members form hetero- or homodimers and act as anti- or 
pro-apoptotic regulators that are involved in a wide variety of cellular activities 
(Oltvai et al., 1993). This protein forms a heterodimer with BCL2, and functions as an 
apoptotic activator (Oltvai et al., 1993). The expression of this gene is regulated by 
the tumour suppressor P53 and has been shown to be involved in P53-mediated 
apoptosis (Miyashita and Reed, 1995). From all the above, it seems that TSPY plays a 
potential role in suppressing apoptosis through down regulating BAX gene. 
Up-regulation of GST A2 in LNCaP cells over-expressing TSPY compared to control 
was detected by genechip and validated by RT-PCR. As mentioned in the first chapter 
of the thesis, Glutathione S transferases enzymes are detoxification enzymes. Six 
distinct classes of GST have been identified: alpha, Kappa, Mu, Omega, pi and zeta. 
GST 2A belongs to alpha class and is located on chromosome band 6p21.1. This class 
of enzyme have peroxidase activity protecting cell from free oxygen radicals (Board 
and Webb, 1987). 
5.6 Conclusion 
Microarray analysis tends to suggest that TSPY is a putative regulator of adhesion, 
apoptosis, differentiation and proliferation. Down-regulation of pro-apoptotic gene, 
differentiation gene and adhesive molecules underlie the molecular mechanism by 
which TSPY exerts its functional cellular effect. 
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6.1 General discussion 
Prostate cancer is a multi-staged disease caused by accumulation of multiple genetic 
changes in several genes regulating normal cellular proliferation, differentiation, 
apoptosis, adhesion and metastasis. Gene amplification and/or over-expression are 
among the common polygenetic alterations contributing to transforming normal 
cellular prostate cells to a malignant form. During the cellular transformation, cells 
acquire enhanced abilities to continuously divide, resist growth inhibition, inhibit 
apoptosis, overcome senesce, metastasise and induce angiogenesis. Evolutiong of 
cancerous clones from their normal parental cells is accelerated by genomic instability 
and consequently chromosomal aberrations. Sex chromosome abnormalities 
(aneuploidy) are common events associated with CaP. Gain of Y chromosome has 
been frequently detected in CaP. Although Y chromosome is the smallest human 
chromosome harbouring a limited number of genes, the functions of the majority of 
Y-chromosomes genes are not known. Y chromosome has been postulated to 
participate in male sex organ development and oncogenesis. TSPY, a sex specific 
organs (testis and prostate) gene is a candidate gene for the gonadobalstoma locus on 
short arm of Y chromosome. TSPY gene is polymorphic in copy number and over- 
expression of TSPY has been detected in gonadoblastoma and testicular cancer. 
Although the exact function of the gene product is not yet known, it has been 
suggested that the gene can regulate proliferation of spermatogonia (testicular 
dividing cells). In the current study, the role of this gene in prostate carcinogenesis 
was investigated using the following approaches. First, the expression levels of TSPY 
were analysed in prostate cancer compared to BPH. Second, CaP functional analysis 
was carried out on LNCaP stably transfected to over-express TSPY. Third, TSPY 
genomic copy numbers in CaP and BPH were determined to test if expansion of copy 
numbers may be an underlying cause for its over-expression in prostate cancer. 
Finally, global transcriptional analysis of LNCaP cells expressing TSPY was 
investigated using the Affymetrix GeneChip oligonucleotide microarray method. 
TSPY genetic alterations (over-expression and/or amplification) and its role in 
prostate carcinogenesis were investigated. In the current study, anti-TSPY peptide 
polyclonal antibody was generated and used in IHC to detect and quantitate TSPY 
expression in clinical prostate tissue specimens. The expression of TSPY gene 
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product was primarily detected in the prostate epithelium of normal, BPH and 
malignant glands. Stromal expression was not observed in prostate gland sections. 
The expression of TSPY protein was predominantly located in the cytoplasm of 
prostate cells. Nuclear expression was not observed in any prostate sections 
investigated. In similar but limited study analysing TSPY expression pattern in 
prostate cancer, TSPY expression was also located in the cytoplasm of prostate cells 
without nuclear expression (Lau et al., 2003). Similar findings were observed from 
lummunofluorescence analysis of LNCaP cells stably-transfected to express FLAG- 
TSPY transgene. FLAG-TSPY protein is predominantly located in the cytoplasm with 
no signal detected in the nucleus. In spite of the fact that TSPY protein structure 
analysis indicated presence of potential nuclear localisation signal in the N-terminus 
of the gene product, it seems that in prostate, TSPY functions in the cytoplasm and 
only proteins that are located only in the cytoplasm and those are expressed in both 
the nucleus and cytoplasm may interact with it. Whether TSPY expression is cell 
cycle phase specific remains to be explored using bio-imaging system and GFP 
tagged to TSPY gene. Although Schnieders et al have detected similar pattern of 
cytoplasmic location of TSPY in testicular spermatogonial cells using IHC, nuclear 
and cytoplasmic expression was detected in subpopulations of spermatogonia of the 
testis. It seems from the current observations that TSPY is generally expressed in the 
cytoplasm and nuclear expression is tissue specific controlled by tissue specific 
gene(s). 
IHC expression analysis has shown that in normal and BPH epithelium, moderate 
TSPY expression was detected in the basal cells and expression was close to absent in 
luminal cells. This pattern of expression was also observed in BPH and normal glands 
adjacent to the malignant epithelium. It is apparent that TSPY is expressed in 
proliferative cells of the prostate epithelium and is absent in differentiated cells. In a 
separate study carried out by Shcienders et al, it has been shown that TSPY is 
expressed in proliferative cell of testis (spermatogonia) and weak expression was 
detected in cells entering differentiated phase (early spermatogonia) and no 
expression was detected in terminally differentiated spermatocytes. Overall, TSPY 
expression is associated with the proliferative status of the cells where it is expressed 
in proliferarive cells and absent in non-proliferative cells (differentiated cells). In 
addition, it has been observed from the current expression analysis that TSPY is over- 
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expressed in prostate cancer compared to BPH. The same was observed by TSPY 
transcript analysis using TISH, where there was preferential expression of TSPY in 
malignant glands compared to BPH glands. Furthermore, a similar trend of TSPY 
expression was reported by Lau study, where he detected over-expression of TSPY in 
CaP lesions compared to BPH glands. This tends to suggest that up-regulation of 
TSPY can increase cellular proliferation and thus contribute to CaP development. 
Functional analysis has demonstrated that TSPY over-expression in LNCaP increased 
cellular proliferation as confirmed by the proliferation assays and colony forming 
assay. Thus, TSPY over-expression can cause enhanced cellular growth in LNCaP 
cell line and its over-expression is linked to prostate cancer development. Furthermore, 
increased TSPY expression was observed in high Gleason score prostate cancer which 
is rapid growing tumour and tends to be undifferentiated compared to low Gleason 
score that is slow growing and well differentiated. 
Strong correlation has also been detected between the expression profile of TSPY and 
metastases. This tends to indicate that over-expression of TSPY associated with 
prostate cancer progression can lead to alterations in genes that are involved in 
metastasis, specifically genes regulating adhesion which will be discussed later. It is 
well known that prostate cancer metastasises to the bone at high frequency in patients 
with advanced disease status. Approximately, 90% of advanced stage prostate cancer 
patients develop bone lesions causing morbidity that includes bone pain, immobility 
and spinal cord compression (Bubendorf et al., 2000, Rubin et al., 2000). Metastasis 
is a multi-step process that includes growth in the primary organ, neoangiogenesis, 
detachment, intravasation, immune evasion, attachment to distal organ, extravasation 
at the new site and growth of secondary neoplasms (Tantivejkul et al., 2004). 
The current observation that TSPY is over-expressed in CaP tends to suggest that this 
abnormal expression might be a direct consequence of gene amplification. Gene 
amplification is among one of the common events associated with prostate 
carcinogenesis (Quinn and Babb, 2002, Saramaki et al., 2001). Increased gene copy 
number has frequently been reported in CaP and can lead to increased gene expression 
(Linja et al., 2004). To investigate whether the over-expression of TSPY detected in 
the current study is related to increased gene copy (amplification), quantitative real 
time PCR based on Taqman assay method using a standard curve approach was 
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established and used to determine the genomic TSPY copy number from prostate 
clinical samples (blood and tumours). The exact genomic TSPY copy number for each 
case was identified. TSPY genomic copies were always present in all samples tested. 
The minimum copy number detected in CaP was 6 gene copies and the maximum was 
85 copies. These extreme values (high and low) were infrequently detected in the 
cases assessed. In spite of the extreme value of copy number, the most frequently 
reported copy number range in all cases investigated was 20-50 copies. Similar 
findings were reported by Manz study where he estimated TSPY copy number to be 
between 20 and 50, using semi-quantitative Southern blot. Upon comparing TSPY 
copy number in prostate cancer cases relative to BPH, it was found that although there 
were inter-individual variations in copy number among cases, there were no 
amplification of TSPY in CaP relative to BPH samples. This strongly suggests that 
TSPY polymorphism in copy number is not linked to prostate carcinogenesis and 
over-expression of TSPY in prostate cancer is not due to gene amplification and 
therefore another mechanism is responsible for abnormal expression of the gene. 
Several evidences have been accumulated indicating other transcription factors 
including androgen receptor and c-myc can potentially play a role in regulating TSPY 
transcription. Up-regulation of TSPY expression was detected in LNCaP induced by 
DHT (Lau et al., 2000). A recent study has also shown that c-myc is a potential 
transcription factor that binds to TSPY promoter region. The effect of this binding is 
not yet known (Li et al., 2003). 
Although TSPY over-expression is found to be linked to prostate carcinogenesis, the 
molecular consequences of abnormal expression remain unknown. Global gene 
expression using Affymetrix Genechip method was performed to identify genes with 
altered expression by TSPY over-expression in LNCaP prostate cancer model cell line. 
Several hundred genes have been altered by TSPY. Ten genes related to 
carcinogenesis were clustered into pathways that mediate three major cellular 
biological processes, differentiation, apoptosis and adhesion. Evasion of apoptosis, 
suppression of differentiation and deregulated adhesion are among the common 
cellular alterations associated with cancer development (Hanahan and Weinberg, 
2000). It is generally accepted that net tumour growth and tumour progression are 
regulated by the balance between proliferation and apoptosis. Acquired resistance to 
apoptosis forms an essential step in prostate carcinogenesis. Bcl-2 oncoprotein and its 
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family of related genes products such as Bax play a central role in regulating 
apoptosis. Blc-2 expression has been shown to be an independent prognostic marker 
in prostate cancer (Moul et al., 1996). Bcl-2 is an anti-apoptotic protein and BAX is a 
pro-apoptotic protein. The proteins physically interact with each other to form homo- 
and heterodimers. When Bax predominates, programmed cell death is accelerated and 
the death repression activity of Bcl-2 is counteracted. Thus the ratio of Bcl-2 to Bax 
determines survival or cellular death (Oltvai et al., 1993). Over-expression of Bax 
protein in prostate cancer LNCaP cell line induced apoptosis (Honda et al., 2002, 
Lowe et al., 2001). Down-regulation of BAX expression mediated by over-expression 
of TSPY in LNCaP cell line may lead to suppression of apoptosis and thus enhanced 
proliferation. Both protein products are located in the cytoplasm of the cell. Whether 
TSPY protein product can interact directly with BAX protein or indirectly through 
intermediate, still remains elusive. Interacting ability between TSPY and BAX can be 
evaluated using immunoprecipitation. 
Inhibition of cellular differentiation genes can be a primary event that initiates 
tumourigenesis. NDRG 1 is differentiation gene that has been reported to be 
abnormally expressed in different types of cancer. It has been found that the gene is 
deregulated during colon epithelial cell differentiation and is down regulated during 
colorectal neoplasm (van Belzen et al., 1997). Functional analysis studies have shown 
that NDRG1 suppresses colon cancer metastasis by inducing colon cancer cell 
differentiation (Guan et al., 2000). The gene has also been found to be deregulated 
during keratinocyte differentiation and is linked to skin carcinogenesis (Gomez- 
Casero et al., 2001). The expression is significantly inversely correlated to Gleason 
grading and metastasis to lymph node and bone. Our data has shown that over- 
expression of TSPY in prostate cancer cell line modulates differentiation through 
down-regulating the NDRG1 differentiation gene. Another differentiation gene is C- 
MAF transcription factor that has an important role in embryonic development and 
cellular differentiation. It is expressed in a variety of tissues including, spleen, kidney 
and liver (Ogata et al., 2004). C-MAF plays a significant role in myeloid cell 
development and induces differentiation in the myeloid cell progenitor (Hegde et al., 
1999). The role of C-MAF in prostate carcinogenesis has not been fully investigated. 
Although the role of BMP 11 in prostate cancer is no yet investigated, the gene plays a 
vital role in regulating kidney organogenesis, neurogenesis and anterior/posterior of 
179 
Chapter 6: General discussion 
the axial skeleton during embryogenesis (Esquela and Lee, 2003). Functional analysis 
of BMP 11 and its role in the carcinogenesis of prostate is not yet known. Overall, 
TSPY over-expression contributes to prostate carcinogenesis by suppressing apoptosis 
and differentiation and thus enhancing proliferation. 
Metastasis of tumour is a major cause of cancer-related death (Ahmad and Hart, 1997). 
Cancer metastasis occurs as a result of disruption of cell-cell and cell-extracellular 
matrix (ECM) interactions (Cohen et al., 1997). In the early events of metastasis, 
cancer cells detach from the tumour primary site and evade ECM. Functional down- 
regulation of intercellular adhesion between malignant cells is a pre-requisite for 
tumour invasion. Development of abnormalities in cell adhesion of prostate cancer 
cells is one of the prominent steps in progression of prostate cancer. Adhesion 
molecules play a central role in mediating cell-cell and cell-matrix adhesion. 
Protocadherins are transmembrane glycogoproteins belonging to the Cadherin 
superfamily which critically regulate cellular adhesion, cytoskeletal organisation and 
morphogenesis. Although the role of Pcdh7 in prostate cancer is not yet known, it 
seems that TSPY has a significant effect on modulating PCDH7 expression by 
deregulating its expression and thus permitting detachment. This provides evidence 
that TSPY can potentially regulate adhesion of cells. 
Extra cellular matrix (ECM) is composed of two classes of macromolecules. The first 
class is called glycosaminoglycans which is made up of polysaccharide chains 
covalently linked to protein to from proteoglycans. The second class is made up of 
fibrous proteins like collagen. Glycosaminoglycans form dehydrated gel like 
substance in which members of fibrous proteins are embedded. Collagen and 
polysaccharides that are secreted locally and assembled into organised meshwork. 
Collagen is predominately synthesised by fibroblast and constitute major protein of 
the matrix. Collagen molecule is long triple helix structure that is composed of three 
polypeptide chains called a that are wound around each other to form super helix. 
Collagen helixes are assembled to from collagen fibres which give the ECM strength 
and resilience (Alberts B., 2002). PLOD2 is lysyl hydroxylase enzyme that catalyses 
the hydroxylation of lysine residues during the post-translational modification of 
collagen protein. The hydroxylysine residue formed during lysyl hydrolysine reaction 
has two important functions: first, the hydroxy group serves as an attachment for a 
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carbohydrate unit and second it is essential for the stability of intermolecular collagen 
crosslink. Deficiency of PLOD activity causes Enhler-Dnalos syndrome, characterised 
by hyper flexibility of the joints and hyperelasticity of the skin (Brinckmann et al., 
1998). The role of PLOD2 in the carcinogenesis of prostate is not yet known, but 
over-expression of TSPY can destabilise ECM by changing collagen cross linking. 
Discovering candidate proteins that can potentially interact with the TSPY protein 
will facilitate better understanding of its molecular function, influencing its protein 
activity, stability, post-translational modifications and its contributions to prostate 
carcinogenesis. The molecular mechanism of TSPY expression regulation is still 
unknown and investigating potential candidate regulatory transcription factors can 
highlight its abnormal expression in prostate diseases status. Searching for TSPY 
functional inhibitors can be potential target for designing intervention therapy at early 
stages of prostate cancer. 
In this thesis, the role of TSPY in prostate carcinogenesis has been examined and 
confirmed with abnormal TSPY expression seen in high grade and metastatic disease. 
Hence, TSPY can be a potential molecular marker for prostate cancer diagnosis, 
prognosis and designing best strategy for therapy intervention. 
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